var title_f25_52_26432="Epidural hematoma";
var content_f25_52_26432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidural hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This large temporal epidural hematoma is associated with midline shift and compression of the ventricular system. The dark swirls within the hematoma represent rapid arterial bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26432=[""].join("\n");
var outline_f25_52_26432=null;
var title_f25_52_26433="ECG sustained monomorphic VT";
var content_f25_52_26433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    12 lead ECG of sustained monomorphic ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are the six precordial ECG leads (V1-V6). The QRS complex is wide and bizarre and the rhythm is ventricular tachycardia (VT). The sixth (+) and seventh (*) QRS complexes show a change in morphology, resembling a normal QRS complex; these represent fusion beats, with partial (+) or complete (*) normalization of the QRS complex. The seventh QRS complex (*) is preceded by a distinct P wave, which is probably conducted, capturing the ventricle for one beat, but not terminating the VT; this is also known as a Dresseler beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Samuel Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26433=[""].join("\n");
var outline_f25_52_26433=null;
var title_f25_52_26434="Multiple vitamins (injectable): Drug information";
var content_f25_52_26434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Multiple vitamins (injectable): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/54/37731?source=see_link\">",
"    see \"Multiple vitamins (injectable): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Infuvite&reg; Adult;",
"     </li>",
"     <li>",
"      Infuvite&reg; Pediatric;",
"     </li>",
"     <li>",
"      M.V.I. Adult&trade;;",
"     </li>",
"     <li>",
"      M.V.I.&reg;-12 ;",
"     </li>",
"     <li>",
"      M.V.I&reg; Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dietary supplement:",
"     </b>",
"     I.V. (not for direct infusion): Adult formulation: 10 mL/day added to TPN or &ge;500 mL of appropriate solution",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dietary supplement:",
"     </b>",
"     I.V. (not for direct infusion):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: &ge;3 kg to 11 years: Pediatric formulation: 5 mL/day added to TPN or &ge;100 mL of appropriate solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;11 years and Adults: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Content varies depending on product used. For more detailed information on ingredients in these and other multivitamins, please refer to",
"     <b>",
"      Multivitamin Product",
"     </b>",
"     comparison table.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for direct infusion; solution must be diluted prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, ampicillin, cefazolin, clindamycin, diltiazem, erythromycin lactobionate, fludarabine, gentamicin, tacrolimus.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nutritional supplement in patients receiving parenteral nutrition or requiring intravenous administration",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angioedema, edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, hypervitaminosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; pre-existing hypervitaminosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Megaloblastic anemia: Should not be used prior to testing for megaloblastic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Additional vitamin A may be required in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Some formulations contain aluminum which may reach toxic levels with prolonged administration in renal impairment or immaturity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbates: Some formulations may contain polysorbates which have been associated with the E-Ferol syndrome in low birth weight infants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; RDA values: Are not requirements, but are recommended daily intakes of certain essential nutrients.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual vitamin monographs for requirements during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14191358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual vitamin monographs for requirements while breast-feeding.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10314 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26434=[""].join("\n");
var outline_f25_52_26434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234608\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234618\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234609\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234615\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234610\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234597\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234587\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234600\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234623\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234598\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234616\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234602\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234590\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234603\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14191358\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10314|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/54/37731?source=related_link\">",
"      Multiple vitamins (injectable): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_52_26435="Rubin manuever";
var content_f25_52_26435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Rubin manuever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 653px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The clinician places one hand in the vagina behind the posterior fetal shoulder and then rotates it anteriorly (towards the fetal face). If the fetal spine is on the maternal left, the operator's right hand is used. Alternatively, the Rubin maneuver can be attempted by placing a hand behind the anterior shoulder, if it is more accessible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26435=[""].join("\n");
var outline_f25_52_26435=null;
var title_f25_52_26436="CHS smear giant granules";
var content_f25_52_26436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone-marrow from a male patient with Chediak-Higashi syndrome after cord blood transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFDAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1L4iOyS6VAGO0bmznrWHETt+8fzra+IUavp2lX1s2YFLJv9AehrnraT92MncQOTXhYuTjWd+p69DWJYkLbflJOPU1Z8Nzrba9aSSMR+8C59jxVNpQByah0yOa81m0hiyz+YHOP4VHJJrKjUfto2Lqpcjue0WkkU8e+MsVBxyMGornB2/Nt5/OuI1Xx9tvZIdNtvNRWIMrnAJ+lUI/GWpmQvNaW5T+6DivU/tClexwrDS3PRNzFSqnJ7GpYyxUb+HzyB2rA0DXINWU+TuimUZaJv5j1raDSFTsADZ5z6V1xqKa5ovQylFxdmTxOX3dgDSqoA28sDzzSbsnj9TTo2Vj8vX0xVXZAp4Bz93GaQMDHuGdopcl1IjJDHpnvRA7NEDIuxuhFFxCAgkNnBqpfWovIpIp2ZYtwZWjbDcVZlJSRdgGCfnzSkKCAp/DNNS1GgiTdP0+UD1q7gAc1Stm2zEEdau5ySMdKLikLjPpWdcKFkBVuD1A7VoNtCH0rF1W9WK5toQrM0pIyBnBHc0JhBXLKsMYPf171IvCDHAqumWjVTyQeoqUsNg3k4B/OncpoeMsOWH4Uu8iTbgDjg9jS4GeF+UDgimxMsnzKD+NFwGq0jwHoJM8GkuYmlSIFmUggkocU8vsiZ3yAKEIMQOSVI70X6AJcNgAgqAxwdxxQxVELZO0evWgqkmC6529vSoxEGSSMqVXfkk96LsY4nLjEo2sMgDr9aqhF3liN7jhWJ6VPMq+chVM44DegqKRV80SEn5VxyeKdykI7uGXAyh5z3qOQ7k68EU5iw+6M+hrA1jxNpmnTGOaZ5JB95IV3YqalWNNXk7Fxi3sazys0oAQ/KvU9ahMzEDGQ3bPesnT/EdhqrNFZSOJevlyKQa300tp4wd58wDggdKdOrGouaLuVJcnxHE+N/E/9iNHa2UAuL9gHG44VB710nhLx3Y6ppKS6kYrC7TiWJ34HuD6Vx/xA0z7Jrls8gBknQnPfA4rKutNtTANpLSHnG3OK8qviKtOs1c3jSjVhczPHPxCkm8bO2lFpNIt9qkKSomYdW+nauj8L3umazpvk6V5D3TSbpxGdjIc55DcV51r1rGgZlUB1PSuZuHaI+bbu9vIvOYzg1hQzhxm1NFvCpRSPctV065a7t47rXFhimJjdI0G+Rs/KN1U9Y1G00zTJJtssjRzMYxMQNjKMfjmuX+FTtq7TQnzDLbsLvzAwYyN0xz0NdB4j0vSY4tXOtXgiUJ9pJePG0HogPqTivoqVZTipN2X9f8AAOScZQWmv9f8OcN4h8d2uphJLDTnj1N2Vnm3kBMdOO9Ysl5cXNzJeahcySSkZLO3Qf0rl7C5ilupJIsiMnK59Kb4qvC9gIY5NnmHB9x6V5M5VcZi1hE7K9rm8bQp89jSuvHEMDukJeULxuBwPwrQ07xfb3Aj+0O8BcdCcj868mmZVlCtGVAGOf51OVkG1wWaE8A19m+FsCoKKvfvfX/IwhipN6n0bpsxmgWZX3KTyVPH1rbtCec5x2ryn4a3ptYhZy3aO7jcqg9B6V6VaXQJGDke9fB43CvBV5UW722fdHoRfMrm7Gr7cgkhugpQnJBJ496rW8uI+HO01OJQoPOT2FRGegmi/wCH7l7LV4cMfKlOxxn16V6CyncAD06+9eeaLazXupQFEbYjBmbHAAr0LO6bZn5h14r08JzKLvsctWzsTbiD7+9C5BOCc+oppDIckED3ozufy04LcAntXW31OdkgcAk9u4pUIZcDke3aqWsv/ZNjJeSbp1iQuygZZsDtXB6p440/X/COtx28moaMEs/tK3d5bGJWVXAO3uwJG38eKuFOc7NLS6V+1+5nOpGKbvqle3U9LAG4uP8AWEcCnrkpnbggcgmuL8PeIdR1r4dNrIsZNIuWhLwC5UNnHAfb6HtmtbwmmpCxt/t1ylxEYgxmJ+eRjySR2rKXPF8rWuqfyLaTbV9jlfA6x6jDqujXql7V18xRnOw5xx+lZWq+FdZ0ksba3fULfOEeEjdj3HWtDSb5dFsbp4xi8uujY4RR0rEl1HUd5JvZlkBzgPgVx1MPCrFRktV1NIzlB3TJIfD2v3MuxNNnHYFwFx+ddbp3hm40Dw9q90GEmqNAR8vRB3A964r+3NS+1LO15MXU8Yb+lbjeNtSeONSysVxnI4f2NRDC06UWorV+dxzqzm1d6I5jTdjW0YH16VqoiZyvp1p93oj3Vs2raCvmWz5aW0By8DZ5x6isy0vhI2wkhh69fxHavIqUp0JWktDtpzjNabl/dJazJPbuyOnIK/yr1KwnW5tYJkPyOgYZ615S8wZfp716V4cjki0SwjkUhxHyD7k4r0culfmtsc2JS0NjdhGKsFYDIJ7VLGPkBZhuPVh3qKNkkyoIcDg8U948qFAxt6LXonESkhAWx+FQwAKCI1IQnILc0sRky/muGYnIAXGB6U9mGM9cUwFUEctjjnJpjAM2T94c0uV6rk49ulHBxnoDQBG+5sFTgdc1It0VwH5PbApvO87ATjr9KbIp3AoAffHai4xJrzKNsA+pOBUNnarNC7yt8498Yp8kKOpQ9Dzj0quLNBMZQCGON3PXHSq9CvQVGUOqNuySRx0q8uDjjj0IqDBUjALZPY1PtPv/AIUXBiwPISxkjCENxznIpI/3ZlzuYZzzQWKqMKWOaI5RK8qqrL5Z25YdaVyRQQ4BOQMdPSkdQ42ufkx+WKR9wYbVG3+IkU7OCOn40DEUhosqeBxTBnzS288jG3tTWjZCDCwQZy64zupVbbtDg5Y8ADtQn3GNJBkdTntx2NQy8oUHJHTmrEEfykO7Nz1NQXYWJGZtqKO5OAPxp301Gtzj/G+rXEBh0+0cxyON8pU847CuPFsCCX5NbHiu5t7vWDcWtxHMjIo3Ke46islJjnDlc+1eBjKqlUbvdHpUIWiUEnbTb1LqBSGjYH8K9a8L+MNI1S1Y/a44515eJzhvwz1ryi/VTGz7twJrk7qQWt5FJCfmVwQelYYfGSoT5ejKrUFUWp6Z4/1JdQ8XWZgbdbrb4RsY6tyamstIlkuI5EuhH/FnaD+dLrMMeo6XbTxKBcIoeNsdQRyK5u+8SXFlZ+XJbsjkHIHA+ua9upQXN7Rq90YwXIuS9rHK+OJni1ed3mDxsxyxXbn8K4DWNUjdSIwSOmQK0fEl5JfSSGXKxqeSe+a1tF02NtMU28AmuFYExhsEk9Metc2EyhYis6tVWRc6vLHlRyfhA6wl482mRzRDBw0TkHHvzU/iG01zVjIbueSVs7iJnJAHbHvXrem6HDpUMFy8X712UssZwF9Afz5rJ8UwC51pxZL5aOQqq3ygnHNfWYdUFO6jocsYuTSk9DxM2F9ZzZWdXAHPYUzXZnFrBJKo3I2CM9q9bfQ4Z4lyQ0qMyyZA4B6D2rk/Enhi5tJmliiWa1kTLKRyOByPX6V2VcNhueNWjFc6+Vy69NQhaFzy66uTPK7uPoM1NBePGUAHyr2PIpusWJsLxo1O6M8q1S2cCIYzKwwxyRjpXq08RFxR51JTlN20N3wvJJDr1nMwIBfkDvXuumlXCo52uWwrdj9a8a8L6S9/rcU8W77NEd7jGMegz6mvd/CqRSo6SL+8B3EkdK+L4mqQr4mmr6pa+XkerSVo2NCLSdU2YjspZF/vLyPzrZt9OtdGiW48R3C+e43R2UJDMfqR0rZsNS/sfwje3kilgHKxrn7zHgVw1rE9w7TXDl535Zj/ACrwqzp4dLlXvMcFKpJq+iOjbxVqbbVsYoLKBT8qBdxI961dG8TyTXCW+pIilzhZU4Gff0rnEjCgDHTvSXEYkQkdqzhXqc3M2aSpRStY9PzufBOT1A70oYZyMjGOnas7w9N9p0y2uJM+YUwzE9SOK0YyWQb1K+nvXtwlzRUu5wTjyuw93eUAs24DpXJah4HsdU8e2/ijUL2afyY1WOxZB5W5QQGJJ55OcY611xHGBg4HT1qOThACARnpW0Kkqd+V2urP0MpQjKzfQmWV5Ms4wD1Dc0kGMAQEBAfmFLCu9hjkU+WJICPLGA38PvUeQ9Njx65uSJJBJ8wxgVjarcx2tq15cMEhUbmJ/l7mtS5lWWRhlBIP4R1ryX4qavLfarFp1uzR21owLyDpv9/pV4TDPE1VT2XX0NacOdjdd8a3yRC6sokgtc7RvGZCfUg9BUVh4r1m+jjngu49x4aF41O4+3tXGrdJcX0v2hpLkSHGS2PxqaG1DhGginjeNsxsecj39PrX1EctoQhyuKv3aOxRj0R6X4S8eveXSxOsttcZwJEP7sn0PpXq+nahYeIZxba7bp57cJdRHY/444NfNj2+r6cZ9rRRWUrAYVwyScdu/frXfeBNXluNMMF+Sl3ZsELHkuOxrxcxy+nTXtqNuXte5z1qfKuZHu2neDdNtLkSvJPOqnKpIQB+ldNbrP5TeeY0kJOwp2Fcx4O1hrm1itrxt0pOI2PXA7V1cbEzFNoKKM7s968lRjFWirHM23qOjUNEy5ILD5mAwc1Iv7qJFySFGPc1GMBCcHg5pwbegIyOhx0NIglU/MGAxnrS5wOWHoKgSUGUbXBUfKQDnn3qX73XP16UwtYe64Iwec9fWgrjJ9BxTed+eNuOuaXaxLgcLjrQIADjGSM+lQqZRIUkiABOEYHPFTBlbkEtx3prb/lx8o789qBoaduCOCf5VGBx6nrTpEYKxQ4x2z1pjqjeUqFi5++ewpjFRCZnyrL8vyuKfF5iyGMrmNRkNmngH0x2GaRxsYyom5+mAaAFV1ZgAwOe46UCbdLLHsbMYzk9DT9oRNqfKeuM/nQM7cM2c+poENU71Bz369qjUMm7O0rn5QKeFWJcIDtHPqaZ5pDriMkNnLZ6UFCbi4bHBFDS7SFPJA6jtTuCcMODUbN16DPWmA3zXAOM89/evPfGupzX2ovp6SEWtvw+P42/+tXfbWMi/OSM9PWvH3lEl5dOzEs8zMc/WuDMajhTVup1YaKlIdHAqRBQAMHgVRuSqM5d2Crk4HNX5Jl2nkHHBrH1KUCIn+dfPVaiSPTUSjc6kjWzpnDZ44rO03TrnXtShtbRSxZgSccKvcmpNF00arrMNvJOIImPJx04rX8Sav8A8I00lnoTLDEcJJdP95ieOPfNehlWXSxc/adjnr1eVWZ6/pOk2MqmCSRg0YCIuccAVgeJtGjspcuweKTlSy88dq8i0nxY2lwIt5rRlui3HmMTjn6da1bn4lLeukd+87sh2R/Lge5zX1zoVaTs1oca1lfa/coeOYrTzILYqoiBL5PH4mofD15p9ikUtvPG12WCCON88E9Sa5r4i3Ru3gurWfNs5KSlDnYMZH5mpdI0rTzZ2kgnkiuZlzhl3KfoetepRoxqYeLct7/0zaNJSbfY61vFksPiLZayiW0OI3QDgNkZI9TWz41smt41vlYypuCGVmznjoB2wa4HR7OW2v5DA8sc6PkHggn6GuyeC8vrCK1uNkdnvMgYYUFu5P51isM6NVSclbqHs3G1zlJLqY6gGdfvcbAOWPrV7WdSdLUI9uzKUAUseR7qasTosNwRABgA7W/Ci8e3n0WLzmEcwOEk9PYiuqnJc6ctf0NYtvfU838YaUtrcWt2imWC4P71XXABpdO0HTnYPh9o6gPxW94kvDHoDpG0MzPICQeoAPv/AEr0D4ceDLbxnpn2ybbZSxsBtiXKsOtebnCqR5J058jd1vv8jCUFTk3bTczvCNgksBSCDZEp4IHFdb4T0q5vL6drQb487C54GO5zXpVl4PsrOzjtlbbbqCGVBt3D3NYWva+1nbix8NxRQwQ/L5pGR/wEf1NfPexjD3qjuT7XmdojPiFbfZvDNjb264hjuF3YHt1rm7DgD1qX+1NSv7OW01O4M0EpBztAZSOQRUMME8a/d3KO681wYt+2nGcVtodND3E0+pfXkjg0kzBEwB29KhMrImdhJ9CKv6RYT6pcxKI2WAEGRyOB7D1qacJSdki5SS6nX+G4Wg0a1jk4LKWP4mtVCCNrZOO1MEZUgLnHGB049KJJkj++UTcduWOOfSvdguSKXY86T5m2SA4DEkADjpSRT7ZGVM7lHIx60gbGd5AUUoYONy9O/vV3IFiEgOfut7cipQGLZdsn1pAOy+tSxrkcmn6CZ4eskEOpTSyod4J+hxXgWv373K3L3UuPMnZhGp5GTnJr3S4mLpDK+NkikE+uDg14/wCJNMgh1ec3NnLLHbpg7Djf/dP8q9LIqsFOTl1SOqjpdLc5vT7C5EAmVVxIdiOTggkZ6H1q3p6Xzf6MZtmV2mFm2lx35rM1LUZLhzENyxLwiA8AVJbQXdxbW+6RZImk2Iu8bgfT1FfUyUpK8rItSSdkaOoWkcUdvuvEXyPl8rHzHn/PNegfC6CNtdlhkePEqs8kZ52kEYH615UtlO91tCOzKxLDGSMV7f8AAvTEeTUNUkgVFndY41PO3HJ/pXnZmuTDSUpX/wCC/wCmKrL3Hoew6XpSWs0DBecjGDXYvBtYsi4Pf3rP0rZIyRvyynp6it4qCDkYNfINnnt2ZQOXVgDtJ4zR91fvFmHcjmkIG9x1IPSpCd2Cy0BsVLLT7O1Nw0MQjklcyMwJ5fuatfNgbACc8A0yGPy0K7t3YVKiN8w3YA6DHShu4EjA4PTnqKVeBk59abyRx17n1p4PTPAoEMAyMjANDrkDg5x2pzZ2nYcNjjNRhnjiJn25LdVoGBJwu0ZpiKyqAR8wOanIIY+namb137DxkZoGRuPLlMgJO7gjinlpTLtWIeUVyHJ5zTgwBbOBj15p9mzJGfOfcwPb0oEyKKVJFb58kcEgdKRYwyqzjcUOVINSXKqUPkqmW5PbNR+Wd8bF8bVwVHQ0DQshwRk4B/lTGKq+4n5j8tOR0cZVgaY4BAztYk8ZFNDGSM4AAwD0x1qNyzTZJGwKSR6YpXz5wJbMeMEUmuSRwaPdSYKkLgN65OKG7K4zlp73Ub+6c2lwbWNfuKF5b3Nct4jsjDvvUUDccyAdm7/SuvsZljjQgjGMcCsDxHcXFvY3Elh5bXG04SQAqx7Ag9q8utacfee53QTi9DgXvwMhPwyazr2+3qwbg9sVqaja20sXnRqbacgGWLqhbHJX057Vz11CiS7mk3rj+HivnatOLlZM7VN21Q/RleG4kvGmWEKCEBPJNcX4z1afUdZkSMl4IiFUKOOOc/nzXUqn22+hjtVCtAm5Q/3Wyef0rA1OCMateNFcJCshIRTgDI6D6V+lcN0IYakm1dtXOKM+etr0MK3gjntZXlR/OLcN12j3rPubZ3LICWIHGM4rqra2DhoZyPNR8Fg3y8/StRtFjsNsgfazqCu07gfU5FfTuvCMuV7vY6movRnnOnSvpl80soaSCTKzRnoV+nt1r0DTftECCXeF8kLsbG4SRnkMPSsq/wBEa+lk8sb5XQsuBjOBW74Jkgl017G9V47uCP5OcB1BPGfqa5cXJU17aKv/ADeS7/oZcvsXpsaFlqQvNRMt3EJGPHDbSP6Gtqe8kaIkuptwfljCY2keorm72L7PBG8LbZH5KM/zoc4wfWtyKNriweHUWkjuMKUyMBgOxrjcqda0qb/zQ5OM1eJNZSRy2spaZSUOOnzYNZ1zYl7N58bo1OMsccfSo7y906GCaIpIt7xt2N8oHoa5rxTrN3b6fHLvKBRgD1J9K1pUqnNeOi8x8tve2RzviK6Euu21jFMdmQZGxjbzXoOhpdWwjktb24hI+6Y3K/yrzzw9pXnXH2q43NM/OW7Zr0fTUkjt0iThVr4TiTM41sQqcG7R09X3KopyvJ9T2HQPEeoXnhG9tr65MtypVFlIwwU9QazpZ40gxjkcAY6muY0jU5rC7851EsEi7J4um5f8a6GLSnuIHvdLl+02aH5s/fjB/vD+tcWFrOtBQ6oyqQjTbl0Y6Ff9nmrSL3A561FHG8RUuOB+VW48sxbGM9hXVGPcm5JH5gx5bsuO9b3hy+uJpTaXErMoG9D6Y7ViBgBzkYrpPDtlt33TfxjCAjtXRRi3LQzm9NTdQjb8wzms/VNIstUWAX0PnCCQTR5JGGHQ8VpKAoAXj/Cnbfm6cD0ruTad0crGLFuUB+R1p7LtBZACeOM4qbb0BoZQRtIpIlsjijRCdvO45PepgMdOlJs2qFHFKWC43euB9afmS2cVH4GtpfDcVlJOWuljJSYHKhic8D0rw/xr4T1eFHa9tpLe4hBUuBlJk9M9PpXpfwo1m7hv7zTLmYmwjjacK/JTB6A9hXGePvG+peIZrpVme30RSQkK8bwp+8x69ulcqzFUIwrU1q9jpp05qdr7HhEsUZEy3R2CNvkdhtOO4Iq/odxAZWjt4UEUa73uWbG3nIrmvEWrXWq3LSTTHyAcRxbuFFUtPvprGZXiIZP4o3G5WHoQa+8Xt6tG80uZ9L6IzljIxna3zPTtD02S7muIoJWMUw3PejqM9VAr1TwlLFpkVvaWu9YI+nqT3J965bwvOLrTYWjt1MMi5QLwV9hXZaTqaWPl7dOjaVT8xd8jHoBXxmJzhYqVqmlnt57G1RSnseweGGMkIuZcjOAuRgmtu5uAqnA9vxrE0m4GqabHe2iEQNxtPGCDgiriMqBnc4UDqal2a0ORrUmVFPJ4brnpzSxhtwZmGSOVH86arCSNXXv0zSsisCCCBj1oESc8mMAmnDBKnO1j2pIkCJjAwB1qQAEZOMdzQAduM8nihgpQE5D57Ujuq7d20KeAc04DGRyO3NAhsbvufzwirn5ccnFOzncuBgc81FLuQysYRLwSijAz7f8A66WVgYv3qsA2MqOoouCHYJfdu98UvG77vzY60hIREEUfHT6UyTdHIrKu5T94k42j1oGKjF49+wjtg0cmMhcqRjGAOnpSPMoXcCSDyMe1M5facMoBzkGgY9gfmIPJ6DrzQuVI3HLdyKiZg4ZA2CeBim8LsBbJA455NMqwRFHDN93BOABxmklZQu49iMHNIzkHAOfTJpHfOV5I+tCQ7EVzdQQW7Tzyqka/eZjXJav4otLi1ms4oLiWGT5fMzjHoQKp+LLiW61mS0CN9nt8ALz94jJJrJkwpYNGAO2a83E4qd3GOiOulSTV2TJqEsETRMCx4GRyCPWqOo3Ej4DFgn60+ToMcgdPas68klVGzhwenPIryqk20dcVYoak2ASNuPWuR1UuU+QZJOPrW/fmRzsUDcc7ain0eeHR3v7kruyPLjHzE5PfFPA4KVeum1oKrUUYsoaLA1rPIlkrXLucTMRgR8VxsdukeoyRojTByVPmDBB9a7yW4vtCt7Uw2rjzH3u0q/fx2+nNcvq1mkmqtNFDJbi5HmGOTgq3+ye4NfpWArqEnTta60+RxYSaU2m9yzYQxiNopFUTxjg45bFdBp1kps9hlQvj7in9ay9P05o2ty6PH5gO5z0I9veu60y3hhjWK0mDOVIZduGA7H3rWrJQ1T1Z3NJao5+5064+wwoihUjQt5igAkn1rm7nSZ4QLi2tmLkb2Ujgj1r0uXRpruzRzINpbG1yRkZ7c1He6KBD+6kuISkZUEnOPWohiOjtqJyTTR534gtXllS4S5jYSw7wqrkcdRn1q9oXjiG/0aXT9Q8qxSBBGhmG53x71qWujBlb7VEHtklBhuHyvmOeMKO9cHq2hwnW51IGN2cdK+fzOrDBptbrqjjjTfO4x2J9TvNJdYpxcyPcOctF5XTn+9T7M2+vTrHe6eXVGzGoY9PSpbHRrWLDFPphSx/IV0ekwtZh2to1cSrgNj1r5/E8TYiraEG1bzO5UZNWm9DU8Z2nhybStHufDrCC7T91cWIBOwYJ3Z9j+eaz7OBm2Y+XBwc4+b0qfS/JsL2N9Qi32kp2y/7KnjP4ZrW1XRpdJnaIjfCvMcvZlPQ1wYiTxlppapW835+qFBKjdX0f4Fzw7pdhqM8NtcTXUNy8pBOFEWwdvUk16l4W8NR6TdyzrK5RlKbCOGHv614zG1w8sCWm4zlx5YX7xbNe+WdzN5MazL+8CjcfU4r0ssipK7jt5djlxN0tGZeueHI5Y2NiQjNz5bfd/A1z8OgaorbWiQA994xXbzPJLjaCFJ5PSk2kgbhlj+hr1pUoyd2jmhKUVa5g6d4djjIe8fzZB/AB8orfCn5f4R0AWn7PfvkYqKFxI7hRIgRyh3LjOO4/xqoxUfhE5X3JYwoYgHmlZBIqgsUwc5HWmjIJAU7R1JqQd+M+1NokUyZzwAeuKkB+Uf4VEAHwGwCR0zTh8pwOv1osSSDGOKU4/DNMDEEZ/OlHIz3otYVjxPSb610M3jNAbq7vFMJAOFiT69ya4HULJWtZrUncpQrwc13cds6xYmYPJk8gdqzbzS0aMhF2jORjmvlqlSba7LY9dU1q0fLuq6dNp99LbzIVZTjnuPWk0zTp7+7W3t4y8jHAAr3zU9AtbxgL+0jkI4DMKl0vRtP0tWa0ghQHrt6/nX2y4wXsLey/eW+V+55by/3730LnguyGiwWbs2BbKpBxnJrqL1hrWqtNFAkJk5fYOCfWsNdxUSLDMU/h/dkCu9+Hekz3BN1PEVt0IOXGMn2FfLUadWtL30+7Ouc4QWjOw8G2U1nosdqxYLuLDtwa2JrVRGy43KeMGrUDbmZV4C8fSpmHGBXsLRWR57lqc8DMhjhQkMuTmrkHIBJBY8NjpTZ4xJKwBKt0yKVIlDKR1HBxQiifoQg+6O+elGCrqcjywPmU063IZyr4XA6A9aaWYT7DFmErnzM9PagQrqDGGIDRjnB/nUkbh1D4+92NQLIrRq2GwcjnmpGxGrMDuXHCg8fWgAJKgiVvvHilmkeFA0Sh89RS4DgF1GfQ0khbaDHjI7mmASsQreVy2OAfWhCdg34JI5FNJ5xxg9PeoNzLIV28dR9KBpEjMUT5VBwevpTDgv5iscdMY6UMxAzgc/nVXHzPIAVZjjHYUykiV9jOck7l6Y7moy2cHC7vXPaqcty2QcjaPvAcmq8k77spGTx8p55qi7GihfYdwAx0q5aWyvmRslmqKxubTyUaQr5i9R61fhdCSYsAHkDpUpkSbMfVdFE9w9zGgLkAOvrjuK5fWNPUI+Fwo6HpivSgw288+tYfiDSVv4WaBljnxxnhW+tYVaPMnbcqjWadnseRXMnkls5G3rgVms8YJIJCHk5rX1nQPEUd2wTSZJQzY3REMtXrDwDcz2vnarObZs/6teSBXi/Uq852UbI9H6xC2jMLQrBtd1WK1h4iLDzHA+6vevS9d8I2RsUNvEsckIyAO69xVXR47Dw/PH5aLFbEbTI/GCPU1vX3iLR00+S6/tC0eMKR8soOT0xwa+kwsfq0VTjv1PPrtzlcwIdOgaKNZQjBemRmuL+Jnh152ttQj+ZYEKFAVXHPBGe1aouruWO3mjvZYY0xK6RR7i4HOzn2p/i+ys9S0yw166tdRdFXYLWNcEhz/EO2K7qdWdOalEUZezfMjh/D9nPbs6TrI5U7QEbdtz2IFdLYWBjnIW1m+1JhAWiIwOuc16Jo+nWNmivZW8cLzhWY/wAT4HesTxBp5gbUF1bXpo7TUWWGBAgDRN6A96csa53bR0SxUtmjmdUWTS7+KDUFaSSfPlxo275ep6cCnasheCNYlceeD8u042kdRW3o0Fnpvisafdebc6m0JZbjadqx4wFP+1gV11x5ccbSsE+VcZx0HpWccS+xP1h2PFNIg1bW7m3kvxNBp9qx2xSH+IcAgYqLxB4Wt5Fn1OZnVv4SDwa9QVZLiR5FRtpGQWHGPSvN/idq8LyxaXp8nmRJ80xTop9K8/HygqT5tgpN3Wupz+lWzsisCwK9CCQfzFbtrBsjVQqjHA+lUNHbCBSgXKhgQwYEfUd/at6JQV45xzXwtOKk72PZ2RnXNu0iFCF2YOa6r4fLqN9fRrLdCbSLRPLeCYhj04wpGR9ayiqAAHGT0xSaHLJYeJrOa3OFkkEcg7Op45r1MHU9jU20ZzVocyPULHRtNtbk3FnZRRTc4cA5H09K10j9ufemxj52xzz6dasBeRjg19V6HlNhxu649MdKRRg8Lz0608+h5x0poIK57E/jSJDAPbketA9CM8dDVS4W+SS5mt3imJiPkQSHau/HG5h0GantjMbWM3KIlwyguituVW7gHuKNgJfMYxbMYx0xSDoO1GBg55BpQf0qgHDBPrSjg03OeOMilDZAGBTRI8dxQDjGc800ZA6Zp2eBx3osB47Gd2eec0y4hWSIoxwCO1Iksf2u4gjkVpoSN6jqoPI4qdupx1r5qcOjPXjIx7u3Cx4XkAY5Gc1t+AtN0lppJ72KOIRkBDK/yO34+lUp1Xad/wB3+dZd7bNdBRMMoPuoOij6UqNX6tLntcmrD2ise4S3EEUSlvLMR4Xbgg1fiVSiqRgHtXhnhS5m0/xDp8RmkNq8oQxlsqM8fhXuB6cEgA4+le3h8Qq9PnPMrU/ZvlZOVwpAwQarS3WzIOVY9iKtKAAOv4VS1IBU8zGcdOOa16mUdyGPc6E5BftS/MMb+GxyKrsPMCDeVKnIx3NTOzMNzDafQ07F2BplEoVgNwHFK0vUe3btXO+INdGnX9uJIA0JHLB8Nn6VVsoLttemvrO8aWwu1BIL7gmP4QKrlZXKdbFMrxvkHyh1J5qeIKIgE5Ujj3qjbwbHULgQ4wFHI61cDxpIkZJDScgYqWS0hZY/MKFWwynPBp/zZDHpzxnijB3DaCB6U1pF3rGWHPpQIrXLI7pG+5ZH4QgcinIWBUYLHpmtINGsqx4/eYyOKp3jCPDEFTnGBTQKVzPXyoyGJZWY4wx/z61HcybXjXaSXO3gVclwxG4gkfjis67nNvNC2CRnt6U7WRojXiso0QKEGMZzjNRTE4xEi5HA4/OrNu8ihS4+RhkYOcVEB87kYw5yB61LMkVY7OzOwGEeYvOQe/eq2uXo0KF7yR98I4RT2Y+9Xb6e3sYXnuMQRoMlnPavLPFvipvEeyzslK2ETbvMYYMh+npWNauqcd9TWnByeh0r+JnmiZ3mYeycVnHxpeW83lxkXSN0SQ9D7GuXhj8qJeWOTxUTJsuEZjjmvNVed07nb7OJ6P4NUTTX2otPclrqUM0cj7kiYDog7A1094IZ4iCQS3P5V51oFzepo2oTabClxcCVAqSNtBHc/Wu10+Oe4AlmxFEi7pGPcY7V7FOTlFM5ZxSdzw3xtqc3iDWZoHd1sLcmOOLoDjqTXPabb2ena3ZXE8UaQLOnmSbM7Rnriu9+JWgS6NrYvYISdNujuSUcqDjv6GuQuoUnt2OBjHSvm8TVr4XFc0m7P8juo8lWndbnsD20IZxbHcrHcrqeo9au2l5NaMvnsWXoTnmue+H12974UtRI5LwFoGOMnAPH6V0c9pDceWJYhII2DLnjBFfVwmqkEzkmrOxHrGn2viCS0u0uJLLUIAwiZHyACccj6VneHroa9Z3NhrcKypp7BIb2UYZpRkFwPbitWaCMlQikbu1Z2sC3GnXcJuY4rnyyE3ED5qJyjBXk7djNUr7Hi+r+PrvQ9burfRi883mETaiyZadweMA8AYrtG+LdrcWSLJY3HnbR5hyMM3euAuNNtmuiJgdx67ali0y3jVniIOOocdK+dxGc2k1TjqdlPC+7qzs/FXxKvda06Ox0Wwawib/WyNJliPQY6CuW02yKFnnYySP8zE9zU1lZuxUKvHXFbdppr7R8pIXnpXmVcTXxa5HsdFOjCk7obpUcULsZQfLYfdAq8obDCDD46JnBP0pFgaNwGXrTbqJlVJFHzowdfqDmlCDi+WRq3pdF9dN1g232r+zrhYsZzt5x9Otbfg3w5dTX0WpajE0EEXMUbcM59SOwrstD8QWGuWxks52+0KAZIm4dD7ir5G75j36k19DQwOHVqiZ50q9R6MmhwPf1qSHBOT8pJrH1rWbHRFt5NQldFuJRDGApb5j9K01bJ+b1yMCvR7M5tywehwc9s0vQ0zd1xg47U7cBgEjJ7ZpEi5x0IxSZH40ZyRQSd2O2OtAgzk8euOKQYXgDBzS8gY9aYMhjxx2P+NMYu8biMjI60u7LHPNMy5UlUH49qYHzk+nU015BYsbuT1FLyRgYFQo27ODn2qQH5hgZNWJo8muRGIxOAocN5bHHJB5AP61G5T/WOeOwHers8aW/h24luI9z3VwqwA9tuct+tUYowwyefc14OIVp2PQoyuiHaZnBPTsOwqUwgLz1qcIMDFI4J6da5HA2TMmC3km12xihwJTOhX6g5r2Cyvru5llSW0aFEYrlj16815PI72l9b3kX+sgcSA+uK9Xh1WJo45mQ7ZgGTjIwa9PLmlTcetzhxSfNexfhvo0k8qVtsuPuk1k+JdXkggjFrayXTNIqkJ2B7025dZZ/NZCxGAB6Cp0ChiBwfpXeonOopaj0yc/yqG6eO1Et3ISABzk8D3qeBEjlkZc7n685pGt/tCyrdKjRk/IB/dNMfU8/8Wj7XNDctLCLa5ISCVu59PrWx4J0mbSo5I5TlZG3AHqO1dEulWyW8duttH5EZyiFcgH15qrb6HHH4il1Rbm5E0sIiMJf92B6getaJpKyC63NezDbWMiAc/LjuKsjAYMfvDpkfyqExfuwpc4GQT/eptlaw21nHa2xk8uIEAO5dh9SeTWXUlkrtHHIZHJ+bjilRURsAAlTnPpTLsF4iAxVsg8CnKjZyAAcdO9AFhbxQG3jBXqevFVZZJJ7jBASDblXznc3pinsUEgRslnzgY44qFtpcyLNlFG3YOBmmJJLYgZwsqpuYswyABxVLU9QsrBCb65ihHXBOW/KqfiXWDp0f2e2P+luMk9fLH+NcQ1sZZPOmZpHbqzck1x18X7N8sFdnXSpc2rOjk8Y6WVMUeoS+UOAPJPH51rT+IPtvhe6l01xPcRRkhoeXXtnbXAS2MYBGOOwxVKOK5027W80+V7e4To68ZHofUe1cazCafvrQ2lhk1puNkjvdbdHvNUnvVxz5x4U/wC7VlNNkhUrH8w9QK63SINM8T2TX7w/Z79W2T+QNvzepHQ+uary+G9UhDfYniuoieDu2Ej3zXQ8NzrnjqRGSjo9DnntpMANkbecDpVC/JXJztY8DjNdi2ha1t8sWqH/AGvMXFXNI8KKk63WpSLPNGcpCo+RT6k96mOElJ7WG6qtoWPA9gbbSoo7w+XPgyDp82e35Yrs7CDYrSH5c9AKwpt0bpKU6HJ710NlMJ7dXTp6V6VlBJHHVu9UVte0qDWdFu7G7G5ZYyOeqnsfbmvmcbkjlRiCyEqfqDivozxrrtt4e8P3V5MwEpQpEmeXc8AAV862cDSQnerZbqcdTXh5xKMoqK3udOATu2eifDSAw+HldnZRLKzc9M9BXoNpaIYuQA7Dk9a8l0LxR/Y9mLC/BNsoO2dVy0ZPqO4r1DR9SBsYZHdJlZNwkj6OOxr1sHXhUpJQew60JJ3Od+JWpSaPYRQaaSmoXWdrL1RR1b6noK8q02BzI/2ktI7clnOST710vji7lm8a3wuCwTYixZ7Jt4/XNRaI1pA9wL4lyV+QAV4mPqTrV/Zt2SOjDxShzMyItOTcccc1YtInspWbykuIJFKvDIDhh9eoNXICqliQdue9SyshTpg/SvNdOSbZ1JqxnxWphZprTc8A/hY5ZPau00PULZrVQ8Sqeh96wfDyq3iWwTAMbPhwRwwx3r0qbw1pEqfJatbvnrC5UD8OlexgKEpxc07M5atXk06HLamlpJFvSQA+nrXMXkqouGICAcV6SvhLTcYke5kB/vSY/kKli0DSbNg1vYRGUEYMjFv5101MvnWfvNIzWIUdkcp4OjGhaDqniO+h+ZlCQIcgsOg/MmuaubrUdZnae/upWduQisQij0AFeheO4JLvwvO6jJSRJGVTxgHFcTZKPLz61hjouioUoPQqglNylIsaTq97pTKJD9rtVOTDN8233Unoa9N0y7j1CyiurUl4pBkHPI9jXmMyAryMCui+G0spur2wjYbcCVAeg7GqwVeUZcjegV4K1zp9V1GaxNoLewmvGmlEb+XjEY/vH2qR9Lsr7ULe9uYibm2J2FXIGD1BHfpVoIY5WQ/eHFQRlxdjBXZ/FnOfwr2rtao4HqaCkYGOlKTx3ApFYleCDSMcDP50kIbJnC8jA6035mYmPr0ANDK4XJBYCkiBaQANweetUPoWYnG0KevQ+1QXERkOIuvf3qeSIBOD81QksDlThiOcUiPNCWwQpktzjpnmnxtyOhH161AYmjfKnCmpVHzgDG0HseTVW0KZzvirSG1Ozi+zYE1sxaNMYDDuK5ODT70jDW8keODkV6dHEWnyScCtFY8jkD8a5a2FhUlzMccQ4Kx4/cWs0C7nHy5qDzVye4r2C5sredSJoY3z2YVy83hnS9xk+zSISeQHIFcs8C2/dZvHFJ7o8/aKS9vLe0gUFp22jnp716CbGSKfT0tpwtraoVljZM+YMcYPardrplnaMrW9tGhUEBgOQD1q4dqhR0JOM4rpoYeNFW6mVSq5u5VUgIGVG25x071Fqd7DpdhcX12cQQJvcqMnA9q2TaFXfG1Y8fLjrms8RB1kS4KNuOMEAjHvW1+hmncq6LqEOoxwz2cUrW08QlSZhgEdhj8604wzSNnnHQHvRBEF+VFQKABgYxj2qUKdh2nB6gnih+QrlWPY0aJcHy5yRlM9D6Z71aeJGZTg8dOetOKhuOA/UnHehMlWPUBsH2NIVxq7UZnZgqjjLcDmpWjBXAbb9KjMIkaRZwrxEgoPSpSflY5HoPagCMqkrMBu3DgtTogQNucAdDSknaUDhZMZpHX5SGOTjkg9aABcq2xVO3GdxPeomRASEjUc5NKFVZS29tuNlQvII4v3m0PuIG05yvY00NHn2tuX8T34kXADAAk9RgVXYchieB2rovFugTXsy3lkA02AHjJ27sdwT3rlrxbmyfbe28kTerAgfnXkYilOEm7aHoUpxatcdIvJycGq17jyTn0pr3yYPzD8aqSyyXTeVbK8sjHAVASTXFK8tErnRdLVm18M8/2nexAEwyRZce4PFeiomV2kdDkVgeDdCk0m0ke5IF3PgsOygdFzXRxsTgg8d+Pyr3sJTlSpKMtzz6suaV0OK7cEng9O9NZGLkFQI9vBPX8qdMmY3CsUzxkdveozlUVAd/ABJxk103MiC4jYyDYDg8ECvGPH2r3w8XTPomqzR2cSKqi2lwA+Pmz+Ne0TxGSCW2SQx74mQN/cJBANfOKW82mSSWd7C0VxESrBgRk+o9c15uaTqxpfu1c6KCjKVpGvpNhc6veLdazeTz7OjzvuI+grpnsYI0byx8mOM9ayPD15ZlcTTbCPQV0TXtlCQUs7y6OOhUqteXQouqry3OxyjT2OWvLUkFdmFPrVu0m8SrbaHDpF3Fb2NrI5ud235hkEKc9RjPAqDxLrjpLHC9rHaFgSsZb5vxFZGrwpr+jWUJmlilt7kt+66NleCR+FelluGjHEcq8/yOevUvG52eo+IdF8S+IDZTWsf2VR5cOoxkh1c9iO4zxVmPR7PTbt2ufLvY428qR4nzsb/aA6V5VpqajCt4Tc/ZJseUsrsAEbt+WK7Lw74j07wvBprXN+moX96wS8mALRsm7kn1YV6NbCpu/X8TGFRI6i4l0uID7Ku/n7tMi0y41ObbbWzAZ+8wIUfjXV6PqehaxeXEugC2nghIRyse0q2OoyOldEM4z0Ax8tczwal8TK9u0r2MLRfDtppkSu8Uc11nJkI+79K6SxjDozOMnNVJCzSA4ye/NcPr/jw2ly9roSrcSKcPO3+rB9AO9aznTw0NdEZNSqbbnYeJtOW8szardz2gcq3mQn5hg5xTJmEcaA/M3HPc+9cBYePdRiuFOs2yXNuT80kQ2un0Heu5gMN3FBd2Um6F1yrryMehpUMVTr/CxypSgtSHVhnQNUUfIvkt83pivO7DmFcZJwOK7LxXdLa+HbxGJ8y5IhjX155/SuRtF2xgDtXn5m1zxXqdWEW79CWVtsZ3das+CtRh02fVtXuZfKtbVFjZ8ZGWPp3qhdsApzkkjgetWLDX1sNLOnRaVbXNo53TGVjmVj3PFcuHlCNRSqPRGlZScWonpVlere20VzG/mJMokVgOuatKvz7up965HRPFunTeXbzRGxOAqj+AemD2rq0ZTtIwQRkEHg17tKtCovdZxTg4vYsLnqTnn0wKUEGQDsfXvUYJLDbyPTPSnnB56Y6H3rQyLiAMoOBWBqWo2tjqMED3EKXM4zFGzYZ8egrT+0Mq7cYI4BrCv9EsNR1W31K7tUkvLb/VStn5PpVLZ3FCLT12NOG6aTqzccEHv9KumVUizzu6VRt4XwFaQk9jjFTqCV9cUW1KaQp/eHbklT1zUioAwYLzmmBNvOevbPSpV4AwTmrJYkJKXA6EHrV8Ekgg5rPIHQ8ewp1vNIi4kAPoRUMxauaJwRng4rNvjlwvr1qTz8hhGu3PPPeq8TNK8ysWVkOG4/lWY4qwNHkAqx+TovTNEDb0xJGUYHoRUgO1ApYc55pyKwIAJPse1BVxHMm3BfK+lV0tYkMrYH7z7xJ61ZCAZ75z09aa8ZETAHkjq3QUkCGxQIsMbI+FXjaO9SKV8woSN5GcCorVWt7ZPOkEjKvzMBjP8AnNWEWN8SgckcUCGKvzszqNucA56ikVWjhwC+0djS/LMDtJ+U9xipQcggdu9AEcaMFQR5/Gkd0KnBzzinKBFMZC+Ax6VTkjKjy4sgbixwOPXNA0S3DYTcoAlGOT6USyj5lWQJIQPmHOKoygzWkuy4Lqx+XnGBxxVKWbbPIQu0qMAMcBvoRTSvqirI28hQBId7EYZsd/WqepRfaoTBFczQSnGJI+GGD059elZkmotZiIOztI3Kr1J9jWpZTpMgkVSkhHzKeoNUlbULWHFmaQR/MucYPrQBvEiTNuA4wQCDUzRI80cjDLICFYdgetIke0spO8H1oC5nPpOnO+77BbZPfyxViC2itYytvDFCe2xMVYbC7QDnB56ZFU9cuBHtdCUZhtJFOMbuyK5mVNS1VLOQqqB3B+bPQVzWu+NDp0G57iNJDnbGgBY/4Uazdw6fptzc3BPlxpkn1OeMV4XqF3czalNJcgukh8wSMp+7/h2r1MJhI1dX0/E0oUnVeux02r+P9VuG3C+kQO3+rj+8oHqTSr428R6RNbvHdG5SRQf34GeT0JFef6lqcNwA8aRpMoEasmcY/HvVL7TLNYBJ5G8xSfLbcOnoa9iOBp2ScVb0PQVGFtj6A0D4gG9M9teRCC9I3YyCGH+yR1qWPf4o1QARK8KDy/nbgk9T+A5r52tdSutOsnuwAsoZfKJHII6kV9B+E9B/tLwXb6vd372DRKboFPdeOvvivOxuFjhlzR66HBiKfJJW2Oq/4V3pKLKyLOuVwpU4Kn1FcB4m1bxP4S19dNsNUW5twyyOJI1JVOykkenpXOJrGrW+nzwHXb57uKUTmESthuOW3n89vSuU8b3up69qEd5cPPOz8MEyfm7dK8VW5rWTv5GT5rXudt47zrmtSapDasIAgVWOeRjqPzNYVnqEulwyT6bKIdo2lBy3t1qz4VvdYuvDsun39yI7SyieRVuOMY5A45JzT9In0V2d9U34uYj5YVSVVj39aqNlJN7bFO9mjGuo7vVrOS7KvJtY7txAG49ayrJpbmQ20brFMeUyM/Xit2R5Le2ezVnSE8upHJPrn0qrPb28DNJAR9qQkwTltpx3wP6VrOUUlbfp/XbuOELv3tj1f4barYaYJ4ba0kEKKn2m9IJDtjggenWvTrC+t72Bbi0mjmiJwrocjNfOGmJNAolSSV7hoiCwP7rb1II6ZNdr8GNWvrma9tHEhstokXaB5cT55XPvWOktY62LlF3szvvHl9LZeFr6SGRhNIywhhxtDHn9K85062jWJRjGOlemeJdPfV/D15aR488gPGuerA5xXmWmXAIwylWBwynqD6V4GcxleMuh1YO12upoNAhXaVBFJbSX1jE0dheTQRk7iqHipg4IoLArzivNhLld4s6pJPcju9Rvr23todQl8/yHZkdgN3I5zinQyDHHOKjit5726S3s42knkICgdB9TXW3vhuDRtPQbnnuXJLSHgDHYCuylRqYj3m9jCU403yrqcdIGeQAnJ71OkS8Ko61BNuiuSSODxVhWyODXPLSTTNVsQXUC7Tn9K7T4e6hJPaXNpM5YwEFM84B7VyFx90E5ye9dJ8ObeUSX90QRGQIwf7xFdeCbVVcpjWS5Xc7ldqksBlm4YjvUyAbeMgGoY0UsJF3KQMEZ4qUYVWOc4HpXvnnMCCeMg885qPyyOQMZ6inJIsgwu7JGfmGMU/k9eMdKpMQ05ychQvY0oQhQcdRQqKPugDjoOaeOApHQ+tMQw7hIcBduOPWn5z90fn0pQe465qSeXy7YNFE0zlgNqkDAJ5PPpTJbsRnqTgA4/Gmv8signGece1K3lK0kpB3KOcflTkwwRgoORkZ6ipbIGjcJPlXcjHqO1OYEsDuOBxj1pQih8KxG08qKZKWUAAHqOM9azYxzglflALDkZp4IyGI57+maAcAtk5oRckDsRQA2NUCny+FPPWlVcSk78hh909qSGRZEJUFcEjkURQKk0kpz5rDB54pAPKh/l54pVZWcqARtPP0oOF7c5phk2yqqjLN1FAD2PzHnjsKjbMZkcyEhsYBHApwYebtPLfSkXJBEmD7UARsxeEMpUMfUUs7uGQLsMZHzE96R43MLIsh3n+L0+lNUlMJu3YHBPf1NMZXkEYQJGoRF529qypFGW3gkBuMd6u3BwhwcMx5z1rLu7qG0CvNIqKzBQWbHJ+tXFDJHCLNISwDLwu3p9KjWV0l27iB1x70qIHLhRtO7r/hUrWzMybCDk5O4dPpWisPcu2dw0koDKcqdpWlsL631a3E9hOk1ssjJ5i5HzKSCPwIIqnHFI8EqFpIWcFQyH5lz3HvV9SYokG4BVXDEgAZ9fxrN2uLUnXdLKQCATyB71ka5JhxCwXdtOQa2VO5A8TRsyj+Bs1z2vxvEYpnK/MCD1q6NnOw29DjviHE8/he8WGUKECt6kjPNeKQy7wPtF2GJ+XBJyg9AK9l8YSyXPh++jQHd5eTjqQMZx+ArwudYGh8+2eRZwc7XHv1zX0OXRtTcX3O3CSvFlLUBHb3Tb1jlV0xFxgL71VnLz6dlY1EMR5c9SKbqs7mYyTkbsbRtGc5rHur5pY32ggYx6AYr2IxbS7nTKSitTf0bTD4l16w0m2mklaV1HI4VRyx/IV72PD8Vvq76LNrH/E7u4gBbbD5GwchcjocCvP8A4H6bH4Yh/wCEo1yKfbOvl2kUaZZ+pJOegr0PwlrA+IOoX813ZR6bqNnGr2l1asS45ICnPXHXivnM1rKpU9nHVRVvmzzqtTnlcw9V8AX3hrR72/1y8F9NcXSLB5HSNMHO7I/DiqvhjTrbUdE1q/1ictFHtt7cxShHMnoPfGK2brQdQM9vB4h1V71NNdpb1hMWEUZwQDkZOfb1rodfm8Gp4Z0/yrNl066nMkf2aMod68MW+leZKPNK738lpoZp2joebJbXVvFeGC4RBbgM0cjDeMdjkcmrMkWmSaXaTJiSdzmZ5Bt8nHp65Nd5408Jw6+LO90RoIVcBJJVA2bSOJCO5FQWtlpFxaC0thBObdRFLIFGWI6kjpzislRaV2zdNHnt3DP9qaxdYmuJOUVcEsPWuK8SQTWeoKkiM9xJ8qQgfMPwr0nxd4g0zw632XRYIJr3cd0nXy93J5/oK4u2v0ttSlvkkln1HbzLJgkE9h7V6uDyy65535ei7/5I0hSdX3nsa3h6a6lElpNYIkaxfOskhAXjp9TXuPgeCwi0iE6VDHHDJ8xVe7DuT3rwWzfUvs7sJ5H8w5cb+eeufU9K9F8N65Z2Ov28FwWfykYttOAkm3nCjA5xV4zCwhF+ySSWuhpVp6abnrxHVgFD9Qa5HxN4QTULhrzTpUtbw8yI3+rc+p9DW9oWrQavp4urVJVjLFCsi4IIq6679wAJyMYx3968ScIVY2lqjmi3FnlR0HxFE21dOaUYzujkUg/Q5qS6sptOWMaoNlw4yturZOPViOlemRQOrrHyMYB44FeW3873+u31xISSZCq+wHAFeNi8JRw0OeK1OulVnOXK2OMtyy/upXhHpEduPxFWtP1q9siIr2WS7syeUkbcye4NNVRimToNpzXnxqTjqmdLgmaGpWUcyCW2cSQuNymsXEkD4ZSfetbw3qyabY6hHc2q3UShTDGf7xPOT2FNfVpbrkWVtApPQLux+JrqqezqRUm9TGLkpNJaFKxtbjVLxLeBGK55OOF9zXrukadDYWMVrAPkQcn1Pc15nZ6xqOnM32IxIG5YGMfNXYeHvFUeoAQTx+RekfKuflf6H+ldWClSp6dTDEKclodBcW0YuEnx+8UFAcnofbpQQSwIHWmSz52edhVBwcetOJUN8gyOmTXrbnGk7AwxKTjdkdSeFp5wT8xBxUF2sptZfs6xPKRhFmJ2k++O1SKpSMZwCOuOn4UwJAO4A59qUHaenNRuXLqU4UdfWnpmVsL6ZpiF+hwaXIzz1ppypIIyfX1oPOcEHntVATMAHZwDu6/KOtNGZEZm3LuBHB5HuKkJ6ECopF2s0wGXxjGeKhmSG26LDiMF2bAyz9Wx6nv9acPldmbB3HinIWKKXwG7gUgblvy4pMY4LtLHeeTmmTEGPblxvPVe1DGQOgUp5WPnJ4OfagHDMBwAMdagB44UKDu46nqaRDnjpUBLi7UfNs2/mamYFhjPfI9qbGP3ZJzx60zcd+8hSuMZ701JJHfLDYF4I65pysDGTsxxSFYzPEF7NYafLdWtpLezrgLDF95snHX070zSLm9lsYH1i3FtqBZlZIzlOvBB+mPxrQY+aXQkq4HJ+veiKPATc+8KMDPvTL6CGUiUHcdmOlMuSxQOQARwDmieInaI0yGPzZoeJfKxIzADnAPT2+lNbiMW73lWYHLH7oIOKz9Tsor9YDcwq6ggqCcjNarySFjkZOcDjoPeo3nttPiM+oTRq4B2xggt+ArVzjBcz0QJN7FqztijYOEyM1q2tnHIpLknB4xXGzeNUiAFnp8ki+srAE/gKxNf8UajcXEE+nzT2UaJh4lYHLep9RXBUx1KOqZsqE5aGr481q/0vV4rHS5I408vzHYgM3J4HNcZqt7qupp5N3eTPBuLeWBgEkYwfangtPcveXEzzXEnDO5yTSyyFvlhQ57nFeLWxVSrJtOyO6lQjGKUtzD23Njk2dzLCw/usRXWeDfHtxcX0ej+IQk0cmViuCPmBx0b1+tYV9DsUtKwX2zWBolu9/4ptliGY423k4yOKWDxVaNdU73Q6tCDV0j1PxDobBXl0/5omHMfp9PavnvxtoeqadfSC3jla1yWyFwyDuK+kbOa4uZGRPlA439cirh0ewlAa9j84n+8Qc19zhsc8NK7Vzz4t0n7rPilzPfFYIEmlut2FCq3H6V6h8MPhPLqbRXviQNHaREmOyXrJ7ufTPavepNE01ZWMFtFGAOiADNYdyl1Y3MkNu3l2ojMjTlvu+1dVbN51YctJcv5lOcp6yJ/EltpEXg+FdT1BdPsYW/dTYHzMP4AO/pivLLea5t9SstY8L2/2u5gmyIFBG4Hq20HJHUE1pP4Kvdbs4ILnXLibTQ7XKcblDscZHvVzTEsvhxAusavby3FzH/o9nFFIBvznJb04rzOVJpR1euhk29XLRGjJ8QZ9dk1K0GmQaY+VSSV2BMq9Ch3DH/1qhf7Zb3tzouoOAGjzBFGiskTEZXYPfkE0nhqXwzrc7apqpuRBeTlvLlZVS3IPQnq3+FaN34jutXur6Sz0u0huLBx5cxwzrF68+3865pRU5Np7G0W4RUbblvQE16W6hN7exw6abXYtk2FmDA/eIxmuM8WX0WlXF1pvhzYrSgtc3MhPy452rj8aNW8TXMs1xqLwhJ5QsUE8Odq8c5z3wK51rtRaMFOxmwRg5yD1JzXq4Ch7Re0krrZfLq/Q2p0L+9I577JKb5LWFIw+d2XOVc9etJY3UkssrtGiypJsPTAwcHHrV3VLW3uZoJCzwMFLMQe46YNULM20UxjggmR17MoOeete5BSk2/Ltt8zqhdPXY3NPa4lu5ILZiHnYPiRgowoJx9aiubq5m1fMymJTmPHTZnoSe571DvnF6srsyyLl3UdV7DHvXS3slzJYFVtoxDG6PMZCN7N7DuKhvllqlqv6/Qq9j1/4bRSweFIFlu1nhcmVH5wqnryfcGsXWvEV5qtyyWUz2tipIQRnazj+8xrV09jp3w/ud6rF5FsUACkDc3pnqPmrk9NX90gH3gMcV8Dm1eUXyw0u2c9OCnUbfQt2F3qFhMJ7e8n3g/dZ9wb6g1XfAu5JNuBKxfpxk9RV1l+UHjHSoniLfw7lzyBwfqK8Z80lytnQopO6Q4OMYNQXc6pGTkACrVvoV9fw+dpM1vcRg4ZZG2SIfQgj9a0NN8GTNKsuu3EYtlIJhhO4tz0JrSGDrTtZadyZVoopLB9k8L200wIuNQuPMQEciNAR+pNFug2+9T+KLg3XiadOkNsBBCo6KoHYUxRgAVdZKM+RdBUW3HmfUVgMcAflVG+UookjJV1+ZWHY1eP3TUFrZSatqUGnxHHmn52/uqOpqFq9C5aLU9D0mY6no9nNKuWkQM2PUVeUknjHHbPNeea5rMtzMLHSZXg0y3HlL5ZwZcdST6VmxRyxN5kM0qSf3g5zXqPGqnana7W5xxoup7y0TPWCWUbjnHfJ6UobJ+bP51w2j+Jp4HW31RjLCTgTH7y/X2rrYZjcEja0cRAZZP71dtGtGqrxMp03Dcu56nkDPHNRymN0Mc6b0bDEdOQcg/nSIwwRySOCfWoyS6b4849ev4VujNq5O8/nSAcgn9KmZdhABYg9T3rzTxR4u1HRdaitYrISQkKWYbstk/wn19q761nadI2cnOOmKbVnYHD3eZbGorrxnHBFNRFCEKMgnPPWlO1nUFQeuD1xUbx44UkZrNnOhGcRsN/3T0AHSkU/MQHB3GlkZVjYvuAHX1PamM3mxQ4XCr/ABDripZSJCQflBUHHc9qGZtoIcDHrVeKLDGSQKZB8ob/AGac+XXy/LypPJJx+tJjJXBZkYMCOuR0NDvtT5iSPUdajVx5SIo2gcACkebALZx9KQWFMkqlFRA69+cFam8xc8PnnHFV1ILeYCCWp2E2nKjb9OlMBZEVAxXKljyetKHGenze461E3zYYYz3x0NSXV7GRAgikJdtuUXO36+1CBk4PAPY8ntTJnAXnp3IpsZZlKvt/DtVTXbA6lpdxYrPLAJ0KedEcOvuKBrcxfFmrHToTb2jBLufqe6L6/jXGJASS8vzyN1Y8k/jRqOnyaTqYsrm4muPLiUJcS/ekXHr+lSK65yeDjgV4mJqSnUafQ9CjBKN0L5YDEj6YNRyxKfQ8dqUzK3XFQzXSLnoK5JSidKQyztI5ryOFQRuOOOoNO1CYWxkjtk3MPl3Y71nvdPHMHgciX+Ej+H3rOnuVi+XLO/oOSaj2yS5YrULa3ZU1TzZDuuJcj+6tY+m61caRqsQgkUB2wy+o962Lyzvp4TIItgxkA9TXE/bYre+ma4iDybSFUjIJ9KjCU6v1iLsKq0oHu954oTStJW7WBJVPI/eKvHc9elZN/wDErSoEXzPPkWUYSVRtUHvz39OK8hu3g1mRL67LRLkReRtOFG35RjPAGKj0zVJGeW0eKK6iWMRpIy7liXPUDt9a/SaGWwcFOTb7rb/hzmhQi1zHqt38QYYrETQwvuflBOw2sB6MOhx2NYOjeKF1DxjPd3k7iwmh2iFmJVeO/bFcHrEES6cgs3ea1jkDTMh/5adtvpgda7bS7C0svBNtrclpCXQHz2kB/epuwBjsScVli8J7NRlDZuxFWk1ZrY9NguLWG2TYbeGAKBHlgi49j3pNd0my17TRa39uk0JIfr09wa+eNa8Sy6o0M+oQ/bHXKQWiHbHCD6Ac8cfWt3wB4n1W31vT7OK886CeQxyWDqW8tQPvg9q1lltWEOe+q/rf/NJBKhpqX9R8LXej6utjHHcXFtcORbeUu4H6jsRmuyg0fS/DOmG61yN1uL2Jokt2csrAdTgcjtXSalcSRaZdvAzKZYWXABP48d8cVwj3tvqFnpsF/EsekQForfEhNwoI+YyE8deg9K8maUZe1RhHbkH6pp8Om6RpTXVn9mSZZWZFYzLnIwcemPyrh9WsI7YgrKWaRj5bx8KQOnXtXfWdnYahpt3plnqN1Nd2zMQIh1jI+YIM9elYUNvFJGqSPJBPb7lUXcJ2H13Dqp6V7mBqpU7rpuvxR20Ki5TmtMEk920V3Krxxvna6DC+uM1cmjhhmmut8lxI5KhyRwe3sKfPAhVri989WYAq0YDbz3bHWtDT9KtNR0Ge5nuMtGxfy/uhB647mu2UknzPbY3k7amRJ5Bs2uLqcPK6BdoOdxz39vet3wqU1a+tLRLGW5mjIbylc5KAgdfxzWMkEkhJZI5I/LVW+Xbx6Ad69p+FVjZ2Fo80NnFAJgAkgbLsMchvTntXBj8SqUOVfF+RjVqW91bnQ+I9MuZfDF7bmPJMQKEc52nOK850qQbAeh/rXsM9/BZxtGZoUd+gkcCvOfGOiHSrtdRsgWsbk87eQj/4GvjcdS9rFThq0Y0KnLJ83UoFyDtAGR1NNclgeTn61CJo5FDZAz3z3okkRVPPSvHcjuNbwXeyQ62bORjsuFOD6EDNehbQpHc5HI6CuA8DadJdao2oOCIYAQpx95jx+leiJHxgd+3evfy/mVL3jirtcyscD4ws2s9ea5APkXQ3Bh03DgiqUciNlQeV616HqFlBfWrWtwu+Jz1HVT2I964m/wDDWpWLsbZBdxHo6ffx7iubGYWXP7Snr3KoVklyyKErhVODU+iTNbaNr2pqcSoq2sTHsXOCRSxeH7+ZPN1F00yzX70s5+Yj0Ve5q3PqWk/2JJotlZXH2NiG+0swDlwc7sVlh6LjLnnokFaoprkjqYViirGoHpV329aqCJ7YcHfF2cDg/wCFSJKrCuNJx+I6009hZ49yccA10/hJ7q6tYj9pZY7cmPZjgiuWuZwE6/hXd+ErGSz0WPeCGkPmMfQntXfgU3U02Oeu0os2UUINgGP8acMrwOOM4xQgOMZJGOvrTlHscdK9tM4GVHt0kkBmQEZBGecH2qeNNhwCcE9KmCkHrjH41IqjIyOe1O4OQuARiFtoJ5p7knhTg00KqE7e/J+tLnLYH3vpUMwQ3ICYl5J6nHWorgFQxLbeM5zwKcFwCrHcvXBp7yCZGjYK6nhgaljK6vuQlgpz/d6GiRgBnAJHSmSyCCLcUYooxiMZI/CmSkID15HHvQWkK0u05JxxyKhil2h/MfKk9x2rPuLjeyow+ctwM9OeK14NMj2AysS56/N0NJjdo7jIrjzNoI2be3enrI2CHxx0+lVrm1e0KsFIQnHPasbxbrx0O1iWJA99PkRK3QY6moqVI0488noVGPNsdDnaoJZUj9Sev406MbY8jDKf4gQR+leQv9svyZL+6mnZjk7m4H0AotpbzSJxc6fM8bDqm4lWHoRXnrM431job/VpWPZozhV2jIPBxUqgE8/iK5bQ/EsOp3sdslpdxs0AmM+z91u7qDW/LcRQQPNOwSNFLMT6V6F01zdDlcWnYZq+j2WrWvlX6k4OUkXhk+hrj5PB1ssjKniCFE7CTbuH61ia7r97rk7bZHhs8/JChxkeprG+xK3ofr2ryq2LpSfw3OunRqJaOx1D+FrXeYm8SWu/0AXJ/WtO18KafaLJJMkl5IqMylzlScdgK4JtNiZeVGfpWp4V1y60TUorSaZn0+ZgpVjnyz2I9KjD4ijKXK4WuaSpzir3uc1ZbTIDdNsUnLHvXRRXmi2kWYow744YjrXoU+jaZcq8dzp9u6knPyck1STwtosHKaZFgdFJJrqhgJQbcXuT7focSt7JqjGOCBsEYHHFZHhvwOI/EF1eX3lToMqseMjLev0r1sQxRDy4IY4kxxsFc7aw/Z9VmBK72GT8wOOPSu6hh4wleTu7EyqOVkeW+PbO68O6ks0VqJre4ZijbcqM9VPoQehrzqHU7y5vLqKOz8tGXYRGu3bivT/HF/c32rXEjXxXS7LbHiL+N/ZR1P8AhXDySQmwbUHD+cp27DwW92r6fA15VI2dPyv59NDahNyWqIP3MEFtYRSeVHdEMec7cnGD716J8R72HTfB1/oMcDqqWyCKQdOGFeeqjwPpWpizF5ZRfPLjg5B4ye2TxTL7xfc6xeTR36PdXNzIscexvkiUnBUL3roqUJ1ZwnHaLu/W/wDwC6keY5+ykih0qZ1gR5MY+0ZwQ3ZRXo/gqeDQNMluLS2xduAhkkxsYnHXvTrH4N6pHO9rd6rZnSc7sop8z6gHjPGOtegxaPoOoeXcW6nOnR+W8JGA23j5h3PHWuHNcRCtFRpSum7vf5Iwq1LpJOxe0lZxoqy3U6SzOfM+TGEOegFcf478NWNtAtxDcPHNMzSHzFzGcD7pI6e1a1p4gl1GZrV9Oa0dUGR1GO3PrWtqdja6/pgsrsyLhgwZexFeRGmpRtM5nzLWHU8g+Hlve6t4hhs7ZvLypYyKCPKAGc5Fe86zHckELaJc2nkMZpCN0hI6KF75571m6PaDQ7ZYbOKLaowXxgsPf1rutN0ua6tVluGMZcZ2g00o03zImTaVmeD/ABD0f7Ha2Fzpi3dvDdKS0b8pDxkA9wfaqvg3wlcXF1ZvqIle3niMqOOU4OMNn1r2LXtI8m78m4LywsByUwoz2BNVIllEipGqeXkY7YAHauz67VUOSL079TopVp8u+hHp2hWGk2hEiqLaI73aTB/HNYWp+J3nLwaFbi3h6Gdh8ze4HarPxIvHcadp8bMsUgMkg6ZweAaybGEJDjb+NfMZlmFRT9lB69TejSUrykU0sGmJedmkkbks5ya2dA1u60GdAWebTycSQPyAPVR2NCgHA6VFdICjCvKhOcHzX1N5Qi1ax6BLoui6rCkyWkYWVdyyQjbnP071zs/hWwt7t0i1OH5cbo7iQBlqDTddn0jwvbxQqHnkkdYiT9xB3rnvs5mlkmmO+VzuZj1JNenXxVHlV43kzmhSnzNJ6Hp+hW9va2K21vcQzKCTmNwcVpknBEZG7sTXj6QPBIJbV2hlTkMhxXo/hbVm1WwDzKFuYztlI4HsfxrowuMjV9y1jOrScfeZtAdCcZxzik2jnc21epPtTsjHrniq+psU027YcFYWIP4V37HO3ZXPPdYvp9X1MzSt+5XKxoeir2xUaRhRkd+KhteSMk5q3/DxzXkzk5ybZ2QioxsiAIVzsJGB26fjTVitJXCTs9uzHAljG5fxFW1dBAUxhz/EO4qldICoVeSRik0h3aOm0vwnbW04nupnuivKrtAX64rctJpZL2ZssIEG3af6VH4fEsei2a3ORIqdD6Z4q5aqu5gpbaWJ5PevToqEIe6rNmE5O7TLSMxB2gAe9PVj3XP0oX5QOOnHFPJOMLng1rZ9zBjsZGRTu4wODSL6elOB4B5A9Ka2uQyPeHyBw2eQaC2eGBJ56UIQcnjf+tJlyDjk57Ck0QgUtsBIAkqPhM7QN2efenKzbiHXAA6k/wBaaM7CHwX/AKVNiiHeDJszgnjk4qqyb5Y4/MCIzY9zUpTdI0rKc5wKZtV498ilBGCSc5OAKPNlryNG506ziiWQIodDkMafHFAgkkIJ3DcT1/KvMtb8XarqCva2xSK36btvzEfWq1h4j1uyiCxuku3hfNyQorheOpXaZaw82rnb+P76Oy8G3ElvKUklwsXOGySK8qklvLtYJLyV5xACFZm3EKfetK/lvdakV9Wm84jO1B8qr9BTYUW0aMJGrIvGx+VYdwfrXnYiq687LRHVRpezV3uLbzLtHT6VHeyL5Zz0rcn8GySIs+k3arDKAwhn/g9s96LfwZKp8/W7yJLNDlxGe3uah4Ku9GtO5r7eNrm38P45YPDcZlDfvZGcD/Z7cVT8a3GpDR7mO6hhitGuESJo3yzL1O705qO58YRQBY9GsRLFGNqvIdq4HHAqAeJoNUgl0/xFaCC2n48+Ak+WexxXpTrUnD2MZanLySvztaGJAi4GOlTCMA9qbqun3OhuhnZbiyk5hu4+Uce/oaotqcKjlxXiyjKn7skd0Zxkrpl9sKCKyZ42ur+3ggyZHkULj61PFLc3z+XZQSSueBtHH512HhPw4dNlF5fFWvmHyKORGP8AGtsPhp1qidrJE1KiUbHWLktwCcdeadIVX6dKWP5Y/n//AFVNZWou9zsSEB6A96+k2PNbS1Z5P8SPFVzFqMujaXK8CRAfaJUOGZiM7QewA615qb+/srsXdtcSecuQCWySD1ruvihojaT4wml377e/AnTPVSMKwP6fnWNf6Bb3lqstldrBcdGik+43uD2r5zE1cQsQ2pWsd1GMJQuY2teJbXWYdKsvskVnMWk891GEaTHGceoHWuabxjbwF7SOzSW2Zv3kkgyxPt7D0qx4i0S8tEIuYhtI+/G24H8q4pNCu/tCbF+0ZcfKW2kivr8jzjDVoqjiNH010uXrDQ9GFylvALO3kkdrpeEP90DJLegpml+GpXukmsbmG1uDOFjif5QrepJ6E9q1vC/hzV9Lvbi6m0aW8kVF8sSghFBI4HHOBXX+KbmU3cV1pt0kJZl8yN0XYjD+M5+nWuvF4tNclP5vuYVqyl7sTtdPS4FrbxX8kbXKriR0Hylu9ZeqA6D9quIIWm+1KCY2wIo8dST71yWq/FjQNL0srqF4L/UV48ux/i92boPwrxnx14+1vxgfLuZDY6UPuWsJxkf7R71GGwFWulpyx7v9Ec97u0dWejWvjPw1pN1N9p1DzpnfLeQhdU9s11mh+OvDOp3K2lvqCCdz8iSqYw3sCRivnHT9OUpFIihohySG/n6VrpZrPEzxAROg67eGPqD616f9l0Ercz9dP8jshTdtT6J8Z66ukxR2tuoNxKueOdo9aseHfiBp09jZQ+Khei5s2LRyxM2yb03BSM49DxXjGl3tzO9ol9O8zhNilhyAO309K7bTLZJMRsBtfke1fC5licTgsU6b2CWFjNWkegah8RdM1W4WCS3uIbRWyJWH3vQ47VraXCskZubedJ4JD8jg9v6V5y+nADaVXp0rQ8HXcmk6ykOSbOc7ZEJ4X0b2xUYbMqjnyVFoyXh1CPum38RtMmmt7LU4Y9wtgY5to5Ck8H8K5y0mR4cK5Vj/ABLjivWgEJaLaXiK891bNc3f+B9PuZTJZSy2TE8ogDJ+XatcbgXVl7SnuTRrqC5XscsJVwMAcVE7B5OGGzHI71tWvg2ed5Q17NCkbbQXi+/7jnpVqbwvBpllNN573EijncAAPwrijgqz3Ru68Tls75efuoMAelWEXgknFVLpXiZ2jwWPTdUnnZAPAJ64rjmuWTubJ6FhTnco9M0/QNVGneI4IwZD5+Eddp2kE4HPrmqkLGZ3WLlxjAHeuo8L+G2ivYtS1T/WA/uYQOh7E11YanOpJOBlVkktTs3Xdkbyp46U4okyvG4ykgKt9DxUkMDSybAdnGTkd6y9Q1Ow0uYrf3cEcqjBAOT+Qr6BtJanm3T0PPJonsdQmtZMho2KnPp2q0pH51s36ReJb51sHsZjszFOkpSVMDoyn7wJ49q5iZL20nMM9rOkg7bCR+debVp2blHVHVTndKL3LrMPxpunw/btWghUnLMD9cVkS3p3ldrEg4IBp6XdxnFoWtyerqfmP49q5XXjB6myg3qjqvGmvzabqC2VvCkjqqSSbmICnqBx+tbeg61BrMBeG3lglCqZAyEJk/3G79K858ksS8rF3PVmJJP410fw9unWa+s8nYAJEHoe9dFHHSqVrW02RnOhyw1ep3sfTBJx/KplOep56jHeoI+npjipgCp2vnjjNeucbJev4USKDj1zkEUicAdCTUmDng/lQtCGRqSTnB4PFROXMgxkA9QKecu4ZW/dgEEUpIK88n86ZCEYllK44z+NRPhXCrGcbeXpzcM5Q5LH5s+lNLN8wI/dY+WpGhHXKnacHHcVRvfMOn3HBeTYw471ZPmGUneBF7dTU1tZm5t3EjlQfl+U4P51M1eLRSfK7s8lghdbXz2hcQ7tpkKnaD6E+tW0iBAJ4FW7i5udObUtGAH2V5d22QZI9wfeoFwApBA+vevCqQhF2R6FNya1GhAO36VDOAOvWrLFVXnjFVH3TyKkYLOxwAO5rO2tkW3od5oT/adFsjIPmwcjtjOK5XxlqD3t9/ZsZP2W3/1mD99vQ/Suy0y3+x6ZbxSHHkx5bHY9TXmNpKbmeacjmWRn/Xiu/HzlGmoLqc9GKcizHEEUcfgKWaFWU8c1N34FL05ryeVWO4seE9WbSrmSzvh5ulzKW8phuCsBngH1qmPEk7M7Wuj6NDESSubUMwHuapJALYqgkkkwSS8hyeabbAFVFaPE1FFRizH2EG7s2U8bahGoWfT7Ro+/lAocV0vh/XLLWARbM0dyoy0MmA2PUeorh5I1Ynue9Z3mS6Xfw3ludskTA5A6juK2w+YVITUZ7CqUFy3ieyxsrJnIz29RVO78QWvhu3aS9Yskh/dxJ99z7CiW9trexe/kAS2EYmJ9QRxXlc9xPrGoy396SXc/Ip6IvZRXo4zFqhC8d2c0KPtHysl8Z67J4kvUu2tBFFHH5aIWycZzyfWq1to9pParcNcFoducE4ZfY1aMQA4QEHsah002VtqkcWo25lspm8uWNnIXn3+teLTqOpV/edTs9mqcLROY8Q2KrOLaz3lFUPIWP3iemPbFZ/hL7LbeNdJOqqpsxLzu6Z7frXZeJrJNM8XXtjHGEg+UwgMThCBjBPWuX17SstuA9wRWTf1bEc76f1cdva09Op9VRLGyKy4dWGQeoIr52/a6NlbabottabIr28mYypGdpkiUD7wHbcazND8U+J7OOGyi1eVLRSOv3gPTNeceIr2/8U+KLjUdbaW7umO1I+cRxjgKB29fxr7bIa1PFVvaJ6RV/wDL/M836lUlJJ7HL6bpAZBJtCRgc7h3q6dNR3WNjtLrlRjn8a6W3hilt5gI5leOMFdq8Y7ZpLSPyMb2Vz0VT/rAce9fV+0er6noxhGKskU/DMW9HtCqo3O7cOwq3YSRNazQW7gi2Yksere/NINOmMryIJUM/wBxhk7T3J9qhttPni81fMD4cZYDjPQGnOUZp69i1HU3NICnUbJIgq4YuSVxldvY9+9eg6ajRwxMMA5AGazvh/4Pn1qyvr5C6LChS1Z+BK/8X07itFXa2bybpGilU4KuMYr4DiX38VGSWiVn6j51fludBqEKxmAxsr7gdzKayNQUbCR1xir019HJBCEPyqOnXnvUNpay6vdJaWqF2cjew6IvqTXjyipySiZ3smel+GSx8P6d5u4v5KgitfYMZORUNrALa3hSPaI0UID3GPWrBcYH5elfQQTjFJnnSd27ERUgDcMmqWr2jS6dJtjLb8fd6n61Ld3MFpbSTXU8cEK9XkOM1zMvj2zgzHZW11cr/ebCD8KmpVhTXvuw4qTfumBqVjJCx82NlJ7EVAPDOovAJjCVibpzz+Vb8fi/Sb6ZF1G1ntmB4kYBlH1xXVq0UyI8TK8TD5XU5BHtXDDC0azunc6XVlFbHL+EvDjWDPcXHzTFhgYzgV2W4BlU9hkfXNRqEVm4G48HFSfem2g/I3TJ5+tehTpxpR5YnNUk5u7OY8Z63cacEt7KQrc3Ck+bnmMd8e9cNDbM80hk2kHkOxyzHvmrWq6guqa7czJ/qUby4wOPlXjP405QpAKg5B4rw8dVdWq4p6L8zuw1NRgpdWZt1a7GEsZaOZeVdDgg+xrq9P8AGN5N4G1aeX59SsAsO/HBDnAc/nWHONy846VT0CNp5vEOlqebuwaRR6uh3CowlV06qV9P+CLE01KDZn2K5UFjk+/etWIAkAYHrWNZzgRjP1qw98icDJY9ABXnK/O+be513SSsaE8gjzuYYHeuk+HNlI0V7fOrASsEjPsOprF0Pwzfauwnvla2sgc4P33/AAra8caHb3Gn6dBFr1zoa2kwkEVqTmVeOCBzn0Ne5l2FvP2lV8qOOvVsrLdnbDOQpwPWpowOPTrx3rjpfFygiOytS0Y4Dzt8zAd8CtLRvEcV5L5F2gt5z905+VvavRjiKbdrnK6crXsdGyblU5I96epC9T34xUKHAw3QevapRgqQzcAg8CugwZEdqj5RjHp3prDBzyAR0pFcNI8Yb51AJHpnpTZFkfcpIVj0J5oehKEYHezDBHYE1R1PVLXTYg94+GPSNeWP4VJqN0tnZT3UgBEQyB2JPSvPt73lw9xeMWkfkn0+lceJxHsvdjub0qXPublx4xTaRBZumOQzkH8xXQaTrMF/A72Mh2j/AFkZHzJ+HpXl2r6xp2lT2NtfSmOW+l8m3UKTvb/JFXdLu20rW7adPulwjr2ZTxXFQxk3O09mbVKMUtOh2niDRxqsKXVocXajHzcCQeh964p5zCxinQxyL1RxgivVAuHb+7ngVS1iLThaTXepW0MyQruJZRn6ZrpxGFU/fTsRTquOjOFtNM1HUUE8MSx2x6zztsT8z1ra0Ky0rTrzzbjVrOa5UYQLJ8q575rldSvbvW7jzrxtkC8RW6khIx9KiNkmPujH0rzY4mnSleEb2Oj2U5rV2PUZwt3Y3EcDK3mRsqupyMkeoryfTHCL5TjbLH8rqeoIq7pWp3eg3Ylhctbn/WRHow+nrXW+IPD9rrnl39hKttdOgZZMfLKP9r3966Kv+2x54broTC9GVmc0pHAH86GbaDlSAOhqG4sNVsWKXFq5x/HFllP4063sdV1AhIbWRAf45QVUe9cPs6l+Xl1OjnW4lpE97emKFSxVC7YHQAVVsSrRBlzk+1d7oWkRaTbSwh99zMCJJsY+gHtXnqB7C6ls7gFJImIwe4zwa1xGG9jCLe5NOpzMukDJ4rM1YgQsDyT0q5LcIqk5qfwxph1vVkllU/YYDudsffI6AfjXJTputUUYmk5KKZu+Llkt/AenWzMcloo3z9M4rm7aMCMED8K7zxZAuo6NJaRyxC5DCVEJxkg9PauGhc5CSKUcdVPWu7Hw/eJ9LGOHasyU44yOO1ZOtQbo3ZSeeRWuvIPpVO7VvIcOQT2wK8+Wlmuh0b6HT69paeLfDWmahb7E1SCHCkfxjup/EZrhAxMbQXkbJKhKkMMEGvTPhu2PD0O5RlZHAJHQZrT1XSbLViwurdWl7Ogw3517NbBfWYKcdzihV9m+XoeFS2sm7FvGSWOB71n+I/CuoaLerfOrx21yPkkHG18chj2yele46R4UtNLuxJNMJrtc7Yyy4X0465rXvLFL2B7a+t1ljk4ZHGQ1dOTUXgJuo3e+jRq8QnsfMssMjwuxZow2Cdwwd3Sn2unLewmQzMHUDDk5/E113ibQ9Mt9Vns9IlmkiRtr+cgdVYHOFOeg6VANKhIHLlsY4jAA/Wvop53g4aOdn6GsWpK6OO05b6z1qaWOVNoBXLMSpH0/Gun8JeDtU8TXJnmRYdNz887IVZx/sDvwOvSr1tpEULhxD5pB3DzzvAPrjgV2en+MtRshGt5bQT2w4/drsYD2xXFW4joSly0t9r2Co3FXijq4J9K0O0sLBLiKzjfCW8TMFLfQVpT2cF1gXdpb3AB/5aKCQK5LVfCmmeL9X0vxB9snMUIAES45KnOCe3PWu8j+9hgMnnFcranruee29W9yjc6Lpt0iRy2EDKn3QFxj6YqzaWNvZoY7W2jhjB6IMZ+tWwmCzICT6Zp0qylB5OxZMj7+SMd+nepUYp6Izc33IR5y3TKsaeVxlu9LIEA6kKvJPYY6mrJ49xisvXFddFv2izv8lwAPpTbJTPM9d1OTX9RaUki0jJEMfYD1PuaiEKhfugn1qGwUeSu0cYHQVbyc/N0r5ipN1ZuUj16cFCKSKlzApQkrn6Vs/Dy+lS/m0pyTAymSME/dI6gfWs91GMgHBqgSsP2pvm3SxGFWRtrISQdwP4VWHl7KqneyCpHmRPL8V2/4TgaQtgqWAl8hpnJEmfUDpjNei6L4j0nVNQ+zWd4rTLxtYEE46kE9a8iuNPjvb03EltCJicl1XLE+pJqVA2mXlvdW4xJC4fj07j8q76maKVS0I2RyxwrULSd2WxA+naxeWcwIeGVh9QTkGtOEALwfzrpvFmiDXIoNR04Kt75Y+UnHmr259R2rh3uJbSRobyKSCVTgrIuDXLi6EoVHUirp6/eb0ai5VCW6NGVhtOT+lL4JiMniqaZcgLbupI7Z4rNSeW9kENnG00jHACiu+8LaH/ZFm/n4N3LgyEc7fQCnhKEqlRO2g6s0ou5zkngIy3UhN4Y7Un5dq5f8e1dPpHh7T9KiHkwLLOuP3sgyx962gDtJwcdTnp+FO2DG8gY9D3r3Fh6Sk521ON1XayMvXNR/svTjcfenf5IVY9/X6CuCiWS5lae5dpJX5LE5JNb/AI/y9xp2D+78tiPrnmsiNlRFOM/SuDHVG5qmtjahFWc2SJGgYcDcPzp0yIygLkN/I1TWbM4+YBD71d3DYSCCOxz1rnUbI1vc6/w1qpvbVYZ5R9qj+Q55Lj1/KugVwEBz9c15v4QLyavJ5J6IckV6HFnygGI/CvXw03KHocNaKTv3AswUEcsfUU3B6dRT+ByMH+howQeRzXQcyOX8X3K3GgStC2Y451jkwO4NcsrqQBXoV3YwXFrcW0yZin4YA9PQ1xVx4T1aKQpaPBPCOjvJtIHvXlYyjNz5oq520ZxSszndW06y1C+027ul3TadI0sPpuIxk/TrVzS7KXWNXt4oQTGjB5HHRQDn9elaDadpFg3/ABOL9r65HP2az+6D6Fqjn1m7yo0qKLTIFGFSDqR/tHvXDGlGlJSqvbojRzc01BHpSY3HA+X071zXxDZ10DIY7HlVXGeMVQ8K+I7qS/Sw1WQSJLxHMQAVb0J9K0NY1TR9ctptHW9VZ5DhJHXCBx0+avUqVY1qL5XucyThP3jjoMbTVgAVSlS40+6ex1GIw3EfUHow9Qe4qdLhWGR0rwLcujPSTTV0R3igocjius8HStL4dtw/PlsyDnqM5FcVezbsIg3O5wAOpNeh6Lp7abpdtbSgh1GXCjua9HK4tzlLoYYhrQ1tNnWCQvJGzpjHA6Uwlmc7SQpJOM9B6VFGcHjIz1xUwHI4JB4Ir2jjtZ3GvGAASVAA5qnqmj2eq4+3QbnUfLIvDY+taYBZdrDII5p3J25IJ7VE4qatJXBSa2OVi8G6Skm9vtM6g/ckbg/lXQlIrGxb7PDHEkYwioMAVbVQPWq+qY+zBAfvN2rLkhTi+RWHzuTsznPs+5tz5LtyT61VvLJJV/eLn0I6itry+OlQunNcMoX3OmMrbHIXcD2r/NynY/41SvXAhb6V1eo2ySRlWHXisI+HrmWMvJPBHAODJI+0frXFPDuUrRNlOyOu8IW5t/DdkhXDuC5B9zVDx54gl0i0istPOL+5BIfvCnr9T2rpLRoJYEFpcRTRRqAPLYHbgV5t44Vn8bXRf7oijC59Mf416uKqOhh/c3OWEVUnZ7HNx6e7OZWlkMp5Lljkn610ejeK9U0a4jNw731kOHjlOWA9VPrUUaYjBUA0y6jUoflrwIVq1P3uZs7ZUoSVrDdVtY7bUTNCxewvWM1tPjhgeSp9GByMVNFAvBxxVnws8mo6JrPholfNI+12e4fxKQWX9P1NVdPlDptbIZTggjpW9WlF2qraRFKb1g+hZ8naDkcVHLbeYre1WDJjIY/TFNkZiudp5/WpcFY0uafw+uGttTubAn91LH5ij0Yda9DjI6Ht0Ned+Coj/a9zeuNkFtCdzHpz/wDWFd1YXcN5DHPaSLNBKuUkXoRXuYG/sVc8+vbm0NBSCuV785p6jgAk59fSmDGBgjjuKa0qhyCf8K6jmtckPTHp61XlVXLBsFT8rDHUGns4Zc7sL6d6i35HUZBOdvNNLoUkeS61p03h/UTDKCbZmJglHQj0PuKhN0mOvFd74p13T9OiNpe24v5XGfsxAwvoSe1cUuoaIzbn8N4Oc4S6bA/DFeHisPCNTSVrnfRqycbWuV4LmS5Jit1Z1XLMQMhR6k1HsSZ8o3CjA/xrq/7b0m58OX9no1sbG8kiwIGUDcM84YdTjNcnZgoGDAg/SsK9GNOKs73Nac3Nu6sWgg2hRxVDVcLE6tjI4471pQ+Xv/ekgY7VVjs21bWILGAHaTmRj2UdayUL2SLkz0LQ4s6FpzygiQQgE+o7CrGr3dha2wl1jyBFnCiRQxP0HerICRn5crDEuQMcYAryS/u59Z1OS6uSX3sdi9kXsBXuV66wtFcyuzijF1Z2j6nbReN9CsxJHbWE4icY3Rwqv49a29L1Wy1Rd1hOrsB80Z+Vx+FeaLCi8EZHvVeVZbWVbi0kaKdDlHXqK8+lmklL3o6G0sMt0z2ZT8u0An1qFtZtbi+fTIklFzAFdy6EIQewbuayvDGrprWmJdMFS6X5JkB4DDv+NaV/dx2VtNdTj5YkLY/vHsBXtwnGceZHFKNnr0KmuaMNW08Ro4imiO+J36D2J9K42fw/rsduzLYLPGP4oJVf/wCvWXf6pfatKz3Vw4jPSIMQo9sVDarcWsivayyxOpyCjEY/pXkYjFUKk7WvbqdcKVVLe1zIvRqUGt29rJC7LOSpwM+U2OAT710kNvqBRYDY3HmYxjyzVC8nu3n83y087dv35PJ9SK73wnr11qWiyy3JjjmtXAmY8KV65FdMo4aq4xpt3t+IS/dxv94vgvRpNMhlF2uLiU565wPSupUA4249eCDXlOsa5daxqbiGR4bYn5UUkcDuaWKOVJFaGWSNwchkcgireLp0H7OOpn7KdVcz0PVcck9CecU5yzAbuPSm/wAXHPalbkZJ6dq9BnERkDYf8K43xtfytPHpsLbEC75Sp+9noK7VUBHP3sgYFeZ6s7N4h1DzDlhJgZ7DHFcOOm4wSXU6KEU3qVILdUXAAFS42jAGOalA4pkjAL16147SR3oqsAs2cHgH8OKrCzQxKMYyKtMSeO7HvU68dunSs2uw0SJrMb2kdl4itnvrZBhJ1OJoh7N3Hsas23hS21WAT6PrZktwcFZI/nQ+jCsydFKnP8qteB5pLXxOsUWfLnRg6DvgEg/hXRRqRqTUKyv5mE6bguaD+RHfi08O3httNP2zU1H7y5mAKxeyr6/WqZ1TWPNEjahcFuvzHj8qqWzGe4mnclnkkZmJ69a0Fj34A69qwlWnzNU3ZI0jTi1eWrOm8L+IDqb/AGO+CreKMowGBIO+feumjYcEj/61eULI9jqVvcLkPG4PH1r0y9vrO0YNdXMMAYAgM3IH0r2cHiPaU/f3Ry1YcrsjR3KMFWGT1BNOB7/yrHg1nTJpFWK+ty/QAtt/nWiWaPIfgjovr7iurmT2MrFtSfb6VT1Bt0irzhRSmbjnjI7VSnk81yXzkVz1JdBxjrcbc/Igb5jzjAqFzjqDmnh8bvmJySeRUMrgKc/lWMmbJFK+lWNSXYBQMkmuSvJ31CQtJzBn5UPT6/Wr3iGSd3CsCtvn73941TjA28DivMxE5X5UdVOK3Znxtc6Xcrd2EhjlQ54PB9j611vi60Ou6JY+INPQmVI8zRgcsvfH0Oa5u8I8og4rs/CN/Dpfgi2ub9iId7hF6l+egrXAv2qlSm9DKulBqSONs51kjUqcjGc1IXVlIB/GppIUubmW50yERK5LfZs4K/T1+lQjeQwe2lB90NYOla6TubqV9Q0FpIvFmmTW/wDrDJsxnqCMGu18TeERPc/arZltbmTrjlHPqR2Nc/4Y0q4bUY76OJsQuD83BH4V3t3cSi+s4LsufPcpESMAHGeT716mAw/NRcZo5K07TTR51f2dxpU32e4eBrsgHCvnAPtUS23mIWlmUYHY5NVNQmkuvEeoTTk+Z57Jg9gvAH6VZUZHH6V5tWUVUcYrRHTTu4psjXUrzTpg9i+yIcPEeVkHow716ToF5b3ek2s9nCtvAy/LGuAFPcfnXmd8pjU5xx6d6634c+YdDZWRtnnExsfunPBFdeXVpe0cHsY4iCtdHU3d5b2Fo1xdzLDCDyW/iPoB3Ncxe+N4+f7Ps2lJ6NP8o+uBXO+LL59S8QTRlj9ntW8qNe2R1P51XjhG3oOKvE46Sm6dNbE0sOpLmkaZ8Y60WMmy02D+DyuPzzmun8MeI7bWEKzRG3u42BeJRkPnuMdq4hkDJjAFP8Jz/YvGmnHOFlYxEeuRx+orGji6qmlJ3TLqUIqN4mb5z3+o3FzcHdJLIzHP16VZi8t1DR4IzjgdKqXDwxa3frasXgFw5Q4IyNx7enWr7tHwY1Cj26Vx1o/vp829zek17ONuxC8WyQOowQc5FSxlHsJZGOJUPzH19Kr3NxtXgEn1rf8ABOlW2p2E1xexF9s21Bk4YAc59avDU3UnyIJy5Vc5M3cs8qxWsTyzscBFGa9L8KaB/ZVl51yN2oTDMh/u/wCyK17W0t7Vf9EtYYecHbGAatonysGYk98H/OK9fDYFUnzS1Zx1K/MrIx/EkwtNA1GWQ7MQkA+54FeWacpS3V9p29MivZ2SOTKMu4AAHeOMfj1rjfE3hBLt2l0K9trST7z28j/umPqMdDRj8NKvFOPQKNVU22+pzRkTBRuCe/pTZ4laLCtk4zyain8O+JrckmwS7x1NrOrn8sg1l373+nj/AImFld2b9vOjKgj69K8KVKrHeJ2qpF9TsPhnOwvNStcYBCv9DWz8RZpovDKNDkp5w8045A7frWL8HrKS/wD7T1Fm8uHKxI+M7j3xXfy2yiWS2ukjmiIG4EDBX6V7mCTdCz/rQ4azi5266Hjdlcqow68+9aUMofGzH0rz6406+XxrczQ3KyWCzNskDHlOw212kMhCjaOfavEqw+rVnRUuax3UpOrBTatc1dVu7Zoo0gi/enjgVee3m07wi8FyjQyXlyCfQqo6VB4MsTe600s8e5YF3BSM8+tanxEYxx6dG2QCXYc/QV6mHi+R1uy/Q56zV1B9Wvz/AOAc5aQIgGMn3FXFb5gKgt2Ux5BI47U9XVPmYgjPeuGL0udDPUQCG2sMc96evAAHWuF8P69JaXK2d/I8to7bUZjkxnP8q7npuDdQa+kp1Y1Y80Tx5RcXZgTg5zj6VxHjHSLhL9tStFMsMuBKo6qR3rtJZkijLyMqIByzHAFcF4t1z+0ZfsNkc2i8ySD+M1zY7kUPeNqF+bQyQ8m3JRgB3NWdK0271e7WKAxIg+8zOAQPYdzWf5ZCANn86ZJC6rIyFkJHBU4IPbFeLBx5rzWh2yUre7uT3I8jUbq3KkGF/Lwfapd3QjAq3bWLeJYJ7h7qK31O2RQ0jjaJVxjL+p96yCHikaOSWByDjdE24H6U6tOUHdbMITT06k9xJtH+FaPgaGI6wL67lSGFSYoi52iR2GMCskLEzAzO+wZOFGCTUc15cm0WHcPLRtwQjhD6j3ow7hTnz1AqJyjZFaWJ9O1i/sZdwkilI2sMcHkH9a07aULHvH3u1bkum2nijSLO7nkePUY18o3CjJOOm71rH1Dw7JpWnyXl1qCSRIQFRVILE9quphKkG5x2JhUVkmQMyy/vnwXU/KMdTUTQec5kmO+Rjyx5pLTa2C2PYelXHwrfLyK5bto2SRSltEYN79K2/DHiCa0uF07UG820lIVHfkwt2wfSs4sDnNZ10DNNFHDkyO4ChfXNXQqypTXK9CakFOOp6oyO6uDz6GkksiIVkWYFj/CBWRqviuy026aCNJLqUAB9hwqnHr61HLrkOoeGtVutN81Lm3hJeNvvLnuMfjXtylTlez1OLVakUmp2qP5c915UgYqVA3Y98io5dSgWXakiMit949WrkbBVeEHqSM5Pc1eeGCVB9oVgwGAy9fxryli7u6R1qjpudJ4t1C1uNBiitGtwzMGZVI3cVxkFxPGJBMVwT8m3096sSWRVd9vL5ik4wRgioWtJACzOPUjOazxdZVWmlYunT5ERlZ9QmjtLQF55m2rjt71u+IAsd5BpMTf6Np8YiA9W6s3503wLqVvp2tpBcwJm6OxZyOUPYfQ9KTxJA9t4uvxKCBIwkQnuCP8AGtadNQw/NF6sylLmqpPoRxoc4XipjPOoIEz4+tRosmPlBzSzL5ajPB7ipUbI0L3hG9li8Q+SXJinUhh6Ecg16YI1uIF80Kw6g+h9a808EWwu9WubpwfKgTaD/tGvQIRwVWTYFGSDxXsYG/stThxC97Q8u8W240zxVOVH7m4/epnpnuKiEqFMqcV6DrukWetWfkXqkEHMckfDRn2rhNZ0CLQWjSfUzO0mSkSx4fHqecAV5+Mwk4zdSOzOmjVVlFlG4/0ptgbC/wAT+ldVpPifTbG3g06zgaFUwkcs5+UknktjpXMLHvQZAVeoUdBUNzah42ye3euWhiHQfMlc1qU+c0vGFlJpfiSeR1P2e7bzY3HTJ6j86giuFZcZHHOK6Dwlcx69oNxpmrp9o+zEBWbltvY59RVS78DSxuDpmoAxnos4wR+I611VcLKp++papmdOpyLkkZUs8arkYFSeE7R9T8SQzqD9ntSZGf8A2uwrTg8DyswOpaku3usI6/ia7HTLC20+zS2s4RFCDnI6sfU+tVh8DUc1KpokFSsraHM+OtAe9canpiF5412zRL1kXsR7iuGivwhZZMqR1VuCK9sCANuXOD6cYqlfaVZ3p3zWkBfvI0YLV04nAKrLni7MypV+RWex5Lp1rd63dpbWUblCfmkx8qjuc163o2mxaZp8NpCd0cY5YjBapbW0gtwfssUcaNjPljaDxVyIMmRkBSOMd60wuDVDV7k1a3Poh3QcnHHGKztXvo9NtfMXyxLIwwjcF/X9KuTyrDA80n3IwWOfQCvKde1STUbp7jzCsf8ACK621FXZz9bFnxJ4uu7t5fIXybZT+7iHf3J71xFz42wTEdRjJ6FYuW/Sua+IWsXsCm10+fZJjdLLngD0HvXlESPCROtwFwedjYJNergcpeKp+1qSsnsl/WhUYNbrQ9jHjeCO68nzbhMEYlzgfnmur07xXfmMJHqU1wiklkd94HsVbNfOzXSy3ZkdiFBBG4dfrXT6HqzR3ct/Ex87gCIDgj6eldWKyGKhek3e3XXU2jCMvh3Pqrwn4qjFpbWTxQQyuDx5e1C34d66OaYiYyzEM7YB4/SvFor0zaXb3luzRhlDqp4Ib0r3jQJrW70S1u4jG8ckYZnOOuOc187F8nutGFSSg22tTyDxB4F1G1e7v9IH2uyD7hEgJlUHrgdwKxLDJj4JDdwwwR7Yr3zR5rOWGT7BfR3iIxDusiuVOehxXjvjW6tn8YXzWgXyyygNH0Y4GT+deTmODglKvHdb+Z0YTEc0lT6F3QL6503dcWjKzldrpIMgit/7To3ido4dRzBeRqVWNnxnPOVPf6VxsErRnk5U1U1FfMbcoO7sw4xXLRxbpxs9UdVSjzO63Ok1PwrqFk5OnOLuE9Fb5XH+NZTxXcBUXtq8APA80Y3c12PgvVZdS0EPeuPNtn8p3dsA+h+tcx4yuZL3xNIoYPDDtRNrbh0B4rrrUKTpe2hp5GKqSU1TZHqMa4c45Df1r1SMnCc/wA/oKKK6sB8MvU5sR8SOW+I3GjwKCQrzgMAeork4YkGAF4FFFcmN1rG9D4SfYuRx29aXYvljjqfWiiuayNUynMoXcFyAxAYA9RUqQRpEQqADNFFLdDFaNCnK9qiWCMwuSvb1ooqLahc6fwaAmiy7eMSVD4+UHw/b5HWdM0UV7c/91+Ry/aOYiRVC4GOPWrQUZX6etFFeBHY7UyO4UAkD+dW/C0SeZqN1tBngt2aJzzsPqKKK6MKl7QzrN8plQxI0YLDJPJJPU1u+ClA1xYAP3NxDKkqdnXHQ0UVND+L946v8MwNIRRDgDgEgc9ga1PLUqMiiis5JczNIv3UHloOg6+9II0x0oopDRTs4Y212wyv/AC8J3967b4nxJ/a2lvtG4xyAn1GRRRXfhkvq0jiqv99Ex4UUQqQOeeaydV4RiCc+uaKKUtkatnbeE4IoPDluYkCmTLMe5OetbH/LEv1b1NFFexDSkrHNPdkkQDBcgc5PAxXm3jICTxTcl8kqiAZPQYoorjxzfsH8isP8aIoY18vpTp4025x2ooryUvdO25pfDhFGqagoHBQZGfeuzwNxHbIoor3cB/BRxVviLWnQxyXgV0DDaeDTtirNMqgAL0HpRRXUtznb94ePmGT1oYDaD3oooe4Igl4iYjg0lkS1uCSSelFFIa2MvxnI0fh+fYxXe6q3uCeRXl1yi4XjvjrRRWdb4UKPxP5HkOpoLvWLpLndIhucYLHpUNlp1oJWj8hNh5weec0UV9fNuMEo6KyO+n8KZz2pW0I1AqEAG/GB9a0jbxW+oRGBdmV5wTRRW9eTtBX7GNF6y9T1DwzmXw7GZCWO5hyc9619dllTwzY26TSpAJ3Plq5A5A7A0UV8bjW41ZuOmsvyZE0nNp+Rl6Fm1vozbPJD5isr+W5XcMdDg81vwRIY0JUE560UV8opylG0nc74RSdy8kaZXjrUd6oUR4H3nwfpRRUNaGjZl3ORGkYZhGzElQxwTWiFC30ZXIzt70UVpFuyX9bmduvmf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note chimerism, with CHS cells with&nbsp;giant azurophilic&nbsp;granules and normal cells.",
"    <div class=\"footnotes\">",
"     CHS: Chediak-Higashi syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Roberts, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26436=[""].join("\n");
var outline_f25_52_26436=null;
var title_f25_52_26437="Early stage breast cancer treatment in postmenopausal women";
var content_f25_52_26437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/52/26437/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26437/contributors\">",
"     Kathleen I Pritchard, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/52/26437/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26437/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/52/26437/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26437/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/52/26437/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is the most common female cancer in the United States. Finding and treating breast cancer in the early stages allows many women to be cured.",
"   </p>",
"   <p>",
"    After surgery, systemic (body-wide) anticancer treatment may be given to eliminate any microscopic tumor cells that might remain in the body. This type of therapy is called adjuvant therapy, and it is a very important component of breast cancer treatment. Adjuvant therapy significantly decreases the chance that the cancer will return (or recur), and it also improves a woman's chance of surviving her cancer.",
"   </p>",
"   <p>",
"    There are three options for systemic adjuvant therapy of breast cancer: endocrine therapy, chemotherapy, and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?43/23/44404?source=see_link\">",
"     trastuzumab",
"    </a>",
"    (Herceptin). This article will focus on adjuvant therapy for",
"    <strong>",
"     postmenopausal",
"    </strong>",
"    women with hormone-responsive breast cancer. Adjuvant treatment for",
"    <strong>",
"     premenopausal",
"    </strong>",
"    women with hormone-responsive breast cancer is discussed in a separate monograph. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"     \"Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjuvant treatment for women with hormone-nonresponsive breast cancers, as well as a discussion about the side effects and indications for chemotherapy and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?43/23/44404?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in women with HER2-positive breast cancer, is presented elsewhere. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"     \"Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINING HORMONE-RESPONSIVE BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some breast cancers require the female hormone estrogen (estradiol) to grow, while other breast cancers are able to grow without estrogen. These hormone receptors can be estrogen receptors (ER), progesterone receptors (PR), or both.",
"   </p>",
"   <p>",
"    If hormone receptors are present within a breast cancer (called hormone responsive), you are more likely to benefit from treatments that lower estrogen levels or block the actions of estrogen. These treatments are referred to as endocrine or hormone therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENDOCRINE THERAPY OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of endocrine therapy is to prevent breast cancer cells from being stimulated by estrogen. In postmenopausal women with early breast cancer, two endocrine treatments are possible:",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?5/28/5574?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and a class of drugs called aromatase inhibitors (AIs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?5/28/5574?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    (Nolvadex) prevents estrogen from binding to the estrogen receptor, thereby preventing estrogen from stimulating the growth of the breast cancer cells. It is usually recommended for five years, but the benefits of taking tamoxifen last for at least ten years after the drug is stopped. Taking tamoxifen for more than five years does not add further benefit, and the risk of side effects such as uterine cancer increases with longer treatment. However, there is added benefit from switching over to an aromatase inhibitor after taking tamoxifen for two to three or five years. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Aromatase inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?5/28/5574?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    may increase the risk of the following, particularly in women over age 50 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer of the uterus (endometrial cancer and sarcoma)",
"     </li>",
"     <li>",
"      Blood clots within deep veins (deep vein thrombosis), usually in the legs, which can travel to the lungs (pulmonary embolism) (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Whether",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?5/28/5574?source=see_link\">",
"       tamoxifen",
"      </a>",
"      increases the risk of stroke is controversial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most women, the benefits of",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?5/28/5574?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in preventing a recurrence of breast cancer far outweigh the risks of uterine cancer, blood clots, or other long-term effects. However, the risks may be higher for women with risk factors for blood clots or a stroke (eg, prior history of blood clots in the leg or lung, history of smoking), and for those who take tamoxifen for longer than five years.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?5/28/5574?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    may cause other side effects, particularly hot flashes and vaginal discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors are a type of medicine that block estrogen from being produced in postmenopausal women.",
"   </p>",
"   <p>",
"    Studies suggest that aromatase inhibitors such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18485?source=see_link\">",
"     anastrozole",
"    </a>",
"    (Arimidex),",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?14/18/14629?source=see_link\">",
"     letrozole",
"    </a>",
"    (Femara), and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?0/30/485?source=see_link\">",
"     exemestane",
"    </a>",
"    (Aromasin) are at least as effective and may be more effective than five years of",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?5/28/5574?source=see_link\">",
"     tamoxifen",
"    </a>",
"    alone in postmenopausal women with early breast cancer. There also appears to be added benefit from switching over to an aromatase inhibitor after taking tamoxifen for two to three or five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of aromatase inhibitors include bone loss and bone fractures, pain in the muscles and joints, blood clots, and cardiovascular events (heart attack, heart failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY IN ADDITION TO ENDOCRINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy provides benefit for some women with ER-positive early breast cancer, especially women with positive lymph nodes. It is less clear which women with ER-positive and lymph node negative breast cancer need chemotherapy.",
"   </p>",
"   <p>",
"    Two tools are available to help decide if chemotherapy is needed. Ask your doctor or nurse if these tools would be helpful in deciding whether chemotherapy is needed in your case.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjuvant! Online is website (",
"      <a class=\"external\" href=\"file://www.adjuvantonline.com/\">",
"       www.adjuvantonline.com",
"      </a>",
"      ) that can help to determine your risk of a breast cancer relapse and the possible benefits of chemotherapy and endocrine therapy.",
"     </li>",
"     <li>",
"      Oncotype DX assay&trade;, also known as 21 gene recurrence score assay, can help to estimate your risk of a breast cancer relapse, which can help to predict if there is a benefit of having chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress in treating breast cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learningabout\">",
"     www.cancer.gov/clinicaltrials/learningabout",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     file://clinicaltrials.gov/",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FOLLOW UP AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary of the American Society of Clinical Oncology's recommendations for surveillance after breast cancer treatment is provided in the following table (",
"    <a class=\"graphic graphic_table graphicRef77225 \" href=\"UTD.htm?9/63/10236\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24135732\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"     Patient information: Breast cancer (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=see_link\">",
"     Patient information: Breast reconstruction after mastectomy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=see_link\">",
"     Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=see_link\">",
"     Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24135804\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"     Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"     Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"     Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"     Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34826?source=see_link\">",
"     Adjuvant systemic therapy for older women with early stage breast cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"     Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=see_link\">",
"     General principles on the treatment of early stage and locally advanced breast cancer in older women",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     HER2 and predicting response to therapy in breast cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"     Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     Breast conserving therapy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link\">",
"     Mechanisms of action of selective estrogen receptor modulators",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Cancer Institute",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; (",
"    <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"     www.nci.nih.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Society of Clinical Oncology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"     www.cancer.net/portal/site/patient",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Comprehensive Cancer Network",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nccn.com/\">",
"     www.nccn.com",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Cancer Society",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cancer.org/\">",
"     www.cancer.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus\">",
"     www.nlm.nih.gov/medlineplus",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjuvant! online",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.adjuvantonline.com/\">",
"     www.adjuvantonline.com/",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Susan G. Komen Breast Cancer Foundation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.komen.org/\">",
"     www.komen.org",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient support",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://about.com/\">",
"       About.com",
"      </a>",
"      Breast Cancer Forum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://breastcancer.about.com/forum\">",
"     file://breastcancer.about.com/forum",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26437/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26437/abstract/1\">",
"      Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26437/abstract/2\">",
"      Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26437/abstract/3\">",
"      Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26437/abstract/4\">",
"      Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26437/abstract/5\">",
"      Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26437/abstract/6\">",
"      Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26437/abstract/7\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 879 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26437=[""].join("\n");
var outline_f25_52_26437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINING HORMONE-RESPONSIVE BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENDOCRINE THERAPY OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHEMOTHERAPY IN ADDITION TO ENDOCRINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FOLLOW UP AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24135732\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24135804\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/879\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/879|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/63/10236\" title=\"table 1\">",
"      Breast ca surveillance PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34826?source=related_link\">",
"      Adjuvant systemic therapy for older women with early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=related_link\">",
"      Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=related_link\">",
"      Patient information: Breast reconstruction after mastectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=related_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=related_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=related_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_52_26438="Hepatobil cystadenocarcinoma";
var content_f25_52_26438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic cystadenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: CT scan, during a percutaneous aspiration. Note irregular thick cyst wall with nonhomogenous content. Panel B: Gross pathological examination, revealing a thick wall with multiple papillary projections. Panel C: Histologic examination: Scanning magnification showing complex glandular structures embedded in the stroma of the wall (hematoxylin and eosin, original magnification: x 400). Panel D: Higher power demonstrates glands with a cribriform growth pattern and nuclei displaying mild atypia (hematoxylin and eosin, original magnification: x 2000).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Regev, A, Reddy, KR, Berho, M, et al. Large cystic lesions of the liver in adults: A 15-year experience in a tertiary center. J Am Coll Surg 2001; 193:36. Copyright &copy; 2001 American College of Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26438=[""].join("\n");
var outline_f25_52_26438=null;
var title_f25_52_26439="Tube related complications after gastric banding";
var content_f25_52_26439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Tube related complications after gastric banding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Disconnected tubing after gastric banding causing obstruction. Arrows are pointing to the port of an adjustable gastric band and the disconnected tubing.",
"    <br>",
"     (B) Computed tomography (CT) scan&nbsp;with arrows&nbsp;pointing to the band tubing around dilated and then decompressed bowel near the transition point.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26439=[""].join("\n");
var outline_f25_52_26439=null;
var title_f25_52_26440="Oxycodone and ibuprofen: Drug information";
var content_f25_52_26440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxycodone and ibuprofen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/17/38165?source=see_link\">",
"    see \"Oxycodone and ibuprofen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid);",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F205104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain:",
"     </b>",
"     Oral: Take 1 tablet as needed (maximum: 4 tablets/24 hours); do not take for longer than 7 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Oxycodone hydrochloride 5 mg and ibuprofen 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F205114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088574.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088574.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9603344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (&le;7 days) management of acute, moderate-to-severe pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5978066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (5% to 19%), somnolence (7% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (9% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (&lt;1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (10%), fever (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (5%), constipation (&lt;1% to 5%), diarrhea (2%), dyspepsia (&lt;1% to 2%), flatulence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&lt;1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abdominal enlargement/pain, anemia, amblyopia, anxiety, chest pain, chills, edema, euphoria, hyperkinesias, hypertonia, hypokalemia, hypotension, hypoxia, ileus, infection, LFTs increased, pharyngitis, syncope, rash, tachycardia, taste perversion, thrombophlebitis, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxycodone, ibuprofen, aspirin, other NSAIDs, or any component of the formulation; paralytic ileus (known or suspected); perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; significant respiratory depression, hypercarbia, acute/severe bronchial asthma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk. This combination is only approved for short-term (&le;7 days) use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer NSAIDs to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use with caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with toxic psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use oxycodone with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages. Opioids may suppress cough reflex; use with caution during postoperative period and in patients with pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion: Healthcare provider should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F205107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of OxyCODONE. Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F205098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on",
"     <b>",
"      oxycodone",
"     </b>",
"     component: Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on",
"     <b>",
"      ibuprofen",
"     </b>",
"     component:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Food: Food or milk are recommended to decrease gastric irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D &ge;30 weeks gestation  (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F205105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F205089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F205090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Oxycodone-Ibuprofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-400 mg (100): $147.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F205079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory function;  CBC, chemistry profile, occult blood loss; monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor renal function (urine output, serum BUN and creatinine); observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxycodone: Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ibuprofen: Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which result in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F205086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Ibuprofen, oxycodone: Rapidly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Ibuprofen: 99%; Oxycodone: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Oxycodone: Hepatic to metabolites, noroxycodone (major), and oxymorphone (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oxycodone: increased with food (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Ibuprofen: 1.8-2.6 hours; Oxycodone: 3.1-3.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Ibuprofen: 1.6-3.1 hours; Oxycodone 1.3-2.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Ibuprofen: Urine (&lt;0.2% unchanged); Oxycodone: Urine (~4 % unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/52/26440/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/52/26440/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/52/26440/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10146 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26440=[""].join("\n");
var outline_f25_52_26440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709187\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205112\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205104\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062243\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205082\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205070\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205114\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874940\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603344\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205084\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5978066\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205110\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205087\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205072\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205107\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205076\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205098\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205078\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205088\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205105\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205089\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205090\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989446\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205079\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205071\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205086\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/17/38165?source=related_link\">",
"      Oxycodone and ibuprofen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_52_26441="Adenovirus pathogenesis and vector applications";
var content_f25_52_26441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adenovirus pathogenesis and vector applications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/52/26441/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26441/contributors\">",
"     Phyllis Flomenberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26441/contributors\">",
"     Tsoline Kojaoghlanian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/52/26441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26441/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/52/26441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26441/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/52/26441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses are lytic, non-enveloped DNA viruses that generally cause a self-limited febrile illness but occasionally can disseminate in immunocompromised hosts and neonates, causing significant morbidity and mortality. Adenoviruses cause pathology during the process of viral replication and lysis of susceptible cells, but these viruses can also cause inflammation in animal models in the absence of viral replication. Thus, the clinical manifestations of adenoviral disease in humans appear to result from both the direct effects of infection and host inflammatory responses.",
"   </p>",
"   <p>",
"    The pathogenesis of adenovirus infection and the use of this virus as a vector for research applications will be reviewed here. The epidemiology, clinical manifestations, diagnosis, and treatment of adenovirus infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=see_link\">",
"     \"Diagnosis and treatment of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serotype differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain adenovirus serotypes are associated with distinct clinical manifestations, but the basis for these differences is not well understood. As an example, the group C types 1, 2, and 5 are associated with respiratory tract infections; the group B types 11, 34, and 35 cause hemorrhagic cystitis; and the group D types 8, 19, and 37 are the major causes of epidemic keratoconjunctivitis. Serotype-specific clinical manifestations may be partially determined by differences in cell tropism. Some serotypes, for example, display different cell receptor preferences, which are mediated by the viral attachment protein fiber. Although most adenoviruses from groups A, C, D, E, and F bind to the coxsackievirus-adenovirus receptor (CAR), the group B adenoviruses do not bind to this receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/1\">",
"     1",
"    </a>",
"    ]. Group B adenoviruses have been shown to bind to the complement related protein CD46, as well as CD80 and CD86 (activation markers on hematopoietic cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. After attachment, adenoviruses enter cells via receptor-mediated endocytosis. This internalization process requires interaction of the viral protein penton base with alpha v integrins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, differences in the fiber and penton likely contribute to serotype-specific clinical manifestations. The epidemiology and clinical manifestations of adenovirus infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192088427\">",
"    <span class=\"h2\">",
"     Immune response to adenoviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses elicit both innate and adaptive immune responses. Recovery from adenovirus infection is associated with the development of serotype-specific neutralizing antibodies directed mainly at the major capsid protein hexon. Neutralizing antibodies protect against infection with the same serotype of the virus but not against other serotypes. The commercial assays for adenovirus antibodies, such as complement fixation (CF) and enzyme immunoassay (EIA), detect other adenovirus-specific antibodies that cross react with all serotypes. Nearly all adults have serologic evidence of past infection with one or more adenoviruses.",
"   </p>",
"   <p>",
"    The most important host defense against many viruses, including adenoviruses, is cell-mediated immunity. Fatal adenovirus infections occur most commonly in immunocompromised patients, especially those with defects in cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Adenovirus-specific memory CD4+ T cells can be detected in most healthy adults and can exhibit cross-reactivity against different serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/9\">",
"     9",
"    </a>",
"    ]. As an example, a specific CD4+ T cell epitope on the hexon is highly conserved among different serotypes and is recognized by 75 percent of healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/10\">",
"     10",
"    </a>",
"    ]. Adenovirus-specific CD8+ cytotoxic T lymphocytes (CTLs) are detected at lower frequencies, some of which also target conserved epitopes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adenovirus proteins modulate host responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of mechanisms to down-regulate nonspecific and specific inflammatory responses have been demonstrated in adenoviruses. Several proteins expressed early in the adenovirus replicative cycle may modulate the host immune response. Adenoviruses express early regulatory proteins under the control of the early region 1A (E1A). E1A is a trans-activating region that controls expression from the other early regions E1B, E2, E3, and E4. Viral DNA replication takes place after expression of the early proteins, followed by synthesis of late structural viral proteins and inhibition of host protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/13\">",
"     13",
"    </a>",
"    ]. Virions are then assembled in the nucleus and released when the cell dies. This process of virus release is facilitated by the E3 region 11.6K protein [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The E3 region, which is not essential for viral replication, encodes several proteins that modulate host functions in response to viral infection. The E3-19K transmembrane glycoprotein is localized in the endoplasmic reticulum and binds to newly synthesized MHC class I molecules. As a consequence, the intracellular transport and cell surface expression of class I molecules is dramatically inhibited [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/15\">",
"     15",
"    </a>",
"    ]. E3-19K also binds TAP and may inhibit class I molecule maturation by delaying peptide loading [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/16\">",
"     16",
"    </a>",
"    ]. Down-regulation of class I antigens, which are required for antigen presentation to CD8+ CTLs, may help adenovirus-infected cells evade recognition.",
"   </p>",
"   <p>",
"    Furthermore, the E3 region protects cells from apoptosis-inducing cytokines, such as tumor necrosis factor (TNF), Fas ligand, and TNF-related apoptosis-inducing ligand (TRAIL). The E3 14.7K protein is a potent inhibitor of TNF-mediated apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/17\">",
"     17",
"    </a>",
"    ]. The E3 10.4K, and 14.5K complex, also known as RID (Receptor Internalization and Degradation), down regulates Fas, TNF, and TRAIL receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Fas-mediated apoptosis is a major pathway for CTL-mediated cell lysis. The E3 19K protein down regulates class I MHC from surfaces of infected cells. As a consequence, adenovirus-infected cells are resistant to apoptosis and CTL killing. In fact, these E3 region proteins have been employed in murine models to prevent rejection of transplanted hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/21\">",
"     21",
"    </a>",
"    ] or transplanted islet cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fact that adenoviruses have developed diverse mechanisms to evade host responses suggests that these must be important modes of adaptation for the virus. One postulate is that these proteins play a role in reducing inflammation during acute infection. Another explanation is that these proteins may facilitate the establishment of persistent infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192088549\">",
"    <span class=\"h2\">",
"     Persistent infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses are frequently shed in stool for weeks after acute infection in immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/23\">",
"     23",
"    </a>",
"    ], and for months in immunocompromised patients. There are case reports of transmission of adenoviruses to recipients of infected solid organ transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Adenoviral disease may also be caused by reactivation of endogenous infection in hematopoietic cell transplant recipients, analogous to reactivation of herpesviruses in these hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, the reservoirs and mechanisms for persistent adenovirus infections in humans are not well understood.",
"   </p>",
"   <p>",
"    Adenoviruses can be detected in long-term cultures of tonsillar tissue. Adenoviruses have also been shown to persist in CD4+ T cells isolated from tonsils [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/28\">",
"     28",
"    </a>",
"    ]. Although adenoviruses infect lymphocytes and monocytes very inefficiently in vitro, one study demonstrated that a subset of B and T cell lines supported adenovirus replication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/29\">",
"     29",
"    </a>",
"    ]. There is also one report of a spontaneous persistent adenovirus infection of a cell line maintained in tissue culture that derived from an EBV-positive B cell lymphoma from a hematopoietic cell transplant recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/30\">",
"     30",
"    </a>",
"    ]. These data suggest that adenoviruses can persist in some human cell types without causing cell lysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     USE OF ADENOVIRUS VECTORS FOR GENE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been considerable interest and effort in developing adenovirus vectors for gene therapy. Since 1993, at least 400 clinical protocols have used adenovirus vectors as delivery vehicles. Adenoviruses have several advantages over some other viral vectors such as retroviruses and adeno-associated virus. Adenovirus vectors can infect a variety of cell types, including non-dividing as well as dividing cells, and can be prepared readily in large quantities in tissue culture. First generation adenovirus vectors accommodate large inserts (up to 8kb) and express higher levels of recombinant proteins than most other viral vectors. High capacity, \"gutless\" or helper-dependent vectors can accommodate much larger insertions of DNA (up to 37kb); these adenovirus vectors lack all viral encoding genes (see below). However, because adenoviruses do not normally integrate into the host genome, vector DNA will remain episomal and will be eliminated when the cell divides or dies. Furthermore, because of their tropism to liver following systemic administration, \"retargeting\" is essential for their use in other tissues.",
"   </p>",
"   <p>",
"    Replication-defective E1-deleted adenovirus vectors have been used for most gene therapy studies. These vectors are readily grown in 293 cells, a human epithelial cell line that is stably transformed with the E1 region. Most vectors also have deletions in the E3 region in order to accommodate larger inserts. As described above, the E3 region is dispensable for viral replication in tissue culture. In contrast, conditionally replicating vectors and replication competent vectors have been utilized for cancer therapy and for immunization trials, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transgene expression from adenovirus vectors is transient in vivo",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the first gene therapy applications evaluated was expression of the cystic fibrosis transmembrane conductance regulator (CFTR). Replication-defective adenovirus vectors expressed CFTR in mouse, cotton rat, and simian models, as well as in human bronchial xenografts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/31\">",
"     31",
"    </a>",
"    ]. However, although CFTR expression from adenovirus vectors in lung tissue persisted for over six months in nude mice, expression lasted for only a few weeks in immunocompetent animals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/32\">",
"     32",
"    </a>",
"    ]. Moreover, in early human studies, replication-defective adenovirus vectors expressing CFTR induced inflammatory responses and did not efficiently transduce respiratory tract epithelial cells. Subsequent studies similarly showed inefficient delivery of CFTR by adenovirus vectors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Multiple studies in different animal models have documented that transgene expression from E1-deleted vectors is transient and associated with substantial inflammatory responses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adenovirus vectors are immunogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenovirus vectors induce both an acute, innate inflammatory response and adaptive immune responses resulting in the destruction of transduced cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/36\">",
"     36",
"    </a>",
"    ]. Group C adenovirus serotype 5 has been the primary platform for the construction of vectors, but most adults have detectable levels of neutralizing antibodies against this common serotype.",
"   </p>",
"   <p>",
"    Antigen-presenting cells (APCs), such as dendritic cells and macrophages, play an important role in generating inflammatory responses to adenovirus vectors. The majority of input virions are taken up by APCs independent of the route of administration. For instance, when adenovirus vectors are administered by intravenous injection in the mouse model, most of the input virus is taken up by the liver macrophages (Kupffer cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/37\">",
"     37",
"    </a>",
"    ]. Uptake of virions by APCs directly stimulates the release of cytokines that induce an acute inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/38\">",
"     38",
"    </a>",
"    ]. The capsid protein fiber may play an important role in this process. One group found that adenovirus infection of dendritic cells was mediated by a heparin-sensitive receptor recognized by the fiber shaft [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/39\">",
"     39",
"    </a>",
"    ]. Another group showed that modification of the fiber protein shaft reduced IL-6 expression and liver inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/40\">",
"     40",
"    </a>",
"    ]. The innate immune response is mediated by both Toll-like receptor-dependent and independent pathways that involve the induction of type 1 interferons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/41\">",
"     41",
"    </a>",
"    ]. Antiviral antibodies can amplify these innate immune responses by increasing the uptake of virions into phagolysosomes in macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenovirus-transduced cells are destroyed by CD8+ CTLs, as demonstrated in mouse studies with a recombinant adenovirus administered either to lung or liver tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/36,43\">",
"     36,43",
"    </a>",
"    ]. By contrast, CD4+ T cell-mediated responses were insufficient, in the absence of CTLs, to completely eliminate these cells. Additionally, T cell responses may be generated without expression of new viral proteins via presentation of input virion proteins by APCs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, gene transfer is substantially reduced following a second administration of vector as a result of the production of adenovirus-specific neutralizing antibodies. In order to overcome this limitation, vectors derived from different adenovirus serotypes, expressing the same transgene, can be successively administered. For instance, most people have low prevalence of neutralizing antibodies to the group B adenovirus serotype 35. Group B adenoviruses (unlike other serotypes) also have a special affinity for hematopoietic cells. Thus, adenovirus serotype 35-based vectors have been developed to optimize gene delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. However, unlike serotype-specific neutralizing antibodies, adenovirus-specific T cells recognize different serotypes. Thus, use of the group B Ads as vectors will not evade cellular immune responses to conserved T cell epitopes, such as the hexon epitope [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/10\">",
"     10",
"    </a>",
"    ]. As an alternative strategy, vectors have been developed based on other animal adenoviruses including chimpanzee and canine adenoviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Strategies to reduce immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the use of uncommon or animal serotypes as described above, multiple other strategies have been investigated for reducing the immunogenicity of adenovirus vectors in order to prolong transgene expression. The first approach was to make vectors with additional deletions in order to reduce adenovirus protein expression. Second generation adenovirus vectors with additional mutations or deletions have been shown to prolong survival to a limited extent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/52\">",
"     52",
"    </a>",
"    ]. Additionally, adenovirus vectors with all viral coding sequences eliminated, so-called \"gutless\" or helper-dependent vectors, have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/53\">",
"     53",
"    </a>",
"    ]. Results from animal studies have been promising [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/54\">",
"     54",
"    </a>",
"    ], but these mutant viruses are difficult to purify in large amounts away from helper adenoviruses and must still be packaged within the immunogenic virion capsid proteins.",
"   </p>",
"   <p>",
"    Another strategy for vector design is to insert protein(s) that inhibit immune",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammatory responses. The Ad E3 region, which encodes for several proteins that down-regulate host responses, is deleted or poorly expressed from most Ad vectors. In some studies using vectors that retain the E3 region or constitutively express E3 proteins, prolonged transgene expression has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immune tolerance has been induced to adenovirus vectors in animal models, either by treatment during the neonatal period or via oral administration of adenovirus proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Repeat administration of vectors was successful in these studies. Tolerance, a process that involves clonal deletion of antigen-specific T cells by apoptosis, is mediated by upregulation of Fas and Fas ligand. In a novel approach, one group used Fas ligand to induce adenovirus-specific T cell tolerance by pretreating mice with adenovirus-transfected, Fas ligand-producing antigen presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/58\">",
"     58",
"    </a>",
"    ]. Subsequent administration of an adenovirus recombinant resulted in prolonged transgene expression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Use of adenovirus vectors for transient expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In light of the above obstacles, adenovirus vectors may have their greatest potential in situations that require transient high-level expression of recombinant proteins. Adenovirus vectors express large amounts of recombinant proteins in comparison to other types of vectors.",
"   </p>",
"   <p>",
"    An adenovirus vector expressing vascular cyclooxygenase-1, for example, was shown to inhibit thrombosis in a porcine carotid angioplasty model [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/59\">",
"     59",
"    </a>",
"    ]. In contrast, an adenovirus vector that expressed vascular endothelial growth factor (VEGF) was used to promote angiogenesis post-thrombosis in a murine model [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/60\">",
"     60",
"    </a>",
"    ]. As another example, transient expression of the cytokine thrombopoietin was used to raise platelet numbers following chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/61\">",
"     61",
"    </a>",
"    ]. In a unique approach, recombinant adenovirus was used to express Fas ligand in the blood vessel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/62\">",
"     62",
"    </a>",
"    ]. The vector inhibited neointima formation, as well as adenovirus-mediated T cell responses, presumably by inducing apoptosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=see_link\">",
"     \"Therapeutic angiogenesis for management of refractory angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although adenoviruses infect a variety of cell types, including endothelial and muscle cells, the efficiency of infecting CAR-negative cell types is low. Therefore, alterations in the fiber protein, which mediates virus attachment to cells, have been engineered and are being evaluated to enhance binding to different cell types. For instance, peptide ligands that bind to cell surface integrins have been added to fiber [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/63\">",
"     63",
"    </a>",
"    ]. Insertion of the HIV-1 derived TAT peptide into fiber made otherwise resistant blood and vascular smooth muscle cells transducible with the adenovirus vector [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/64\">",
"     64",
"    </a>",
"    ]. As another approach, adenoviruses have been incubated with bispecific antibodies that target another cell receptor. Use of a bispecific antibody that blocks CAR binding and reacts with angiotensin-converting enzyme (ACE) resulted in 20-fold increased transgene expression in the lungs and 80 percent reduction of expression in the liver in a rat model [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/65\">",
"     65",
"    </a>",
"    ]. In another study, a bispecific adapter blocked CAR and retargeted the vector to CEA-positive epithelial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the most exciting applications under investigation is the use of adenovirus vectors to deliver new cancer therapies. There are several potential approaches, eg, induction of an anti-tumor immune response, expression of tumor suppressor proteins or suicide genes, and inhibition of growth factors such as VEGF that are required for tumor proliferation or metastases.",
"   </p>",
"   <p>",
"    Adenovirus vectors expressing cytokines have induced anti-tumor responses in selected murine tumor models. In one study, breast tumor-bearing mice injected with an adenovirus vector that expressed IL-2, IL-4, or IL-12 exhibited tumor regression and immunity to secondary challenge with fresh tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/67\">",
"     67",
"    </a>",
"    ]. Combinations of adenovirus vectors expressing IL-2 plus the tumor suppressor protein p53 or IL-12 plus the T-cell costimulatory factor B7-1 were even more potent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. As an alternative strategy, adenovirus-transduced dendritic cells have been used to induce anti-tumor immunity in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Use of conditionally replicating adenoviruses for cancer therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As another strategy to enhance delivery to tumors, adenoviruses have been engineered with E1 mutations that allow viral replication and cell lysis in tumor cells but not normal cells. ONYX-015, which contains mutations in the early region E1B, was the first example of an \"oncolytic\" adenovirus that replicates in and lyses tumor cells in vitro and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/71\">",
"     71",
"    </a>",
"    ]. More recently, based on data that CAR expression is variable in tumors, fiber modifications have been incorporated in order to enhance entry of virus into tumor cells. For instance, an E1A mutant adenovirus containing a chimeric fiber protein (Ad serotype 3) lysed primary ovarian tumor cells and significantly improved survival in an ovarian cancer mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, tumor-specific promoters have been substituted for the endogenous viral promoter in the E1 region to allow selective viral replication in tumors. For instance, the human telomerase reverse transcriptase (hTERT) promoter was used to restrict replication of an adenovirus vector to telomerase-positive cancer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/73\">",
"     73",
"    </a>",
"    ]. This vector lysed tumor cells in vitro and inhibited growth of tumor xenografts more efficiently than ONYX-015.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Human studies of adenovirus gene therapy vectors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cancer therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, most clinical trials of adenovirus gene therapy vectors have focused on the administration of first generation E1-deleted adenovirus vectors by direct injection into tumor masses. Overall, intratumoral administration of adenovirus vectors has been well -tolerated. Adenovirus vectors expressing the tumor suppressor p53 have shown modest activity in patients with certain solid tumors. In one study of 28 patients with non-small cell lung cancer, for example, repeated injection of an adenovirus vector expressing p53 into tumor lesions resulted in disease stabilization in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/74\">",
"     74",
"    </a>",
"    ]. In another study of 17 patients with head and neck cancer, two had partial responses and six had stable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/75\">",
"     75",
"    </a>",
"    ]. Administration of an",
"    <span class=\"nowrap\">",
"     adenovirus/p53",
"    </span>",
"    recombinant in combination with radiation in 19 patients with non-small cell lung cancer lead to one complete response and 11 partial responses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/76\">",
"     76",
"    </a>",
"    ]. Several phase II and III trials are ongoing.",
"   </p>",
"   <p>",
"    Clinical trials using E1-deleted adenovirus vectors expressing IL-2 have had mixed results. In one study, pediatric patients with neuroblastoma were treated with autologous tumor cells transduced with an adenovirus vector expressing IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/77\">",
"     77",
"    </a>",
"    ]. Five of 10 patients had tumor responses associated with anti-tumor cytotoxic activity. In contrast, a phase I trial using an",
"    <span class=\"nowrap\">",
"     adenovirus/IL-2",
"    </span>",
"    recombinant in patients with metastatic breast cancer or melanoma did not show clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using another approach, adenovirus vectors expressing the herpes simplex virus (HSV) thymidine kinase have been used as a suicide gene therapy in patients with glioblastoma and mesothelioma. In a phase I trial of intraocular injection of an",
"    <span class=\"nowrap\">",
"     adenovirus/thymidine",
"    </span>",
"    kinase recombinant for the treatment of retinoblastoma, the vector induced local tumor responses without a systemic immune response to the vector [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link&amp;anchor=H14#H14\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Biologic approaches'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=see_link\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The conditionally replicating adenovirus vector ONYX-015 has been evaluated in over 200 cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/80\">",
"     80",
"    </a>",
"    ]. Although therapy with ONYX-015 is well tolerated, efficacy is limited. However, results appear more encouraging when ONYX-015 is given in combination with chemotherapy, particularly in patients with head and neck cancer. In a study of another oncolytic adenovirus expressing granulocyte-macrophage colony stimulating factor in 16 patients with advanced solid tumors, two had complete responses, one had a partial response, and five had stable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"     \"Treatment of metastatic and recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Gene replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the disappointing results of early clinical trials of E1-deleted",
"    <span class=\"nowrap\">",
"     adenovirus/CFTR",
"    </span>",
"    recombinants, most recent trials have focused on using E1, E4-deleted adenovirus vectors for systemic administration. However, an E1, E4-deleted",
"    <span class=\"nowrap\">",
"     adenovirus/CFTR",
"    </span>",
"    recombinant administered intrabronchially induced dose-dependent inflammatory reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/82\">",
"     82",
"    </a>",
"    ]. In another trial, an adenovirus vector expressing ornithine transcarbamylase was delivered into one lobe of the liver by hepatic artery injection, and one of two patients treated with the highest vector dose developed a severe acute reaction and died [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. These data indicate that additional vector deletions do not eliminate the immunogenicity of adenovirus vectors and suggest that other strategies are needed as discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ADENOVIRUS-BASED VACCINES AGAINST INFECTIOUS PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another promising application for adenoviruses is their use as vaccine vectors. Live, oral, enteric-coated, adenovirus serotypes 4 and 7 vaccines were safely used for years in military training camps to prevent epidemics of acute adenoviral respiratory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/85\">",
"     85",
"    </a>",
"    ]. In the 1990s, after the manufacturer of the vaccines stopped production, outbreaks of adenovirus respiratory disease re-emerged. In 2011, a new live, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9524?source=see_link\">",
"     adenovirus vaccine",
"    </a>",
"    against adenovirus serotypes 4 and 7 was approved for use in United States military personnel aged 17 through 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Additionally, live, oral viral vaccines have an advantage in the ability to generate both mucosal and systemic immunity. Thus, replication-competent as well as E1-deleted (replication-defective) adenovirus vectors are attractive candidates for immunization against other infectious pathogens.",
"   </p>",
"   <p>",
"    A large, international phase II trial (the STEP study) of a replication-defective adenovirus serotype 5 vector expressing HIV-1 gag, pol, and nef proteins demonstrated failure of the vaccine to prevent HIV-1 infection or to reduce early HIV replication after infection, and the study was discontinued early [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In fact, there was a trend towards an increased infection rate in immunized volunteers with the highest levels of pre-existing neutralizing antibodies against adenovirus serotype 5. The mechanisms underlying this enhanced infection rate have not been established.",
"   </p>",
"   <p>",
"    Priming with recombinant protein or DNA, followed by boosting with a replication-defective recombinant adenovirus may improve vaccine efficacy by evading pre-existing memory immune responses to adenoviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/90\">",
"     90",
"    </a>",
"    ]. For instance, administration of a recombinant adenovirus expressing the Plasmodium circumsporozoite (CS) protein, followed by a boost with a vaccinia",
"    <span class=\"nowrap\">",
"     virus/CS",
"    </span>",
"    recombinant was highly effective in protecting mice against infection with malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/91\">",
"     91",
"    </a>",
"    ]. In another study, sequential immunization with HIV-1 gag protein mixed with a cytosine guanosine oligodeoxynucleotide adjuvant, followed by recombinant adenovirus expressing gag, induced strong B cell and CD8+ T cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another promising strategy is to administer recombinant adenoviruses via the intranasal route. As an example, in mice, BCG priming followed by intranasal boosting with a replication-defective adenovirus vector expressing mycobacterial protein Ag85A was much more effective in protection against pulmonary M. tuberculosis than intramuscular boosting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/93\">",
"     93",
"    </a>",
"    ]. Furthermore, in mice with pre-existing immunity to adenoviruses, only those vaccinated with a replication-defective adenovirus expressing Ebola glycoprotein by the intranasal route (compared with intramuscular and oral routes) survived virus challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/94\">",
"     94",
"    </a>",
"    ]. These data suggest that intranasal administration of recombinant adenoviruses may be highly immunogenic and may help evade pre-existing immunity.",
"   </p>",
"   <p>",
"    As an alternative strategy, vaccines based on animal adenoviruses have been developed. For instance, a single administration of a replication-defective chimpanzee adenovirus expressing anthrax protective antigen was 100 percent effective in adenovirus serotype 5-preimmunized mice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/51\">",
"     51",
"    </a>",
"    ]. In another study, heterologous priming with an adenovirus serotype 5 vector followed by boosting with a chimpanzee adenovirus, each expressing the same SARS protein, protected ferrets against SARS pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenovirus-based vaccines may also have potential for preventing influenza infections. For instance, a bovine adenovirus vector-based H5N1 influenza vaccine was fully protective against a lethal viral challenge in human adenovirus-primed mice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/96\">",
"     96",
"    </a>",
"    ]. In another murine model, an influenza matrix protein 2 DNA prime, followed by a recombinant adenovirus boost, conferred broad protection against infection with influenza A strains, including H5N1 influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26441/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1328948514\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenoviruses are lytic DNA viruses that generally cause a self-limited febrile illness but can potentially disseminate in immunocompromised hosts and neonates, causing significant morbidity and mortality. Adenoviruses cause pathology during the process of viral replication and lysis of susceptible cells, but these viruses can also cause inflammation in animal models in the absence of viral replication. Thus, the clinical manifestations of adenoviral disease in humans appear to result from both the direct effects of infection and host inflammatory responses. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recovery from adenovirus infection is associated with the development of serotype-specific neutralizing antibodies. Neutralizing antibodies protect against infection with the same virus serotype, but do not cross react with other serotypes. However, the most important host defense against adenoviruses is cell-mediated immunity. Fatal adenovirus infections occur most commonly in immunocompromised patients, especially those with defects in cell-mediated immunity. (See",
"      <a class=\"local\" href=\"#H192088427\">",
"       'Immune response to adenoviruses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain adenovirus serotypes are associated with distinct clinical manifestations. As an example, the group C types 1, 2, and 5 are associated with respiratory tract infections; the group B types 11, 34, and 35 cause hemorrhagic cystitis; and the group D types 8, 19, and 37 are the major causes of epidemic keratoconjunctivitis. Serotype-specific clinical manifestations may be partially determined by differences in cell tropism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Serotype differences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of mechanisms to down-regulate nonspecific and specific inflammatory responses have been demonstrated in adenoviruses. Several proteins expressed early in the adenovirus replicative cycle may modulate the host immune response. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Adenovirus proteins modulate host responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There has been considerable interest and effort in developing adenovirus vectors for gene replacement, cancer therapy and vaccines. Numerous clinical trials have been conducted using various adenovirus vectors. However, no adenovirus vector has yet been approved by the US Food and Drug Administration for clinical use. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Use of adenovirus vectors for gene therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Adenovirus-based vaccines against infectious pathogens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/1\">",
"      Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72:7909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/2\">",
"      Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/3\">",
"      Segerman A, Atkinson JP, Marttila M, et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003; 77:9183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/4\">",
"      Short JJ, Pereboev AV, Kawakami Y, et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004; 322:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/5\">",
"      Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/6\">",
"      Zahradnik JM, Spencer MJ, Porter DD. Adenovirus infection in the immunocompromised patient. Am J Med 1980; 68:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/7\">",
"      Shields AF, Hackman RC, Fife KH, et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/8\">",
"      Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003; 13:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/9\">",
"      Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. J Infect Dis 1995; 171:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/10\">",
"      Olive M, Eisenlohr L, Flomenberg N, et al. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 2002; 13:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/11\">",
"      Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19K in the presence of gamma interferon. J Virol 1996; 70:6314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/12\">",
"      Leen AM, Sili U, Savoldo B, et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2004; 103:1011.",
"     </a>",
"    </li>",
"    <li>",
"     Shenk T. Adenoviridae: The viruses and their replication. In: Fields Virology, 3, Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven, Philadelphia 1996. p.2118.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/14\">",
"      Tollefson AE, Scaria A, Hermiston TW, et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/15\">",
"      Burgert HG, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985; 41:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/16\">",
"      Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol 1999; 162:5049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/17\">",
"      Gooding LR, Elmore LW, Tollefson AE, et al. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 1988; 53:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/18\">",
"      Benedict CA, Norris PS, Prigozy TI, et al. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem 2001; 276:3270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/19\">",
"      Elsing A, Burgert HG. The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proc Natl Acad Sci U S A 1998; 95:10072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/20\">",
"      Chin YR, Horwitz MS. Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex. J Virol 2005; 79:13606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/21\">",
"      Mashalova EV, Guha C, Roy-Chowdhury N, et al. Prevention of hepatocyte allograft rejection in rats by transferring adenoviral early region 3 genes into donor cells. Hepatology 2007; 45:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/22\">",
"      Kojaoghlanian T, Joseph A, Follenzi A, et al. Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice. Gene Ther 2009; 16:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/23\">",
"      Fox JP, Hall CE, Cooney MK. The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 1977; 105:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/24\">",
"      Myerowitz RL, Stalder H, Oxman MN, et al. Fatal disseminated adenovirus infection in a renal transplant recipient. Am J Med 1975; 59:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/25\">",
"      Koneru B, Jaffe R, Esquivel CO, et al. Adenoviral infections in pediatric liver transplant recipients. JAMA 1987; 258:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/26\">",
"      Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/27\">",
"      Veltrop-Duits LA, van Vreeswijk T, Heemskerk B, et al. High titers of pre-existing adenovirus serotype-specific neutralizing antibodies in the host predict viral reactivation after allogeneic stem cell transplantation in children. Clin Infect Dis 2011; 52:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/28\">",
"      Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002; 76:10608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/29\">",
"      Lavery D, Fu SM, Lufkin T, Chen-Kiang S. Productive infection of cultured human lymphoid cells by adenovirus. J Virol 1987; 61:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/30\">",
"      Flomenberg P, Piaskowski V, Harb J, et al. Spontaneous, persistent infection of a B-cell lymphoma with adenovirus. J Med Virol 1996; 48:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/31\">",
"      Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/32\">",
"      Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91:4407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/33\">",
"      Bellon G, Michel-Calemard L, Thouvenot D, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/34\">",
"      Grubb BR, Pickles RJ, Ye H, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994; 371:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/35\">",
"      Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci U S A 1994; 91:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/36\">",
"      Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/37\">",
"      Wolff G, Worgall S, van Rooijen N, et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/38\">",
"      Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/39\">",
"      Cheng C, Gall JG, Kong WP, et al. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 2007; 3:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/40\">",
"      Koizumi N, Yamaguchi T, Kawabata K, et al. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 2007; 178:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/41\">",
"      Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007; 81:3170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/42\">",
"      Zaiss AK, Vilaysane A, Cotter MJ, et al. Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response. J Immunol 2009; 182:7058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/43\">",
"      Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/44\">",
"      Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A 1998; 95:11377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/45\">",
"      Molinier-Frenkel V, Gahery-Segard H, Mehtali M, et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000; 74:7678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/46\">",
"      Flomenberg PR, Chen M, Munk G, Horwitz MS. Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. J Infect Dis 1987; 155:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/47\">",
"      Kna&auml;n-Shanzer S, Van Der Velde I, Havenga MJ, et al. Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B. Hum Gene Ther 2001; 12:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/48\">",
"      Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/49\">",
"      Seshidhar Reddy P, Ganesh S, Limbach MP, et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003; 311:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/50\">",
"      Xiang Z, Gao G, Reyes-Sandoval A, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002; 76:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/51\">",
"      Hashimoto M, Boyer JL, Hackett NR, et al. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 2005; 73:6885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/52\">",
"      Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 1994; 91:6196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/53\">",
"      Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998; 95:7866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/54\">",
"      Gilbert R, Dudley RW, Liu AB, et al. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet 2003; 12:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/55\">",
"      Poller W, Schneider-Rasp S, Liebert U, et al. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther 1996; 3:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/56\">",
"      Takahashi M, Ilan Y, Chowdhury NR, et al. Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J Biol Chem 1996; 271:26536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/57\">",
"      Ilan Y, Prakash R, Davidson A, et al. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest 1997; 99:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/58\">",
"      Zhang HG, Liu D, Heike Y, et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol 1998; 16:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/59\">",
"      Zoldhelyi P, McNatt J, Xu XM, et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 1996; 93:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/60\">",
"      M&uuml;hlhauser J, Merrill MJ, Pili R, et al. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res 1995; 77:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/61\">",
"      Ohwada A, Rafii S, Moore MA, Crystal RG. In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression. Blood 1996; 88:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/62\">",
"      Luo Z, Sata M, Nguyen T, et al. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 1999; 99:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/63\">",
"      Wickham TJ, Tzeng E, Shears LL 2nd, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71:8221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/64\">",
"      Kurachi S, Tashiro K, Sakurai F, et al. Fiber-modified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity. Gene Ther 2007; 14:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/65\">",
"      Reynolds PN, Zinn KR, Gavrilyuk VD, et al. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2000; 2:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/66\">",
"      Li HJ, Everts M, Pereboeva L, et al. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 2007; 67:5354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/67\">",
"      Addison CL, Braciak T, Ralston R, et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A 1995; 92:8522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/68\">",
"      P&uuml;tzer BM, Bramson JL, Addison CL, et al. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther 1998; 9:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/69\">",
"      P&uuml;tzer BM, Hitt M, Muller WJ, et al. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci U S A 1997; 94:10889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/70\">",
"      Wan Y, Emtage P, Foley R, et al. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression. Int J Oncol 1999; 14:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/71\">",
"      Heise CC, Williams AM, Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999; 59:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/72\">",
"      Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/73\">",
"      Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003; 63:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/74\">",
"      Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/75\">",
"      Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999; 5:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/76\">",
"      Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/77\">",
"      Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998; 92:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/78\">",
"      Stewart AK, Lassam NJ, Quirt IC, et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 1999; 6:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/79\">",
"      Ildefonso CJ, Kong L, Leen A, et al. Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma. Mol Ther 2010; 18:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/80\">",
"      Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/81\">",
"      Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70:4297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/82\">",
"      Zuckerman JB, Robinson CB, McCoy KS, et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 1999; 10:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/83\">",
"      Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/84\">",
"      Stephenson J. Studies illuminate cause of fatal reaction in gene-therapy trial. JAMA 2001; 285:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/85\">",
"      Gaydos CA, Gaydos JC. Adenovirus vaccines in the U.S. military. Mil Med 1995; 160:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/86\">",
"      Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008; 26:2890.",
"     </a>",
"    </li>",
"    <li>",
"     Adenovirus type 4 and type 7 live oral vaccine prescribing information. file://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247515.pdf (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/88\">",
"      Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/89\">",
"      Fitzgerald DW, Janes H, Robertson M, et al. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis 2011; 203:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/90\">",
"      Yang ZY, Wyatt LS, Kong WP, et al. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003; 77:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/91\">",
"      Bru&ntilde;a-Romero O, Gonz&aacute;lez-Aseguinolaza G, Hafalla JC, et al. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci U S A 2001; 98:11491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/92\">",
"      Tritel M, Stoddard AM, Flynn BJ, et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 2003; 171:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/93\">",
"      Santosuosso M, McCormick S, Zhang X, et al. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006; 74:4634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/94\">",
"      Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008; 3:e3548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/95\">",
"      Kobinger GP, Figueredo JM, Rowe T, et al. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine 2007; 25:5220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/96\">",
"      Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 2008; 16:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26441/abstract/97\">",
"      Tompkins SM, Zhao ZS, Lo CY, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007; 13:426.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8300 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-7D7969DF47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26441=[""].join("\n");
var outline_f25_52_26441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1328948514\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serotype differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192088427\">",
"      Immune response to adenoviruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adenovirus proteins modulate host responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192088549\">",
"      Persistent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      USE OF ADENOVIRUS VECTORS FOR GENE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transgene expression from adenovirus vectors is transient in vivo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adenovirus vectors are immunogenic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Strategies to reduce immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Use of adenovirus vectors for transient expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Use of conditionally replicating adenoviruses for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Human studies of adenovirus gene therapy vectors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Gene replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ADENOVIRUS-BASED VACCINES AGAINST INFECTIOUS PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1328948514\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=related_link\">",
"      Therapeutic angiogenesis for management of refractory angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_52_26442="What's new in family medicine";
var content_f25_52_26442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in family medicine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/52/26442/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26442/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/52/26442/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/52/26442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ADULT GENERAL INTERNAL MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Reassurance provided by diagnostic testing",
"    </span>",
"   </p>",
"   <p>",
"    Diagnostic tests are often ordered for patients with a low pretest probability of serious disease to provide reassurance, as well as to rule out illnesses. A meta-analysis of three open label randomized trials compared initial diagnostic testing (eg, cranial magnetic resonance imaging) with no testing in&nbsp;more than 700&nbsp;patients with a low probability of disease (eg, headache) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;Illness worry (concern that symptoms may represent serious illness) was comparable for both groups in the short term (&le;3 months) and long term (&gt;3 months). Additional analyses found that testing did not reduce nonspecific anxiety or resolve symptoms, but did lead to a small decrease in the number of subsequent visits to primary care.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H15#H15\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cardiotoxicity in women with breast cancer after radiation therapy",
"    </span>",
"   </p>",
"   <p>",
"    A&nbsp;case-control study of women treated for breast cancer with surgery and radiation therapy (RT) found that incidental radiation to the heart is associated with an increased risk&nbsp;for a significant coronary event (myocardial infarction, revascularization, or death from ischemic heart disease)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/2\">",
"     2",
"    </a>",
"    ].&nbsp;The increased risk can be seen after relatively-low doses of radiation and the presence of cardiac risk factors markedly increased the impact of radiation. Despite this, the absolute risk associated with RT appears to be small and to be outweighed by the benefits in patients for whom radiation is typically recommended.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Effect of radiation dose to the heart'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-term regular aspirin use and age-related macular degeneration",
"    </span>",
"   </p>",
"   <p>",
"    In&nbsp;a longitudinal&nbsp;population-based study of individuals aged 46 to 83 years at baseline, regular aspirin use was associated with a small&nbsp;increased risk of age-related macular degeneration (AMD)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/3\">",
"     3",
"    </a>",
"    ]. The estimated incidence of late AMD, comparing individuals with regular aspirin use (twice or more a week for at least three months)&nbsp;for at least ten years and non-users of aspirin, was 1.76 and 1.03 percent respectively. Aspirin use started five years before retinal&nbsp;examination was not associated with increased risk for AMD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link&amp;anchor=H11#H11\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient understanding of acetaminophen dosing",
"    </span>",
"   </p>",
"   <p>",
"    Accidental acetaminophen overdose remains a major cause of morbidity and mortality. According to a prospective study of 500 patients tested about their understanding of acetaminophen dosing at one academic and one community internal medicine practice, up to 46 percent of patients would ingest excessive amounts of acetaminophen because they misunderstand dosing directions or fail to recognize that acetaminophen is found in more than one medication they are using [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/4\">",
"     4",
"    </a>",
"    ]. Such errors occur most often among patients with limited literacy or frequent acetaminophen use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H2#H2\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Proactive, intermittent therapy for long-term control of atopic dermatitis",
"    </span>",
"   </p>",
"   <p>",
"    The long-term control of skin inflammation is a major challenge in the management of patients with atopic dermatitis. The 2012 European and American guidelines&nbsp;for the treatment of atopic dermatitis recommend proactive, intermittent topical&nbsp;therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. After induction of remission with continuous topical therapy, twice weekly&nbsp;application of topical&nbsp;corticosteroids&nbsp;to eczema-prone areas may prevent relapses in both adults and children with atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H41442152#H41442152\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Prevention of relapses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute kidney injury after synthetic cannabinoid use",
"    </span>",
"   </p>",
"   <p>",
"    Synthetic cannabinoids, including tetrahydrocannabinol [THC], cannabidiol [CBD], and cannabinol [CBN], are analogs of naturally-occurring chemicals found in marijuana. In two small case series, synthetic cannabinoid or &ldquo;Spice&rdquo; use has been associated with reversible acute kidney injury necessitating renal replacement therapy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Pathologically, the injury is characterized by acute tubular necrosis and interstitial nephritis. In some instances, these previously-healthy&nbsp;young adults&nbsp;reported smoking a blueberry- or bubblegum-flavored synthetic cannabinoid. A unique synthetic cannabinoid, 1-((5-fluoropentyl)-1H-indol-3yl) (2,23,3,-tetramethylcyclopropyl) methanone (also called XLR-11) was found in clinical specimens and product samples [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the specific chemical agent responsible for causing renal toxicity is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=see_link&amp;anchor=H1913412#H1913412\">",
"     \"Designer drugs of abuse\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Zolpidem dosing for insomnia in women",
"    </span>",
"   </p>",
"   <p>",
"    Zolpidem is a nonbenzodiazepine sedative that is widely used for treatment of insomnia and is known to cause residual daytime sedation, drowsiness, cognitive impairment, and motor incoordination in some individuals. Recent studies reviewed by the US Food and Drug Administration (FDA) suggest that 15 percent of women and 3 percent of men have next-morning zolpidem blood levels capable of impairing driving after a 10 mg dose [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/9\">",
"     9",
"    </a>",
"    ]. Based on these findings, the FDA has recommended lowering the usual dose of zolpidem in women to 5 mg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H947212#H947212\">",
"     \"Treatment of insomnia\", section on 'Nonbenzodiazepines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Statins and myalgias",
"    </span>",
"   </p>",
"   <p>",
"    Despite common clinical experience, higher rates of myalgia with statins, compared to placebo, have not typically been found in randomized trials designed to evaluate treatment for cardiovascular prevention. However, a six-month randomized trial in 420 healthy adults designed specifically to examine the effects of statin therapy on skeletal muscle function has found a higher incidence of myalgia in patients treated with atorvastatin 80 mg daily than with placebo (9.3 versus 4.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/10\">",
"     10",
"    </a>",
"    ]. Although there have been concerns about the effects of statin therapy on exercise tolerance, no statistically-significant differences were seen in muscle strength, muscle endurance, or aerobic performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link&amp;anchor=H4#H4\">",
"     \"Statin myopathy\", section on 'Myalgias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral couples therapy for PTSD",
"    </span>",
"   </p>",
"   <p>",
"    Cognitive and behavioral psychotherapies can reduce symptoms of patients with posttraumatic stress disorder (PTSD), but there has been little research on interventions for relationship problems associated with the disorder. A randomized trial compared a manual-based, cognitive-behavioral couples therapy to a waitlist control in 40 couples that included a person with PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/11\">",
"     11",
"    </a>",
"    ]. Couples with PTSD who received the 15-session intervention experienced more improvement in intimate-relationship satisfaction and greater reduction in PTSD symptoms in the partner with the disorder, compared to the control group. This intervention shows promise, but needs further testing in larger samples of couples that have relationship difficulties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link&amp;anchor=H324030410#H324030410\">",
"     \"Psychotherapy for posttraumatic stress disorder\", section on 'Couples therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Statins and cancer outcomes",
"    </span>",
"   </p>",
"   <p>",
"    Prior observational studies have suggested that statin therapy may reduce the risk of cancer; however, these results were almost certainly due to bias and residual confounding, since meta-analyses of randomized trials have shown no comparable benefit. An observational study has now suggested improved outcomes in patients with cancer who were taking statins prior to their diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/12\">",
"     12",
"    </a>",
"    ]. This result, like those in the prior observational studies of statins and cancer risk, is most likely due to residual confounding and bias and is unconvincing until confirmed with evidence from randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=see_link&amp;anchor=H3#H3\">",
"     \"Statins: Possible noncardiovascular benefits\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GERIATRICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Discontinuing antipsychotic agents in patients with dementia",
"    </span>",
"   </p>",
"   <p>",
"    Because antipsychotic agents are associated with an increased risk of mortality in patients with dementia, it has been recommended that discontinuation of these agents should be attempted at regular intervals. One trial showed that this is not always possible. Among 180 patients with Alzheimer disease and psychosis or agitation who had initially responded to treatment with a 16 week course of risperidone, those randomly assigned to immediate drug discontinuation had an increased risk of relapse of psychosis or agitation over 16 weeks of followup (60 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/14\">",
"     14",
"    </a>",
"    ]. Those who were assigned to drug discontinuation after an additional 16 weeks of treatment also had a higher rate of relapse over the ensuing 16 weeks compared to those who continued treatment throughout (48 versus 15 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Antipsychotic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aspirin for the primary prevention of cardiovascular disease and cancer",
"    </span>",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have shown aspirin to reduce the risk of non-fatal myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/15\">",
"     15",
"    </a>",
"    ],&nbsp;and long-term aspirin use reduces overall cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/16\">",
"     16",
"    </a>",
"    ]. While several published guidelines have considered the benefit of aspirin for&nbsp;the prevention of either cardiovascular disease (CVD)&nbsp;or cancer versus&nbsp;the risk of increased bleeding, most have not addressed the&nbsp;potential net benefit of aspirin in preventing both CVD and cancer.&nbsp;A meta-analysis addressing this combined outcome suggests that aspirin use in 1000 average risk patients at age 60 years would be expected to result, over a 10-year period, in&nbsp;six fewer deaths, 19 fewer non-fatal myocardial infarctions, 14 fewer cancers, and 16 more major bleeding events (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ).&nbsp;For individuals age 50 years or greater without excess bleeding risks, we suggest daily aspirin at a dose of 75 to 100 mg. Patients who are more concerned about the bleeding risks than the potential benefits may reasonably choose to not take aspirin for primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=see_link&amp;anchor=H1761594#H1761594\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\", section on 'Recommendations for primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mediterranean diet and prevention of cardiovascular disease",
"    </span>",
"   </p>",
"   <p>",
"    A large randomized trial compared three diets in patients at high cardiovascular risk: a Mediterranean diet supplemented with olive oil, a Mediterranean diet supplemented with mixed nuts, and advice to reduce dietary fat [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/17\">",
"     17",
"    </a>",
"    ]. The trial was stopped early after a median follow-up of 4.8 years. For the primary composite cardiovascular endpoint of myocardial infarction, stroke, and cardiovascular death, event rates were similar for the Mediterranean diets supplemented with olive oil and mixed nuts, and lower than for the control diet (8.1 and 8.0 events per 1000 person-years respectively, versus 11.2 events per 1000 person-years; HR for both Mediterranean diets combined 0.71). Although this trial suggests possible substantial cardiovascular benefits from a Mediterranean diet, there was a surprisingly large reduction in events, a low total number of events (288), and the trial was stopped early for benefit. This raises concerns that the apparent benefits of a Mediterranean diet could have been overestimated, since this can be a problem in trials that are stopped early for benefit, particularly when there are also relatively few events [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H20#H20\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Mediterranean diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Role of folate or folic acid in cancer prevention",
"    </span>",
"   </p>",
"   <p>",
"    The role of folate or folic acid in cancer prevention is uncertain. Several large observational studies have suggested a decrease in risk of colorectal and other cancers with dietary folate, while some randomized trials of folic acid supplementation have raised the possibility of harm (increased cancer risk) from folic acid supplementation. In the largest meta-analysis of individual patient data from randomized trials of folic acid for the prevention of cardiovascular disease (10 trials, n = 49,969) and colorectal adenoma (3 trials, n = 2652), during an average of 5.2 years of treatment, there was no significant difference in overall cancer incidence for patients assigned to folic acid or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/21\">",
"     21",
"    </a>",
"    ]. There was also no significant effect on the incidence of specific cancers, including cancers of the large intestine, prostate, lung, or breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link&amp;anchor=H23#H23\">",
"     \"Cancer prevention\", section on 'Folate and other B vitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Long-term use of postmenopausal hormone therapy",
"    </span>",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) has published an updated meta-analysis of postmenopausal hormone therapy (nine trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/22\">",
"     22",
"    </a>",
"    ]. Results were largely based upon the two Women's Health Initiative trials, and the mean age of subjects was &gt;60 years. Estrogen plus progestin, as well as&nbsp;unopposed estrogen, decreased fracture risk but increased&nbsp;the risk for stroke, venous thromboembolic events, and gallbladder disease. Estrogen plus progestin increased risk for breast cancer, but unopposed estrogen decreased breast cancer risk. Based upon these data, the USPSTF continues to recommend against the use of both combined estrogen and progestin and unopposed estrogen for prevention of chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, they note that this recommendation does not apply to women considering&nbsp;hormone therapy for relief of menopausal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H91121219#H91121219\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Risk for nonmelanoma skin cancer in users of tanning beds",
"    </span>",
"   </p>",
"   <p>",
"    Tanning bed use has been associated with increased risk for cutaneous squamous cell carcinoma and basal cell carcinoma. A 2012 meta-analysis of observational studies found a 67 percent higher risk for cutaneous squamous cell carcinoma&nbsp;and a 29 percent increased risk for basal cell carcinoma among subjects with a history of any tanning bed use compared with subjects who had never used tanning beds&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'UV light exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'UVA radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Multivitamins and cancer",
"    </span>",
"   </p>",
"   <p>",
"    Observational studies have not identified a consistent decrease in cancer risk with multivitamin use. A large randomized trial of multivitamins, involving over 14,000 men, demonstrated a small, statistically-significant reduction in total cancer risk (HR 0.92, 95% CI 0.86-0.998) for the multivitamin group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/26\">",
"     26",
"    </a>",
"    ]. The study population was male physicians 50 years and older at recruitment, and thus generally well nourished and highly educated. With a mean follow-up of 11.2 years, there was a reduction in total cancer from 18.3 to 17.0 events per 1000 person-years; there was no impact on cancer mortality. Trials of other vitamin supplements, including limited combination supplements, have generally not shown similar effects and a meta-analysis incorporating all such trials would be helpful. While awaiting further analysis and trials, it remains uncertain whether multivitamin supplements provide added benefit to a balanced, healthful diet for most individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H48#H48\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Multivitamins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link&amp;anchor=H14#H14\">",
"     \"Cancer prevention\", section on 'Vitamins and micronutrients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vitamin D and prevention of colds",
"    </span>",
"   </p>",
"   <p>",
"    A role for vitamin D in the prevention of upper respiratory infections was suggested by data from a US survey population that found a relationship between higher serum levels of 25-hydroxyvitamin D and fewer reported respiratory infections. However, in the largest randomized trial evaluating whether vitamin D supplementation can prevent upper respiratory infections, there was no difference in the incidence of colds over 18 months (two winter seasons) comparing groups who received monthly vitamin D3 injections or placebo; 25-OH vitamin D levels (comparable between groups at baseline) were 48 and 25",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for intervention and control groups respectively during the course of the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=see_link&amp;anchor=H21#H21\">",
"     \"The common cold in adults: Treatment and prevention\", section on 'Vitamin D'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Screening colonoscopy and incidence of late stage colorectal cancer",
"    </span>",
"   </p>",
"   <p>",
"    There are no randomized trials of the effectiveness of screening colonoscopy in average-risk patients, and some observational data suggest that colonoscopy might not be effective in detecting right-sided (proximal) colon lesions. In a case-control study in four health plans in the United States in which rates of screening colonoscopy were low in both cases and matched controls (reflecting practice patterns going back 17 years), late stage (IIb or higher) colorectal cancer was associated with failure to undergo screening colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/28\">",
"     28",
"    </a>",
"    ]. The association was the same for right- and left-sided cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H16#H16\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Evidence of effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Screening women with a familial ovarian cancer syndrome for ovarian cancer",
"    </span>",
"   </p>",
"   <p>",
"    In the largest cohort study of high-risk women, the United Kingdom Familial Ovarian Cancer Screen Study (UK FOCSS), 3563 women with a familial ovarian cancer syndrome (estimated minimum lifetime risk of 10 percent) who had declined or deferred risk reducing salpingo-oophorectomy (RRSO) were screened annually for a mean of 3.2 years with a combination of transvaginal ultrasound and CA-125 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/29\">",
"     29",
"    </a>",
"    ]. Sensitivity for the detection of incident ovarian",
"    <span class=\"nowrap\">",
"     cancer/fallopian",
"    </span>",
"    tube cancer was 81.0 to 87.5 percent. The positive predictive value of incident screening was 25.5 percent, which exceeds the threshold of 10 percent considered necessary for ovarian cancer screening. 30.8 percent (4 of 13) of incident cancers were stage I or II.&nbsp;",
"    <br/>",
"    <br/>",
"    Although&nbsp;RRSO&nbsp;remains the only reliable method of decreasing mortality from ovarian cancer in this high-risk population, this study suggests that screening&nbsp;has the potential to somewhat reduce risk for women who wish to maintain their childbearing potential until they are ready to undergo surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening for ovarian cancer\", section on 'High-risk women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Rescreening for colorectal cancer",
"    </span>",
"   </p>",
"   <p>",
"    Although colonoscopy is frequently chosen for the first-round of screening for colorectal cancer (CRC), the choice of screening modality following an initial negative study may differ. Since the risk of disease is significantly lower for second-round screening and beyond, options for subsequent testing may include no screening or testing using less-invasive or less-costly modalities. In the absence of trial data, a computer simulation model found that, compared with no screening, rescreening by any method following an initial negative colonoscopy reduced the risk of CRC&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/30\">",
"     30",
"    </a>",
"    ]. Rescreening with colonoscopy was projected to cause more complications and greater cost compared&nbsp;with other modalities (highly sensitive stool guaiac, fecal immunochemical testing, or CT colonography), with equivalent benefit measured as life-years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link&amp;anchor=H3759928#H3759928\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Other factors that may impact screening test choice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     CT colonography for colorectal cancer screening",
"    </span>",
"   </p>",
"   <p>",
"    In a study of colorectal cancer screening comparing optical colonoscopy with laxative-free CT colonography (CTC), in which stool was tagged with orally-ingested contrast material and software was used to &ldquo;electronically cleanse&rdquo; the bowel images, the sensitivity and specificity for adenomas &ge;10 mm were 91 and 85 percent for CTC and 95 and 89 percent for optical colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/31\">",
"     31",
"    </a>",
"    ]. A survey of the study participants, who underwent both procedures, indicated preference for CTC. The performance characteristics of laxative-free CTC was comparable to the performance of CTC with laxatives reported in other studies.",
"    <br/>",
"    <br/>",
"    An earlier report of a randomized trial in the Netherlands compared outcomes for two colorectal cancer screening strategies: invitation for colonoscopy or invitation for screening CT colonography (for which patients did not use a cathartic preparation) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/32\">",
"     32",
"    </a>",
"    ]. The diagnostic yield for advanced neoplasia was greater for individuals who underwent colonoscopy than for CT colonography. However, participation rates were significantly lower for those invited for colonoscopy than for colonography (22 versus 34 percent), so that the diagnostic yield for advanced neoplasia per 100 invitees was essentially the same for both strategies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H18#H18\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Computed tomographic colonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Flexible sigmoidoscopy for colorectal cancer screening",
"    </span>",
"   </p>",
"   <p>",
"    Results of the flexible sigmoidoscopy arm of the Prostate Lung Colorectal and Ovarian (PLCO) Screening Trial have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/33\">",
"     33",
"    </a>",
"    ]. A total of 154,900 men and women aged 55 to 74 were randomly assigned to screening with flexible sigmoidoscopy or to usual care, with median follow-up of 11.9 years. There was a 21 percent reduction in the relative risk of colorectal cancer and a 26 percent reduction in the relative risk of death from colorectal cancer, comparing the screening arm with usual care. Although the incidence of both proximal and distal CRC significantly decreased, a reduction in mortality was seen only for distal cancer. There was significant contamination in the usual care group (among whom 47 percent underwent either sigmoidoscopy or colonoscopy), suggesting that the impact of sigmoidoscopy compared to no screening might be even greater than was seen in this trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H11#H11\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Sigmoidoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ADULT CARDIOVASCULAR MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Azithromycin and torsades de pointes",
"    </span>",
"   </p>",
"   <p>",
"    In 2013, the US Food and Drug Administration issued a warning about the risk of QT interval prolongation and potentially fatal torsades de pointes among patients taking azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients at particular risk include those with existing QT prolongation, hypokalemia, hypomagnesemia, significant bradycardia, and those receiving certain antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The warning was based on a review&nbsp;following the publication of a study that showed an increased risk of death in patients receiving azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/37\">",
"     37",
"    </a>",
"    ]. Clinicians should assess the risk of torsades de pointes when considering antibiotic treatment options for patients at risk for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/34\">",
"     34",
"    </a>",
"    ]. Other macrolides and certain non-macrolides, such as fluoroquinolones, also have the potential for prolonging the QT interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Duration of beta blocker after myocardial infarction",
"    </span>",
"   </p>",
"   <p>",
"    Although beta blocker (BB) therapy reduces mortality in patients with recent myocardial infarction (MI), the optimal duration of beta blocker therapy after MI is unknown. Beta blocker therapy is continued indefinitely for many patients,&nbsp;based on studies performed in the 1980s and 1990s. A 2013 observational study evaluated outcomes in&nbsp;over 5000&nbsp;patients with ST-elevation MI treated with primary percutaneous coronary intervention&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/38\">",
"     38",
"    </a>",
"    ]. Adjusted mortality rates over approximately four years&nbsp;did not differ between patients who did or did not continue&nbsp;BB therapy. However, subgroup analyses revealed that BB treatment was associated with a significantly lower mortality for high-risk patients, such as those with heart failure. We believe the available evidence supports the use of&nbsp;beta blockers in patients with MI for as long as three years. We make a weak recommendation for BB beyond three years in patients with high-risk features such as cardiogenic shock, heart failure, or chronic kidney disease.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link&amp;anchor=H346544189#H346544189\">",
"     \"Beta blockers in the management of acute coronary syndrome\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Apixaban for prevention of embolic events in atrial fibrilllation",
"    </span>",
"   </p>",
"   <p>",
"    Apixaban has been approved by the US Food and Drug Administration and the European Medicines Agency for use in patients with atrial fibrillation to reduce the risk of stroke and systemic embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Approval was based on the results of the large randomized ARISTOTLE trial, which found that apixaban was non-inferior to warfarin in terms of efficacy and superior in terms of safety [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/41\">",
"     41",
"    </a>",
"    ]. In patients with atrial fibrillation who meet criteria for anticoagulation, we prefer either a factor Xa inhibitor (apixaban or rivaroxaban) or a direct thrombin inhibitor (dabigatran) to warfarin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982962#H147982962\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H485506384#H485506384\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Indications for and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Bleeding rates with warfarin and dabigatran in atrial fibrillation",
"    </span>",
"   </p>",
"   <p>",
"    Despite favorable results in the initial randomized trials, post-marketing reports have raised concerns that patients with atrial fibrillation may have a higher rate of serious bleeding with dabigatran than warfarin. In November 2012, the US Food and Drug Administration issued a statement that a review of information from insurance claims and administrative data sources suggested that the rate of bleeding with dabigatran did not appear to be higher than with warfarin in patients who were using either drug for the first time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982501#H147982501\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Studies of anticoagulant monotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     ADULT GASTROENTEROLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Blood transfusion thresholds for acute upper GI bleeding",
"    </span>",
"   </p>",
"   <p>",
"    The decision to initiate blood transfusions in patients with acute upper gastrointestinal bleeding is based on the rapidity of bleeding and the patients' comorbid conditions. A randomized trial of patients with and without cardiovascular disease suggests that in patients who are not at increased risk for complications from anemia, outcomes are improved if a lower hemoglobin threshold (&lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is used for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients transfused when the hemoglobin was &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had lower mortality rates, were less likely to have further bleeding, and were less likely to suffer complications.",
"    <br/>",
"    <br/>",
"    We recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    rather than &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    for the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. Additionally, we suggest transfusing to maintain the hemoglobin at &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     ADULT HEMATOLOGY AND ONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Apixaban for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    The randomized, double-blind AMPLIFY-EXT study compared the efficacy and safety of apixaban with placebo in over 2000 subjects with venous thromboembolism (VTE) who had completed 6 to 12 months of anticoagulation and for whom there was uncertainty regarding the further continuation of anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/44\">",
"     44",
"    </a>",
"    ]. Symptomatic recurrent VTE or death from VTE occurred in 8.8 and 1.7 percent of those receiving placebo or apixaban, respectively, for an overall 80 percent reduction in the risk of VTE recurrence with apixaban. Major bleeding was not increased in the group receiving apixaban. A randomized trial comparing this agent with standard-dose warfarin will help to determine the future role of apixaban for the continued treatment of VTE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H7480111#H7480111\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Issues to consider'",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Aspirin for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    Two randomized trials, WARFASA and ASPIRE, examined the use of low-dose aspirin (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for the prevention of recurrent venous thromboembolism (VTE)&nbsp;following&nbsp;6 to 18 months of anticoagulation for a&nbsp;first unprovoked episode of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. WARFASA showed a significant reduction in the rate of VTE recurrence, in contrast to&nbsp;ASPIRE, which failed&nbsp;to meet&nbsp;its primary end point of significant&nbsp;risk reduction of recurrent&nbsp;VTE.&nbsp;A prospectively planned combined analysis of both trials indicated that aspirin, compared with placebo, significantly reduced both the rate of VTE recurrence and major vascular events (a composite&nbsp;secondary endpoint of&nbsp;recurrent VTE, myocardial infarction, stroke, and cardiovascular death) by 32 and 34 percent, respectively, with no excess bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/46\">",
"     46",
"    </a>",
"    ]. After completing anticoagulant therapy following a first-time unprovoked VTE, switching to low-dose aspirin,&nbsp;is an option that may reduce the risk&nbsp; of VTE recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/47\">",
"     47",
"    </a>",
"    ].&nbsp;Direct comparison of aspirin and warafarin for the prevention of VTE was not performed&nbsp;in either&nbsp;trial and warrants further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H11015892#H11015892\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Use of aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     ADULT INFECTIOUS DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Fecal microbiota transplant for Clostridium difficile infection",
"    </span>",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients with Clostridium difficile (C. difficile)-associated diarrhea have recurrent disease after an initial course of antibiotic therapy. In an open label randomized controlled trial, 43 patients with recurrent C. difficile infection after at least one course of antibiotic therapy were randomly assigned to one of three treatment arms: duodenal infusion of donor feces preceded by an abbreviated regimen of vancomycin (vancomycin 500 mg four times daily for four days) and bowel lavage; a standard vancomycin regimen (vancomycin 500 mg four times daily for 14 days); or a standard vancomycin regimen with bowel lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/48\">",
"     48",
"    </a>",
"    ]. A single infusion of donor feces resulted in significantly higher rates of resolution of C. difficile-associated diarrhea without relapse at 10 weeks as compared with a standard vancomycin regimen with or without bowel lavage (81, 23, and 31 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link&amp;anchor=H11299943#H11299943\">",
"     \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\", section on 'Administration via nasogastric tube'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     2012-2013 seasonal influenza vaccine effectiveness",
"    </span>",
"   </p>",
"   <p>",
"    In a case-control study of 2697 individuals with acute respiratory illness enrolled between early December 2012 and mid-January 2013, the United States Centers for Disease Control and Prevention estimated that the effectiveness of the 2012-2013 seasonal influenza vaccines in preventing medically-attended influenza infections in all age groups was 56 percent (95% CI 47-63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/49\">",
"     49",
"    </a>",
"    ]. Effectiveness against influenza A was 47 percent (95% CI 35-58 percent) and against influenza B was 67 percent (95% CI 51-78 percent). However, the age-stratified effectiveness estimate against H3N2 influenza A was only 9 percent for individuals &ge;65 years of age (compared with 46 to 50 percent for individuals from 18 to 64 years of age).",
"    <br/>",
"    <br/>",
"    Given the moderate overall effectiveness of the vaccine (and poor effectiveness against H3N2 influenza A in older adults), influenza infection will occur among some individuals who received the influenza vaccine. This highlights the importance of early antiviral therapy (regardless of vaccination status), particularly for those at risk for severe or complicated influenza infection.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H205840196#H205840196\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Effectiveness for the 2012-2013 season'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Recurrence of erythema migrans: reinfection or relapse?",
"    </span>",
"   </p>",
"   <p>",
"    When patients develop a second episode of erythema migrans after being treated for early Lyme disease, some clinicians have been uncertain whether this represents reinfection with a different strain of Borrelia burgdorferi or relapse of the initial infection. In a study that included 22 paired (initial and second) episodes of erythema migrans, molecular typing of the B. burgdorferi gene encoding outer surface protein C (ospC) was performed using B. burgdorferi strains that were detected in cultures of skin or blood specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/50\">",
"     50",
"    </a>",
"    ]. The ospC genotype was found to be different at each initial and second episode of erythema migrans, demonstrating that repeat episodes of erythema migrans in appropriately treated patients were due to reinfection rather than relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Reinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Meningococcal vaccination for men who have sex with men from New York City",
"    </span>",
"   </p>",
"   <p>",
"    In the fall of 2012, an outbreak of invasive meningococcal disease was detected in men who have sex with men (MSM) in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Since 2010, 14 cases have been detected, with 9 cases occurring in 2012 (as of late October). Nine of the 14 cases have been in HIV-infected men. As of late October 2012, four patients have died, three of whom were HIV-infected. Given the current outbreak, we recommend meningococcal vaccination for MSM, especially if HIV-infected, if their residence, travel, or social interactions have put them (or will put them) in close contact with other MSM from New York City since September 1, 2012 (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H2#H2\">",
"     \"Meningococcal vaccines\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H21#H21\">",
"     \"Meningococcal vaccines\", section on 'In adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H19#H19\">",
"     \"Immunizations in HIV-infected patients\", section on 'Meningococcal vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Egg-free influenza vaccine",
"    </span>",
"   </p>",
"   <p>",
"    A trivalent inactivated influenza vaccine (Optaflu), produced using cultured mammalian cells, was approved in Europe for use in adults beginning in the 2007-2008 influenza season. This same vaccine (called Flucelvax) was approved for individuals &ge;18 years of age for the 2012-2013 season by the US Food and Drug Administration in November 2012&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. A second egg-free vaccine (Flublok), made using an insect virus (baculovirus) expression system and recombinant DNA technology, was approved in January 2013 by the FDA for adults aged 18 to 49 years. The efficacy and rates of serious adverse events seen with&nbsp;both egg-free&nbsp;vaccines were comparable to standard available influenza vaccines. For&nbsp;patients age 18 or older with egg allergy, we recommend administration of&nbsp;an age-appropriate,&nbsp;egg-free, trivalent inactivated influenza vaccine (TIV) rather than an egg-based inactivated vaccine. However, if the&nbsp;an egg-free&nbsp;vaccine is not readily available, immunization should proceed with egg-based vaccination with appropriate precautions (eg, observation for 30 minutes following vaccination in patients with mild allergic reactions to egg, and immunization supervised by an allergy specialist for patients with a history of severe egg allergic reactions).",
"    <br/>",
"    <br/>",
"    We recommend not using&nbsp;the egg-free vaccine in patients younger than age 18, since the",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccine appears to be less immunogenic in young children and the immunogenicity of these vaccines and the rates of side effects in this population are otherwise not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H8#H8\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Alternative methods of vaccine production'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H9#H9\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Options for testing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     ADULT NEUROLOGY AND PSYCHIATRY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Deep brain stimulation for early Parkinson disease",
"    </span>",
"   </p>",
"   <p>",
"    The potential benefit of deep brain stimulation (DBS) in early Parkinson disease (PD) is illustrated by the results of the EARLYSTIM trial that evaluated 251 adults (mean age 53 years) with levodopa-responsive PD, mild motor complications, and no dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/55\">",
"     55",
"    </a>",
"    ]. Compared with the medical therapy group at two years, patients in the DBS plus medical therapy&nbsp;group showed a statistically-significant and clinically-meaningful improvement in quality of life&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, the DBS group had significant improvements in motor disability, activities of daily living, levodopa-induced motor complications, and time with good mobility and no dyskinesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H92694887#H92694887\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Effectiveness in early PD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Updated guidelines for early management of acute ischemic stroke",
"    </span>",
"   </p>",
"   <p>",
"    The American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association has&nbsp;published updated guidelines&nbsp;for the early management of acute ischemic stroke. One important change is that a&nbsp;number of conditions previously considered strict exclusions for the use&nbsp;of intravenous thrombolysis are now considered relative exclusions (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/57\">",
"     57",
"    </a>",
"    ]. These include minor or rapidly improving stroke symptoms, major surgery or serious trauma in the previous 14 days, gastrointestinal or urinary tract bleeding in the previous 21 days, myocardial infarction in the previous three months, and seizure at the onset of stroke with postictal neurologic impairments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link&amp;anchor=H209963#H209963\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Role of eligibility criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors and bleeding",
"    </span>",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors (SSRIs) are believed to alter platelet aggregation. A meta-analysis of 16 observational studies (n = 506,411) found that the risk of intracranial hemorrhage was elevated in patients who received SSRIs compared to controls who did not; heterogeneity across studies was small to moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/58\">",
"     58",
"    </a>",
"    ]. In a separate analysis, the risk of brain hemorrhage was elevated in patients taking the combination of SSRIs and anticoagulants, compared with anticoagulants alone. However, the clinical significance of these findings is not clear. Based upon the meta-analysis, it was estimated that SSRIs may lead to one additional intracerebral hemorrhage for every 10,000 patients treated for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H12543449#H12543449\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     GYNECOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     New levonorgestrel-releasing IUD",
"    </span>",
"   </p>",
"   <p>",
"    A lower-dose (13.5 mg) levonorgestrel-releasing intrauterine device (IUD; Skyla) became available in the United States in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/60\">",
"     60",
"    </a>",
"    ]. It is smaller in size than the 52 mg levonorgestrel IUD (Mirena)&nbsp;and thus may be easier to insert in nulliparous women. Because of the lower levonorgestrel dose, it is approved for up to three years of use (the 52 mg dose is approved for up to five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of intrauterine contraception\", section on 'Levonorgestrel-releasing IUD'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     \"Levonorgestrel: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Levonorgestrel intrauterine device for menorrhagia",
"    </span>",
"   </p>",
"   <p>",
"    The levonorgestrel intrauterine device (LNG-IUD) is an effective treatment for menorrhagia. Quality of life outcomes were evaluated for the first time in a randomized trial that assigned women to the LNG-IUD (Mirena) or treatment with other medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/62\">",
"     62",
"    </a>",
"    ]. Women in the LNG-IUD group had significantly higher scores in six domains of daily life at six months and two years. Significantly more women in the LNG-IUD group continued treatment at two years (64 versus 38 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H19#H19\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Levonorgestrel-IUD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     OBSTETRICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Use of selective serotonin reuptake inhibitors (SSRIs) to treat pregnant patients does not appear to be associated with stillbirth or infant mortality. In an observational study of over one million pregnancies, registries from five countries were examined for information about prescriptions, maternal characteristics, pregnancy outcomes, and neonatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/63\">",
"     63",
"    </a>",
"    ]. More than 29,000 women had filled a prescription for an SSRI. After accounting for maternal age, smoking, diabetes, hypertension, and hospitalization for psychiatric illness, the risks of stillbirth and infant mortality were comparable for women who used or did not use SSRIs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H8#H8\">",
"     \"Depression in pregnant women: Management\", section on 'Pregnancy complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Tdap during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    The prevalence of pertussis in the United States has been increasing, in part because pertussis immunity after vaccination or disease wanes over time. Infants younger than three months of age are at highest risk of morbidity and mortality from this infection, and many infants contract pertussis from their mothers. Vaccination of the mother can thus significantly decrease the risk of infant exposure, and placental transfer of maternal antibodies may additionally provide a degree of passive protection to the infant for two to six months. In 2013, the United States Advisory Committee on Immunization Practices (ACIP) recommended that all pregnant women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during",
"    <strong>",
"     each",
"    </strong>",
"    pregnancy, optimally between 27 and 36 weeks of gestation, regardless of prior vaccination status, to increase the likelihood of optimal protection against pertussis for both the mother and her infant during the first few months of the infant&rsquo;s life [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/64\">",
"     64",
"    </a>",
"    ]. Previously, Tdap was recommended only for pregnant women who had not previously received the acellular pertussis vaccine during adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Safety and efficacy of influenza vaccination in pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Influenza vaccination is recommended for pregnant women because both mother and fetus are at increased risk of complications related to this infection, including fetal death. In addition, maternal vaccination provides passive protection to the infant. However, concerns about vaccine safety have interfered with compliance in this patient group. The safety and efficacy of vaccination of pregnant women were confirmed in a retrospective analysis of over 100,000 pregnancies during the 2009 influenza A (H1N1) pandemic in Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/65\">",
"     65",
"    </a>",
"    ]. Vaccination during pregnancy substantially reduced the risk of a maternal influenza diagnosis (adjusted hazard ratio, 0.30) and was associated with a trend in reduction of fetal death. All women who are pregnant or will be pregnant during influenza season should receive the inactivated influenza vaccine, regardless of pregnancy trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link&amp;anchor=H5795661#H5795661\">",
"     \"Influenza and pregnancy\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     New guidelines for umbilical cord clamping",
"    </span>",
"   </p>",
"   <p>",
"    The optimal timing of clamping of the umbilical cord during delivery has been an area of some debate. A December 2012 American College of Obstetricians and Gynecologists (ACOG) committee opinion concluded that the decision to perform early versus delayed cord clamping in term deliveries should be based on patient-specific factors, particularly the infant&rsquo;s risk of developing iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/66\">",
"     66",
"    </a>",
"    ]. For preterm deliveries, they recommended delayed cord clamping given the significant reduction in intraventricular hemorrhage associated with this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H30#H30\">",
"     \"Management of normal labor and delivery\", section on 'Cord clamping'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h1\">",
"     PEDIATRICS: GENERAL PEDIATRICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Diagnosis of hypertension in childhood requires repeated blood pressure measurements",
"    </span>",
"   </p>",
"   <p>",
"    The need for confirmation of the diagnosis of hypertension based on three&nbsp;blood pressure (BP)&nbsp;measurements at separate clinical vists&nbsp;was illustrated in a large cohort study of children cared for in community-based practices [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/68\">",
"     68",
"    </a>",
"    ]. In the United States, normative BP percentiles are based upon data on gender, age, height, and blood pressure measurements from the National Health and Nutrition Examination Survey (NHANES) and other population-based studies (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 6",
"    </a>",
"    ). Initial BP measurement was normal (below the 90th percentile), prehypertensive&nbsp;(systolic or diastolic BP between the 90th or 95th percentile)&nbsp;and hypertensive (systolic or diastolic BP &ge;95th percentile) in 82, 13, and 5 percent of children. At follow-up, subsequent hypertensive measurements were observed in only 4 percent of the 10,848 children who had initial hypertensive values. In this cohort, the overall prevalence of hypertension&nbsp;was&nbsp;0.3 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H7#H7\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Topical ivermectin for pediculosis capitis",
"    </span>",
"   </p>",
"   <p>",
"    The emergence of resistance to treatments for pediculosis capitis (head lice) has fueled the desire to identify additional effective treatments for this condition. In two randomized trials, a single 10-minute application of topical ivermectin was superior to a placebo lotion for the eradication of lice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/69\">",
"     69",
"    </a>",
"    ]. A combined analysis of the trial results revealed that among the index patients (youngest household member with at least three live lice detected on examination), 131 of 138 (95 percent) treated with topical ivermectin and 46 of 147 (31 percent) treated with the placebo lotion were free of live lice on day two. By day 15, live lice were absent in 74 and 18 percent of patients, respectively. Adverse events were infrequent and occurred at similar rates in both groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link&amp;anchor=H2579574#H2579574\">",
"     \"Pediculosis capitis\", section on 'Topical ivermectin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Oseltamivir treatment approved for infants &ge;2 weeks",
"    </span>",
"   </p>",
"   <p>",
"    In December 2012, the US Food and Drug Administration approved oseltamivir for the treatment of influenza in infants &ge;2 weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/70\">",
"     70",
"    </a>",
"    ]. Oseltamivir had previously been approved in the US for treatment of influenza in children &ge;1 year of age. For prophylaxis of influenza in the US, oseltamivir continues to be approved only for infants &ge;1 year of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H5#H5\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Neuraminidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h2\">",
"     Vision screening with photoscreening or autorefraction",
"    </span>",
"   </p>",
"   <p>",
"    &shy;Photoscreening uses optical images of the red reflex to detect risk factors for amblyopia (eg, refractive errors, cataracts, and strabismus). Autorefraction uses automated retinoscopy or wave-front technology to evaluate refractive error. Photoscreening and autorefraction can be performed with minimal patient cooperation and may be particularly useful in preverbal, preliterate, or developmentally delayed children. In an updated policy statement, the American Academy of Pediatrics, the American Academy of Ophthalmology, the American Association for Pediatric Ophthalmology and Strabismus, and the American Association of Certified Orthoptists recommend photoscreening or autorefraction as an alternative to visual behavior and visual acuity screening in preschool children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/71\">",
"     71",
"    </a>",
"    ]. The 2002 policy statement indicated that instrument-based screening was promising, but additional study was necessary. Since then, observational studies have confirmed the potential benefit of instrument based screening [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H3092026#H3092026\">",
"     \"Visual development and vision assessment in infants and children\", section on 'Photoscreening and autorefraction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Obesity and sugar-sweetened beverages",
"    </span>",
"   </p>",
"   <p>",
"    Accumulating evidence suggests that consumption of sugar-sweetened beverages (including fruit juice) is an important contributor to the development of obesity in some populations. A randomized trial demonstrated that reducing consumption of sugar-sweetened beverages among overweight and obese adolescents is associated with a modest decrease in body mass index (BMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/74\">",
"     74",
"    </a>",
"    ]. In a separate randomized trial in children (most of whom were in a healthy weight range), consumption of one serving of an artificially sweetened beverage daily was associated with less weight gain and fat accumulation as compared with consumption of a sugar-sweetened beverage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H19815865#H19815865\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Sugar-sweetened beverages'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h1\">",
"     PEDIATRICS: DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h2\">",
"     Prevalence of autism spectrum disorders",
"    </span>",
"   </p>",
"   <p>",
"    In the 2011-2012 National Survey of Children&rsquo;s Health, the prevalence of parent-reported autism spectrum disorder (ASD) among 6- to 17-year-old children in the&nbsp;United States was 1 in 50, an increase from 1 in 86 in&nbsp;2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/76\">",
"     76",
"    </a>",
"    ]. The increase was largely&nbsp;due to&nbsp;newly diagnosed ASD in&nbsp;6-to 13-year-old children,&nbsp;suggesting&nbsp;that&nbsp;the increase&nbsp;is related to improved awareness and ascertainment of ASD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H9#H9\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h1\">",
"     PEDIATRIC IMMUNIZATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h2\">",
"     Combination vaccine for meningococcus and Haemophilus influenzae type b",
"    </span>",
"   </p>",
"   <p>",
"    A combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type b (MenHibrix, HibMenCY) was approved by the US Food and Drug Administration in June 2012 for infants and children 6 weeks to 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In prelicensure trials, this vaccine was safe, immunogenic, and did not interfere with immune responses to routine immunizations. In January 2013, the United States Advisory Panel on Immunization Practices began recommending HibMenCY for certain infants and toddlers at increased risk for meningococcal disease, beginning at two months of age (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/52/26442/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. It is the first meningococcal vaccine to be recommended in the United States for use in infants younger than nine months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H937132#H937132\">",
"     \"Meningococcal vaccines\", section on 'Combination conjugate vaccine against meningococcus and Haemophilus influenzae type b'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H182642754#H182642754\">",
"     \"Meningococcal vaccines\", section on 'In infants and toddlers'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/1\">",
"      Rolfe A, Burton C. Reassurance After Diagnostic Testing With a Low Pretest Probability of Serious Disease: Systematic Review and Meta-analysis. JAMA Intern Med 2013; 173:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/2\">",
"      Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/3\">",
"      Klein BE, Howard KP, Gangnon RE, et al. Long-term use of aspirin and age-related macular degeneration. JAMA 2012; 308:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/4\">",
"      Wolf MS, King J, Jacobson K, et al. Risk of unintentional overdose with non-prescription acetaminophen products. J Gen Intern Med 2012; 27:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/5\">",
"      Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/6\">",
"      Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/7\">",
"      Bhanushali GK, Jain G, Fatima H, et al. AKI Associated with Synthetic Cannabinoids: A Case Series. Clin J Am Soc Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93.",
"     </a>",
"    </li>",
"    <li>",
"     Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses Including Ambien, Ambien CR, Edluar, and Zolpimist file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm (Accessed on January 20, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/10\">",
"      Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/11\">",
"      Monson CM, Fredman SJ, Macdonald A, et al. Effect of cognitive-behavioral couple therapy for PTSD: a randomized controlled trial. JAMA 2012; 308:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/12\">",
"      Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/13\">",
"      Caporaso NE. Statins and cancer-related mortality--let's work together. N Engl J Med 2012; 367:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/14\">",
"      Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/15\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/16\">",
"      Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/17\">",
"      Estruch R, Ros E, Salas-Salvad&oacute; J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/18\">",
"      Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/19\">",
"      Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/20\">",
"      Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011; 64:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/21\">",
"      Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50���000 individuals. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/22\">",
"      Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/23\">",
"      Moyer VA, U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 158:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/24\">",
"      Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol 2013; 121:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/25\">",
"      Wehner MR, Shive ML, Chren MM, et al. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345:e5909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/26\">",
"      Gaziano JM, Sesso HD, Christen WG, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012; 308:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/27\">",
"      Murdoch DR, Slow S, Chambers ST, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 2012; 308:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/28\">",
"      Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med 2013; 158:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/29\">",
"      Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/30\">",
"      Knudsen AB, Hur C, Gazelle GS, et al. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012; 157:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/31\">",
"      Zalis ME, Blake MA, Cai W, et al. Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults: a prospective evaluation. Ann Intern Med 2012; 156:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/32\">",
"      Stoop EM, de Haan MC, de Wijkerslooth TR, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2012; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/33\">",
"      Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366:2345.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Azithromycin (Zithromax or Zmax): Drug safety communication - risk of potentially fatal heart rhythms. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm343350.htm?source=govdelivery (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Zmax (azithromycin extended release) for oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262866.htm (Accessed on May 18, 2012).",
"    </li>",
"    <li>",
"     ZITHROMAX (azithromycin tablets) and(azithromycin for oral suspension) - prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/37\">",
"      Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/38\">",
"      Nakatani D, Sakata Y, Suna S, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 2013; 111:457.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm.",
"    </li>",
"    <li>",
"     file://news.bms.com/press-release/financial-news/eliquisapixaban-approved-europe-prevention-stroke-and-systemic-embolism&amp;t=634890181706594412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/41\">",
"      Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm?source=govdelivery (Accessed on November 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/43\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/44\">",
"      Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/45\">",
"      Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/46\">",
"      Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/47\">",
"      Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/48\">",
"      van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/49\">",
"      Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep 2013; 62:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/50\">",
"      Nadelman RB, Hanincov&aacute; K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012; 367:1883.",
"     </a>",
"    </li>",
"    <li>",
"     New York State Department of Health. New York State Department of Health expands vaccination recommendation in response to meningococcal disease outbreak among high risk HIV positive men in New York City. file://www.health.ny.gov/press/releases/2012/2012-10-05_meningitis.htm (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     Commonwealth of Masschusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012.",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/55\">",
"      Deuschl G, Sch&uuml;pbach M, Knudsen K, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013; 19:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/56\">",
"      Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/57\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/58\">",
"      Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/59\">",
"      McGrath ER, O'Donnell MJ. Estimating treatment effects in observational studies. Neurology 2012; 79:1844.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.drugs.com/pro/skyla-iud.html (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/62\">",
"      Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013; 368:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/63\">",
"      Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309:48.",
"     </a>",
"    </li>",
"    <li>",
"     Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women &mdash; Advisory Committee on Immunization Practices (ACIP), 2012 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/65\">",
"      H&aring;berg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013; 368:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/66\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. Committee Opinion No.543: Timing of umbilical cord clamping after birth. Obstet Gynecol 2012; 120:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/67\">",
"      Rabe H, Diaz-Rossello JL, Duley L, Dowswell T. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database Syst Rev 2012; 8:CD003248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/68\">",
"      Lo JC, Sinaiko A, Chandra M, et al. Prehypertension and hypertension in community-based pediatric practice. Pediatrics 2013; 131:e415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/69\">",
"      Pariser DM, Meinking TL, Bell M, Ryan WG. Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med 2012; 367:1687.",
"     </a>",
"    </li>",
"    <li>",
"     Tamiflu (oseltamivir phosphate) prescribing information. www.gene.com/download/pdf/tamiflu_prescribing.pdf (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/71\">",
"      Miller JM, Lessin HR, American Academy of Pediatrics Section on Ophthalmology, et al. Instrument-based pediatric vision screening policy statement. Pediatrics 2012; 130:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/72\">",
"      Atkinson J, Braddick O, Nardini M, Anker S. Infant hyperopia: detection, distribution, changes and correlates-outcomes from the cambridge infant screening programs. Optom Vis Sci 2007; 84:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/73\">",
"      Kirk VG, Clausen MM, Armitage MD, Arnold RW. Preverbal photoscreening for amblyogenic factors and outcomes in amblyopia treatment: early objective screening and visual acuities. Arch Ophthalmol 2008; 126:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/74\">",
"      Ebbeling CB, Feldman HA, Chomitz VR, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med 2012; 367:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/75\">",
"      de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012; 367:1397.",
"     </a>",
"    </li>",
"    <li>",
"     Blumberg SJ, Bramlett MD, Kogan MD, et al. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. file://www.cdc.gov/nchs/data/nhsr/nhsr065.pdf (Accessed on March 21, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. News &amp; Events. FDA approves new combination vaccine that protects children against two bacterial diseases. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=Menhibrix&amp;utm_content=1 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     GSK receives FDA approval for MenHibrix. file://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1134059.htm (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/79\">",
"      Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/52/26442/abstract/80\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8349 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26442=[""].join("\n");
var outline_f25_52_26442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ADULT GENERAL INTERNAL MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Reassurance provided by diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cardiotoxicity in women with breast cancer after radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-term regular aspirin use and age-related macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient understanding of acetaminophen dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Proactive, intermittent therapy for long-term control of atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute kidney injury after synthetic cannabinoid use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Zolpidem dosing for insomnia in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Statins and myalgias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cognitive-behavioral couples therapy for PTSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Statins and cancer outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GERIATRICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Discontinuing antipsychotic agents in patients with dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aspirin for the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mediterranean diet and prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Role of folate or folic acid in cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Long-term use of postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Risk for nonmelanoma skin cancer in users of tanning beds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Multivitamins and cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vitamin D and prevention of colds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Screening colonoscopy and incidence of late stage colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Screening women with a familial ovarian cancer syndrome for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Rescreening for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CT colonography for colorectal cancer screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Flexible sigmoidoscopy for colorectal cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ADULT CARDIOVASCULAR MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Azithromycin and torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Duration of beta blocker after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Apixaban for prevention of embolic events in atrial fibrilllation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Bleeding rates with warfarin and dabigatran in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      ADULT GASTROENTEROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Blood transfusion thresholds for acute upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      ADULT HEMATOLOGY AND ONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Apixaban for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Aspirin for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ADULT INFECTIOUS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Fecal microbiota transplant for Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      2012-2013 seasonal influenza vaccine effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Recurrence of erythema migrans: reinfection or relapse?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Meningococcal vaccination for men who have sex with men from New York City",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Egg-free influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      ADULT NEUROLOGY AND PSYCHIATRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Deep brain stimulation for early Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Updated guidelines for early management of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Selective serotonin reuptake inhibitors and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      GYNECOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      New levonorgestrel-releasing IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Levonorgestrel intrauterine device for menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      OBSTETRICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Selective serotonin reuptake inhibitors during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Tdap during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Safety and efficacy of influenza vaccination in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      New guidelines for umbilical cord clamping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      PEDIATRICS: GENERAL PEDIATRICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Diagnosis of hypertension in childhood requires repeated blood pressure measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Topical ivermectin for pediculosis capitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Oseltamivir treatment approved for infants &ge;2 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      Vision screening with photoscreening or autorefraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Obesity and sugar-sweetened beverages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      PEDIATRICS: DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      Prevalence of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      PEDIATRIC IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      Combination vaccine for meningococcus and Haemophilus influenzae type b",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"FM/8349\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"FM/8349|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/47/40702\" title=\"table 1\">",
"      Aspirin for CVD and cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 2\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/31/42494\" title=\"table 3\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/40/32397\" title=\"table 4\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 5\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 6\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=related_link\">",
"      Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=related_link\">",
"      Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=related_link\">",
"      Levonorgestrel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=related_link\">",
"      Pediculosis capitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=related_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=related_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_52_26443="Enterovirus receptors";
var content_f25_52_26443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Enterovirus receptors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Viruses",
"       </td>",
"       <td class=\"subtitle1\">",
"        Receptor(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics of the receptor(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polioviruses 1-3",
"       </td>",
"       <td>",
"        PVR",
"       </td>",
"       <td>",
"        Member of immunoglobulin superfamily; function unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterovirus 71&nbsp;",
"       </td>",
"       <td>",
"        P-selectin glycoprotein ligand-1&nbsp;",
"       </td>",
"       <td>",
"        Transmembrane protein&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxsackie A virus, 16&nbsp;",
"       </td>",
"       <td>",
"        Scavenger&nbsp;receptor class B, member 2 (SCARB2)&nbsp;",
"       </td>",
"       <td>",
"        Transmembrane protein&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Coxsackie B viruses",
"       </td>",
"       <td>",
"        CAR",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DAF (CD55)",
"       </td>",
"       <td>",
"        Complement regulatory protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echoviruses 1, 8",
"       </td>",
"       <td>",
"        VLA-2",
"       </td>",
"       <td>",
"        Integrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echoviruses 6, 7, 9, 11, 11, 12, 20-22, 25",
"       </td>",
"       <td>",
"        DAF (CD55)",
"       </td>",
"       <td>",
"        Complement regulatory protein",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26443=[""].join("\n");
var outline_f25_52_26443=null;
var title_f25_52_26444="Adverse effects - TB and HIV medicines";
var content_f25_52_26444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common side effects shared by antiretrovirals and antituberculosis medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antiretrovirals",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antituberculosis medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis",
"       </td>",
"       <td>",
"        <p>",
"         Nevirapine",
"        </p>",
"        <p>",
"         Ritonavir-boosted protease inhibitors",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Isoniazid",
"        </p>",
"        <p>",
"         Rifampin*",
"        </p>",
"        <p>",
"         Pyrazinamide",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal distress",
"       </td>",
"       <td>",
"        All antiretrovirals (less common with lamivudine and emtricitabine)",
"       </td>",
"       <td>",
"        <p>",
"         Fluoroquinolones",
"        </p>",
"        <p>",
"         Ethionamide (associated with taste alteration)",
"        </p>",
"        <p>",
"         Para-amniosalicylic acid",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrotoxicity",
"       </td>",
"       <td>",
"        <p>",
"         Tenofovir (renal tubular disfunction)",
"        </p>",
"        <p>",
"         Idinavir-ritonavir",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Aminoglycosides (nephrotoxic TB agents carry particular risk of potentiating lactic acidosis common to the NRTIs used in antiretroviral rollout regimens)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropsychiatric disorders",
"       </td>",
"       <td>",
"        Efavirenz (insomnia, drowsiness, vivid dreams)",
"       </td>",
"       <td>",
"        <p>",
"         Cycloserine (headaches, tremor, seizure)",
"        </p>",
"        <p>",
"         Terizidone (mainly headache and seizures)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"       <td>",
"        <p>",
"         Stavudine",
"        </p>",
"        <p>",
"         Didanosine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cycloserine",
"        </p>",
"        <p>",
"         Streptomycin",
"        </p>",
"        <p>",
"         Amnioglycosides",
"        </p>",
"        <p>",
"         Isoniazid (overcome with pyridoxine administration)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Stavudine, didanosine, tenofovir, lamivudine and emtricitabine are NRTIs. Nevirapine and efavirenz are NNRTIs. Idinavir and ritonovir are protease inhibitors. Common global rollout antiretroviral regimens: (stavudine or zidovidine) + (lamivudine or emtricitabine) + (nevirapine or efavirenz) or (tenofovir or abacavir) + (lamivudine or emtricitabine) + (nevirapine or efavirenz).",
"    <div class=\"footnotes\">",
"     MDR: multidrug resistant; NNRTIs: nonnuceloside reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; TB: tuberculosis; XDR: extensively drug-resistant.",
"     <br>",
"      * Rifampin induction of cytochrome P450 reduces serum levels of NNRTIs and protease inhibitors but is not therapeutically relevant for MDR/XDR TB.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Shenoi S, Heysell SK, Moll AP, Friedland G. Multi-drug Resistant and Extensively Drug-Resistant Tuberculosis: Consequences for the Global HIV Community. Curr Opin Infect Dis 2009; 22:11. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26444=[""].join("\n");
var outline_f25_52_26444=null;
var title_f25_52_26445="TNM staging bladder CA";
var content_f25_52_26445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for bladder cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ta",
"      </td>",
"      <td colspan=\"3\">",
"       Noninvasive papillary carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ: \"flat tumor\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades subepithelial connective tissue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor invades muscularis propria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       pT2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor invades superficial muscularis propria (inner half)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       pT2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor invades deep muscularis propria (outer half)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T3",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor invades perivesical tissue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       pT3a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Microscopically",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       pT3b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Macroscopically (extravesical mass)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T4",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor invades any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor invades prostatic stroma, uterus, vagina",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor invades pelvic wall, abdominal wall",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td colspan=\"3\">",
"       Multiple regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node metastasis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"3\">",
"       Lymph node metastasis to the common iliac lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0a",
"      </td>",
"      <td>",
"       Ta",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0is",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage II",
"      </td>",
"      <td>",
"       T2a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage III",
"      </td>",
"      <td>",
"       T3a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage IV",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N1-3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Regional lymph nodes include both primary and secondary drainage regions. All other nodes above the aortic bifurcation are considered distant lymph nodes.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26445=[""].join("\n");
var outline_f25_52_26445=null;
var title_f25_52_26446="Influence of BMI on COPD";
var content_f25_52_26446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prognostic influence of BMI in patients with COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 370px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival is calculated using the actuarial method. The initial numbers in each group were 990 (BMI &lt;20), 1731 (BMI, 20 to 24), 1003 (BMI, 25 to 29), and 364 (BMI &ge;30).",
"    <div class=\"footnotes\">",
"     BMI: body mass index.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Chailleux E, Laaban J-P, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy. Chest 2003; 123:1463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26446=[""].join("\n");
var outline_f25_52_26446=null;
var title_f25_52_26447="Ileocolic anastomosis - Transection of ileum and colon";
var content_f25_52_26447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ileocolic anastomosis - Transection of ileum and colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_52_26447=[""].join("\n");
var outline_f25_52_26447=null;
